[["index.html", "Rat DCIS study Chapter 1 Prerequisites 1.1 Packages and Software 1.2 External software 1.3 Annotations", " Rat DCIS study Anne Trinh 2020-12-07 Chapter 1 Prerequisites 1.1 Packages and Software The following packages are required to conduct the analyses described below. In house scripts are deposited in the rscript folder. library(AnnotationHub) library(biomaRt) library(Biostrings) library(colorspace) library(DESeq2) library(dplyr) library(DT) library(ensembldb) library(EnsDb.Hsapiens.v86) library(GenVisR) library(GenomicFeatures) library(ggplot2) library(gplots) library(GSEABase) library(GSVA) library(heatmap.plus) library(HTSanalyzeR2) library(kableExtra) library(limma) library(matrixStats) library(pamr) library(reshape2) library(RColorBrewer) library(scales) library(spatstat) library(tcR) library(vcfR) library(xlsx) library(writexl) DiffCols=hue_pal()(8) palette(brewer.pal(9, &quot;Set1&quot;)) RdBu=brewer.pal(11, &quot;RdBu&quot;) SetCols=brewer.pal(12, &quot;Set3&quot;) source(&quot;../rscript/cnFreq_fn.R&quot;) #modified version of GenVisR source(&quot;../rscript/merge_contig.R&quot;) source(&quot;../rscript/gseaCode.R&quot;) source(&quot;../rscript/ContingencyTable.R&quot;) source(&quot;../rscript/PvalueHeatMap.R&quot;) source(&quot;../rscript/BootstrapShannonIdx.R&quot;) #source(&quot;../rscript/CreateRnor87db.R&quot;) source(&quot;../rscript/FindRatAAHomolog.R&quot;) source(&quot;../rscript/OutputplotFun.R&quot;) firstup &lt;- function(x) { substr(x, 1, 1) &lt;- toupper(substr(x, 1, 1)) x } ColMerge=matrix(c(&quot;#FFC82F&quot;, &quot;#FFEDBC&quot;, &quot;#73FDFE&quot;,&quot;#D2FFFF&quot;, &quot;#FF41FF&quot;, &quot;#FECAFF&quot;, &quot;#5D5D5D&quot;, &quot;#BEBEBE&quot;), ncol=2, byrow = T) rownames(ColMerge)=c(&quot;LY&quot;,&quot;PDL1&quot;, &quot;PDL1+LY&quot;,&quot;Vehicle&quot;) ColSize=c(&quot;#008E00&quot;, &quot;#FF9300&quot;) names(ColSize)=c(&quot;small&quot;, &quot;big&quot;) Hsedb&lt;-EnsDb.Hsapiens.v86 1.2 External software The following external software was utilised: Software Function bwa Alignment of WGS data to reference GATK4 Mutation calling, done by NYGC. Mutation calling from RNA (Haplotype caller) strelka Mutation calling, done by NYGC BICseq CNV calling GEM3 create mappability files for CNV calling STAR Alignment of RNAseq data RSEM Calculate RSEM, TPM, FPKM from RNAseq data TRUST4 assignment of T and B cell clonotypes from RNA-seq data Oncotator Annotation of genetic variants QuPath Tool for cell segmentation and extraction of features from IF images samtools, bcftools querying and dispalying information from bam files, extracting allelic depth at specific genomic locations CIBERSORT inferring immune composition from RNA lumpy structural variants PAM50 code from parker et al 2009 to infer PAM50 subtypes 1.3 Annotations 1.3.1 Genomic properties Information on chromosome sizes, cytobands and centromere locations were obtained from the UCSC genome browser. The following annotation data for the hg19/b37/GRCh37 genome is required: Data Type Download link ref. genome http://hgdownload.soe.ucsc.edu/goldenPath/rn6/bigZips/rn6.fa.gz refSeq annot http://hgdownload.soe.ucsc.edu/goldenPath/rn6/bigZips/genes/rn6.refGene.gtf.gz refSeq annot http://hgdownload.soe.ucsc.edu/goldenPath/rn6/bigZips/genes/rn6.ncbiRefSeq.gtf.gz gff3 file for TRUST4 (ftp://ftp.ensembl.org/pub/release-100/gff3/rattus_norvegicus/Rattus_norvegicus.Rnor_6.0.100.gff3.gz) gene lengths Extracted from GRCh37.75.gtf file from ensembl hg19cytoBand ucsc server of all cytoband locations chromosome sizes uscs genome browser biomart conversion between gene symbol, ensbl and entrez was faciliated using biomart package Below is the summary of chromosome sizes and centromere locations: ## chrom chromStart chromEnd name gieStain ## 1 chr1 0 10704345 p13 gneg ## 2 chr1 10704345 25618263 p12 gvar ## 3 chr1 25618263 40652454 p11 gneg ## 4 chr1 40652454 51356799 q11 gpos ## 5 chr1 51356799 73607402 q12 gneg ## 6 chr1 73607402 95016091 q21 gpos Create a TxDb object from a gtf file and save information: Not sure which version to use?? Below is an example of the gene annotation files ## GRanges object with 6 ranges and 2 metadata columns: ## seqnames ranges strand | gene_id gene_width ## &lt;Rle&gt; &lt;IRanges&gt; &lt;Rle&gt; | &lt;character&gt; &lt;integer&gt; ## Vom2r3 chr1 396700-409676 + | Vom2r3 12977 ## Lrp11 chr1 1702696-1731210 + | Lrp11 28515 ## Nup43 chr1 1771721-1781554 + | Nup43 9834 ## Lats1 chr1 1784078-1817310 + | Lats1 33233 ## Katna1 chr1 1826170-1867786 + | Katna1 41617 ## Ppil4 chr1 1897350-1930311 + | Ppil4 32962 ## ------- ## seqinfo: 22 sequences from an unspecified genome; no seqlengths 1.3.2 Gene name homologs between organisms Biomart was used to convert between rat, mouse and human gene symbols and ensembl ids. Below is an example of the human gene names mapped to the rat homolog Figure out what is required here for later analysis ## HGNC.symbol RGD.symbol ## 1 TAB1 Tab1 ## 2 PHF1 Phf1 ## 3 RNF39 Rnf39 ## 4 IGSF10 Igsf10 ## 5 TMEM130 Tmem130 ## 6 EFNB1 Efnb1 1.3.3 Gene signatures and data-bases Gene sets/signatures were obtained from the following sources: Source Description IEDB database of immune epitopes MsigDB c2, c5, hallmark set of curated pathway gene sets Metacore Process Networks and Pathway Maps data bases COSMIC database of concensus oncogenes ImmPort List of immune related genes InnateDB List of genes associated with innate immune system Rosenthal 2019 genes associated with MHC-I presentation Thorsson 2018 Immune gene signatures curated from studies by Wolf, Calabro, Teschendorff, Beck, Chang Pardoll, Wykes Immune checkpoint genes gil del alcazar 2017 Supplementary table 5: list of activation, dysfunction gene signatures Bailey 2018 List of 10 most comon tumor pathways Chang 2018 Common mutation locations in cancer The PAM50 signature was implemented using the scripts provided in supplementary from Parker et al 2010. These gene lists can be found in the annotations folder 1.3.3.1 Human gene homologs Below, lists of common mutations in cancer are loaded and the “homolog” in rat is determined using an in-house script. The steps involved are: determine the amino acid context in human (find 5 a.a. prior and after) find the region with most amino acid homology in rat (2 or less differences) check whether the amino acid of interest is present in rat An example of the output is shown ## Gene AAno AA1 Variant RatGene Sequence HumProt RatProt ## 1 NRAS 61 Q R Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 2 NRAS 61 Q K Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 3 NRAS 61 Q L Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 4 NRAS 61 Q H Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 5 NRAS 61 Q P Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## 6 NRAS 61 Q * Nras LDTAGQEEYSA ENSP00000358548 ENSRNOP00000036381 ## RatAAno RatSequence ## 1 61 LDTAGQEEYSA ## 2 61 LDTAGQEEYSA ## 3 61 LDTAGQEEYSA ## 4 61 LDTAGQEEYSA ## 5 61 LDTAGQEEYSA ## 6 61 LDTAGQEEYSA 1.3.3.2 GSEA compendiums For pathway analysis, the c2 (pathway), Hallmark and c5 (Gene Ontology). In addition, metacore pathways (pathway maps and process networks) were obtained and loaded below. This gives a list of 7 different data-sets to interrogate CHECK: When GSVA is run, which input is required?? "],["cohort-summary.html", "Chapter 2 Cohort summary 2.1 Size information 2.2 Calculating growth rates 2.3 FACS data 2.4 Summary Table", " Chapter 2 Cohort summary Below we assess summary statistics on clinico-pathological features of this data set. This includes information on: treatment tumor size growth rates (mm/week) number of tumors per rat TumorID Rat_ID Batch Location Cohort Treatment Age.at.injection..days. Date.of.NMU.injection Date.when.tumor.was.first.palpated Date.Sacrificed Tumor.growth.status Time.NMU2Tumor Time.Tumor2Sac Time.NMU2Sac Tumor.dia..sac..mm. Growth2 Tumor.Histology X..CD45..by.FACS. X..DN..by.FACS. X..EpCAM..by.FACS. X..TILs..Histology. Intermixing.with.leukocytes PgR..IF. ER..IF. Nick.s.calls.Basal.Luminal DN.PgR_clust Ep.PgR_clust CD45.ER_clust DN.ER_clust Ep.ER_clust CD45.Ki67_clust DN.Ki67_clust Ep.Ki67_clust WGS CD45.RNA EpCAM.RNA DN.RNA RNA.seqSampleID FqFile.CD45 TRUSTName.CD45 AnyRNAdata starSampleName.CD45 FqFile.Ep TRUSTName.Ep starSampleName.Ep FqFile.DN TRUSTName.DN starSampleName.DN DN.PgRvsd Ep.PgRvsd DN.ERvsd Ep.ERvsd DN.Ki67vsd Ep.Ki67vsd DN.PAM50 Ep.PAM50 Image.Name Image.converted.for.qupath Matrix.available Comments.about.matrix CD8.are…Tumor.infiltrating.vs..stroma.restricted. InfiltratingVsRestricted GrowthRate CD8Fraction EpCAMFraction DPFraction SMAFraction UnclassFraction knnEpDist knnEpstrRatio knnEpAntstrRatio knnSMADist IFEpstrRatio IFEpAntstrRatio IFEpcam IFSMA MHEpstrRatio MHEpAntstrRatio MHEpcam MHSMA 10L_B 10L 2 B Progression PDL1 32-36 2018-02-14 2018-03-29 2018-05-04 growing 43 36 79 35.0 growing well differentiated mammary solid adenocarcinoma 15.2 75.7 8.59 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No Yes 10L_B_DN NA NA yes NA NA NA NA 20190213_47_CGDA6432-3of3_S1_R1_001.fastq.gz 20190213_47_CGDA6432-3of3_S1_R1_001_report.tsv DN_10L_B NA NA NA NA NA NA NA NA 10L PT B 5 HPC18-0971.mrxs 4channel_23samples YES NA Tumor infiltrating Infiltrating 6.2285714 0.0216413 0.2433985 0.1050166 0.3553565 0.2745871 47.98343 0.5529532 2.6586734 18.04789 0.2929498 0.3027004 0.0398611 0.1316849 0.4380387 0.7610091 0.4984859 0.6550328 10L_C 10L 3 C Progression PDL1 32-36 2018-02-14 2018-04-12 2018-05-04 growing 57 22 79 25.0 growing well differentiated mammary solid adenocarcinoma 51.4 35.6 12 NA NA Not done Not done NA 1 NA NA 1 NA NA 1 NA No No No No 10L_C_CD45 20191030_CD45_10LC_CGDA7427_S25_R1_001.fastq.gz 20191030_CD4510LC_report.tsv yes CD45_10LC NA NA NA 20191030_DN_10LC_CGDA7428_S8_R1_001.fastq.gz NA DN_10LC 7.117009 NA 7.187085 NA 7.857674 NA Normal NA 10L PT C-R+P.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating Infiltrating 5.3571429 0.0097353 0.2839173 0.1607107 0.3132420 0.2323947 35.79494 0.6400629 1.9373690 18.47606 0.5069034 0.6408978 0.0729492 0.1138234 0.4584403 0.9208043 0.5219795 0.5668735 10L_D 10L 2 D Progression PDL1 32-36 2018-02-14 2018-03-29 2018-05-04 stable 43 36 79 10.0 stable well differentiated mammary solid adenocarcinoma 49.8 39 13.5 NA NA Mod Neg B NA 3 NA NA 1 NA NA 1 No yes yes No 10L_D_CD45 20190213_25_CGDA6432-2of3_S1_R1_001.fastq.gz 20190213_25_CGDA6432-2of3_S1_R1_001_report.tsv yes CD45_10L_D 20190213_2_CGDA6432-1of3_S1_R1_001.fastq.gz 20190213_2_CGDA6432-1of3_S1_R1_001_report.tsv Ep_10L_D NA NA NA NA 10.582811 NA 9.189996 NA 7.256776 NA Normal 10L PT D-R+P.mrxs 2 halves: ?? Yes NA Tumor infiltrating Infiltrating 1.9729730 0.0655979 0.1706167 0.1711310 0.3895102 0.2031443 48.71052 0.7327214 2.8050670 17.36519 0.3019387 0.3560023 0.0541387 0.1520740 0.4949588 0.9038839 0.6730006 0.7445653 10N_A 10N NA A Progression PDL1 32-36 2018-02-14 2018-11-08 2018-11-15 no data (big) 267 7 274 12.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10N A 1.mrxs 4channel_23samples YES Most double labeled SMA:EpCAM is really just SMA stroma restricted and very few restricted NA 0.0459678 0.5442790 0.0000000 0.2818107 0.1279424 23.93511 0.8744548 0.8744548 27.37146 2.6345083 2.6345083 0.1028948 0.0390566 0.9265348 0.9265348 0.4968038 0.5361955 10N_D 10N NA D Progression PDL1 32-36 2018-02-14 2018-04-05 2018-11-15 stable 50 224 274 15.0 stable mucinous carcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10N D-R+P.mrxs 2+3channel_57samples YES Most double labeled SMA:EpCAM is really just EpCAM stroma restricted restricted 0.3930533 0.0230218 0.4361433 0.0000000 0.3140889 0.2267460 138.52158 4.6320759 4.6320759 29.90486 2.0450368 2.0450368 0.0902820 0.0441469 1.1186318 1.1186318 0.4217567 0.3770291 10N3 NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? FIBROADENOMA? NA NA NA 0.0829106 0.1239425 0.0580833 0.2563836 0.4786800 154.15707 0.4900419 2.5398923 60.69433 1.1238938 1.1651376 0.0118992 0.0102127 1.0178861 1.4905845 0.0720883 0.0483625 10R_BL 10R 2 BL Progression PDL1 32-36 2018-02-14 2018-04-02 2018-05-23 growing 47 51 98 40.0 growing well differentiated mammary solid adenocarcinoma 14.5 19.4 66.6 NA NA Not done Not done L 2 4 NA 1 2 NA 1 1 No yes yes Yes 10R_B_CD45 NA NA yes CD45_10R_B 20190213_3_CGDA6432-1of3_S2_R1_001.fastq.gz 20190213_3_CGDA6432-1of3_S2_R1_001_report.tsv Ep_10R_B 20190213_49_CGDA6432-3of3_S2_R1_001.fastq.gz 20190213_49_CGDA6432-3of3_S2_R1_001_report.tsv DN_10R_B 8.613963 12.034954 8.432534 10.180611 8.327953 7.376086 Basal LumA 10R PT -B4-R+P.mrxs NA Yes, named 10RB4 NA stroma restricted restricted 4.9761905 0.0193134 0.3240520 0.1402713 0.2479772 0.2683861 56.50503 0.5629225 2.7269413 20.72103 0.2613909 0.3191801 0.0627699 0.1966599 0.4976627 0.8998152 0.6177975 0.6865826 10R_BU 10R 3 BU Progression PDL1 32-36 2018-02-14 2018-04-02 2018-05-23 no data 47 51 98 12.0 NA well differentiated mammary solid adenocarcinoma 31.7 40.2 28.2 NA NA Not done Not done NA 2 4 NA 1 2 NA 2 2 No Yes No No 10R_BU_CD45 20191030_CD45_10RBU_CGDA7427_S26_R1_001.fastq.gz 20191030_CD4510RBU_report.tsv yes CD45_10RBU 20191030_Ep_10RBU_CGDA7428_S5_R1_001.fastq.gz NA Ep_10RBU 20191030_DN_10RBU_CGDA7428_S9_R1_001.fastq.gz NA DN_10RBU 9.329606 11.774760 7.241326 9.600055 9.275112 9.422135 Basal LumB 10R PT-B-R+P.mrxs 2+3channel_57samples Yes, named 10RB NA stroma restricted restricted NA 0.0642329 0.1525813 0.3099870 0.2752306 0.1979682 105.58406 0.8967735 4.8631868 21.71088 0.0749408 0.1209147 0.0134511 0.1112444 0.3812351 0.6630232 0.4059670 0.6122968 10R_C 10R NA C Progression PDL1 32-36 2018-02-14 2018-05-23 2018-05-23 no data (tiny) 98 0 98 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10R PT-C-R+P.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” inflitrating Infiltrating NA 0.0384560 0.2909336 0.0262298 0.1399282 0.5044524 40.44271 0.2704214 0.9304911 43.46383 4.6458333 5.3095238 0.1041083 0.0196078 0.6639194 1.1406866 0.7291189 0.6391930 11L_B 11L 3 B Progression PDL1 32-36 2018-02-14 2018-04-19 2018-06-06 growing 64 48 112 25.0 growing well differentiated mammary solid adenocarcinoma 37.3 46.9 11.6 NA NA Not done Not done NA 4 4 NA 2 2 NA 1 1 No No No No 11L_B_CD45 20191030_CD45_11LB_CGDA7427_S27_R1_001.fastq.gz 20191030_CD4511LB_report.tsv yes CD45_11LB 20191030_Ep_11LB_CGDA7428_S6_R1_001.fastq.gz NA Ep_11LB 20191030_DN_11LB_CGDA7428_S10_R1_001.fastq.gz NA DN_11LB 11.344689 12.176955 9.049246 10.539352 8.293527 7.513111 LumA LumA 11L PT B-R+P.mrxs 2+3channel_57samples Yes, No SMA cells: is this expected? Its weird but true. Staining probably did work as antibody was prepared in a master mix for all samples and all antibodies. No SMA Most are Stroma restricted but there are so many that a significant number still infiltrating NA 3.7857143 0.1491413 0.4449584 0.0000098 0.0001400 0.4057505 69.84563 0.0051785 0.0125865 5549.23417 NA NA 0.0464376 0.0000000 192.6326449 607.5145074 0.3284619 0.0005407 11N_D 11N 2 D Progression PDL1 32-36 2018-02-14 2018-05-03 2018-06-21 stable 78 49 127 3.0 stable well differentiated mammary solid adenocarcinoma 70.3 13.2 10.4 NA NA Mod Pos B NA 3 NA NA 2 NA NA 2 No yes yes No 11N_D_CD45 20190213_27_CGDA6432-2of3_S3_R1_001.fastq.gz 20190213_27_CGDA6432-2of3_S3_R1_001_report.tsv yes CD45_11N_D 20190213_4_CGDA6432-1of3_S3_R1_001.fastq.gz 20190213_4_CGDA6432-1of3_S3_R1_001_report.tsv Ep_11N_D NA NA NA NA 10.143842 NA 9.745793 NA 8.934701 NA Her2 11N Tumor B-R+P.mrxs pyramid Yes, labeled 11NB Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating Infiltrating 0.1065574 0.3186158 0.3397687 0.0162144 0.0219573 0.3034436 31.54256 0.1502491 0.3503607 90.02883 61.3033708 136.4000000 0.1197831 0.0008782 0.8228057 1.8422338 0.7552033 0.4099389 11R_C 11R 3 C Progression PDL1 32-36 2018-02-14 2018-04-26 2018-06-06 growing 71 41 112 19.0 growing well differentiated mammary solid adenocarcinoma 23.8 32.5 42.3 NA NA Not done Not done NA 1 3 NA 1 2 NA 2 2 No No No No 11R_C_CD45 20191030_CD45_11RC_CGDA7427_S28_R1_001.fastq.gz 20191030_CD4511RC_report.tsv yes CD45_11RC 20191030_Ep_11RC_CGDA7428_S7_R1_001.fastq.gz NA Ep_11RC 20191030_DN_11RC_CGDA7428_S11_R1_001.fastq.gz NA DN_11RC 6.999032 10.625153 6.817717 8.839119 9.038043 8.565420 Basal Her2 11R PT C-R+P.mrxs NA Yes NA stroma restricted restricted 2.6785714 0.0508051 0.2919956 0.1634848 0.2119945 0.2817199 165.76133 0.6670125 2.4621673 67.32334 0.4583942 0.5395189 0.0072790 0.0134916 0.3825126 0.6480545 0.0493837 0.0762029 11R_D 11R 2 D Progression PDL1 32-36 2018-02-14 2018-04-26 2018-06-06 growing 71 41 112 25.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Pos Neg L 2 4 NA 1 2 NA 1 1 No yes yes Yes 11R_D_CD45 20190213_28_CGDA6432-2of3_S4_R1_001.fastq.gz 20190213_28_CGDA6432-2of3_S4_R1_001_report.tsv yes CD45_11R_D 20190213_5_CGDA6432-1of3_S4_R1_001.fastq.gz 20190213_5_CGDA6432-1of3_S4_R1_001_report.tsv Ep_11R_D 20190213_51_CGDA6432-3of3_S3_R1_001.fastq.gz 20190213_51_CGDA6432-3of3_S3_R1_001_report.tsv DN_11R_D 8.530865 11.988115 8.044929 9.983751 8.717588 7.792052 Her2 LumA 11R PT D-G.mrxs NA Yes NA stroma restricted restricted 3.6428571 0.0308077 0.2501905 0.1422258 0.2913907 0.2853853 156.56719 0.7624120 3.7083404 42.22028 0.4764464 0.5648426 0.0347075 0.0614463 0.4781256 0.8850004 0.1586241 0.1792362 12L_C 12L NA C Progression PDL1 32-36 2018-02-14 2018-05-14 2018-06-21 no data (tiny) 89 38 127 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12L Tumor C-R+P.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” infiltrating Infiltrating NA 0.0846821 0.4423354 0.0120046 0.0102534 0.4507245 25.78770 0.0824443 0.1607888 160.38243 50.1250000 401.0000000 0.1337558 0.0003336 0.7834229 2.0172677 0.5858494 0.2904173 12L_D 12L 2 D Progression PDL1 32-36 2018-02-14 2018-05-14 2018-06-21 stable 89 38 127 6.0 stable well differentiated mammary solid adenocarcinoma 11.2 52 32.9 NA NA Mod Neg B 1 2 NA 1 2 NA 1 1 No No yes Yes 12L_D_DN NA NA yes NA 20190213_6_CGDA6432-1of3_S5_R1_001.fastq.gz 20190213_6_CGDA6432-1of3_S5_R1_001_report.tsv Ep_12L_D 20190213_52_CGDA6432-3of3_S4_R1_001.fastq.gz 20190213_52_CGDA6432-3of3_S4_R1_001_report.tsv DN_12L_D 6.662938 8.412817 7.735980 8.666475 7.050137 6.970116 Normal LumA 12L Tumor D-G.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating Infiltrating 0.7702703 0.0214899 0.7100194 0.0107209 0.0020876 0.2556823 12.95364 0.0201820 0.0363766 356.09812 85.8571429 1202.0000000 0.3365062 0.0002800 2.2281795 4.2922100 0.8515853 0.1984025 12R NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? Fibroadenoma? Stroma restricted restricted NA 0.0099449 0.0882340 0.0443608 0.1261992 0.7312612 392.54901 0.9521448 11.9409693 32.87413 0.5566038 0.6276596 0.0672748 0.1071836 0.3325371 0.5017665 0.2641628 0.5264656 12R3 NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12R 3.mrxs 4channel_23samples YES Normal? Fibroadenoma? NA NA NA 0.0205554 0.0373773 0.0240700 0.5097667 0.4082305 126.86753 0.7843815 8.4113651 15.08287 0.1322115 0.1348039 0.0279046 0.2070015 0.4508201 0.7568310 0.3490011 0.4611348 12N NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples Stroma restricted restricted NA 0.0205510 0.0057682 0.2500734 0.5798918 0.1437157 619.20691 5.5566377 35.4889967 17.44786 0.0020619 0.0036145 0.0005422 0.1500090 0.1702894 0.3065013 0.0523020 0.1706420 13L NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples Stroma restricted restricted NA 0.0180710 0.0042113 0.0960432 0.5240580 0.3576165 735.85177 1.6743701 38.6692751 19.02937 0.0000000 0.0000000 0.0000000 0.1843478 0.1783751 0.3611975 0.1248313 0.3456039 13R NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples Stroma restricted restricted NA 0.1387644 0.0038132 0.0644568 0.2184573 0.5745083 818.46797 1.0186965 2.9375809 278.61972 0.0031746 0.0041841 0.0001205 0.0288056 0.2855829 0.4521210 0.0702582 0.1553968 13N_A 13N NA A Progression Vehicle 32-36 2018-02-14 2018-06-22 2018-07-27 growing 128 35 163 35.0 growing well differentiated mammary solid adenocarcinoma 18.4 36.3 37.7 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13N Tumor A-R+P.mrxs 4channel_23samples Yes Most double labeled SMA:EpCAM is really just EpCAM Stroma restricted restricted 6.2000000 0.0446357 0.3224974 0.0000000 0.3481243 0.2847427 93.50342 3.8593214 3.8593214 24.22794 0.1822103 0.1822103 0.0228302 0.1252959 0.7305441 0.7305441 0.1996603 0.2733036 14L_A 14L NA A Progression PDL1+LY 32-36 2018-02-14 2018-03-29 2018-10-10 stable 43 195 238 1.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA -0.4044118 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14L_B 14L NA B Progression PDL1+LY 32-36 2018-02-14 2018-07-26 2018-10-10 growing 162 76 238 40.0 stable well differentiated mammary solid adenocarcinoma 12.1 32.6 30 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0.5062500 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14L_C 14L NA C Progression PDL1+LY 32-36 2018-02-14 2018-07-12 2018-10-10 stable 148 90 238 2.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA -0.1111111 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14L_D 14L NA D Progression PDL1+LY 32-36 2018-02-14 2018-08-16 2018-10-10 growing 183 55 238 40.0 growing fibroadenoma 9.74 52.8 38 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5.9615385 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14N_B 14N 2 B Progression PDL1+LY 32-36 2018-02-14 2018-05-03 2018-05-04 growing 78 1 79 23.0 growing well differentiated mammary solid adenocarcinoma 19.6 19.9 59.7 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No yes No No 14N_B_CD45 20190213_30_CGDA6432-2of3_S5_R1_001.fastq.gz 20190213_30_CGDA6432-2of3_S5_R1_001_report.tsv yes CD45_14N_B NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14N PT-B-R+P.mrxs NA Yes NA stroma restricted restricted 3.3150685 0.1060734 0.2986938 0.0531320 0.1553705 0.3867304 122.53225 0.4386699 3.2716092 37.45320 1.2652266 1.3606245 0.0573083 0.0421191 0.5479543 0.8810063 0.4353135 0.4941094 14N_C 14N 2 C Progression PDL1+LY 32-36 2018-02-14 2018-04-05 2018-05-04 stable 50 29 79 6.0 stable well differentiated mammary solid adenocarcinoma 36.9 50.1 11.3 NA NA Pos Neg L 3 4 NA 1 2 NA 1 1 No yes yes Yes 14N_C_CD45 20190213_32_CGDA6432-2of3_S7_R1_001.fastq.gz 20190213_32_CGDA6432-2of3_S7_R1_001_report.tsv yes CD45_14N_C 20190213_9_CGDA6432-1of3_S7_R1_001.fastq.gz 20190213_9_CGDA6432-1of3_S7_R1_001_report.tsv Ep_14N_C 20190213_55_CGDA6432-3of3_S6_R1_001.fastq.gz 20190213_55_CGDA6432-3of3_S6_R1_001_report.tsv DN_14N_C 9.965040 11.775665 8.106844 9.947588 7.471002 6.942936 Normal LumA 14N PT C-G.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” mostly stroma restricted restricted 0.5595238 0.0541714 0.5292786 0.1241025 0.0824713 0.2099763 46.46409 0.3846863 1.0479289 44.33897 2.8177677 4.6856061 0.1044322 0.0222879 0.5104408 0.8515194 0.3279479 0.3851326 14N_D 14N 2 D Progression PDL1+LY 32-36 2018-02-14 2018-04-19 2018-05-04 stable 64 15 79 5.0 stable well differentiated mammary solid adenocarcinoma 25.3 49 24.8 NA NA Mod Neg L 2 3 NA 1 1 NA 1 1 No yes yes yes 14N_D_CD45 20190213_31_CGDA6432-2of3_S6_R1_001.fastq.gz 20190213_31_CGDA6432-2of3_S6_R1_001_report.tsv yes CD45_14N_D 20190213_8_CGDA6432-1of3_S6_R1_001.fastq.gz 20190213_8_CGDA6432-1of3_S6_R1_001_report.tsv Ep_14N_D 20190213_54_CGDA6432-3of3_S5_R1_001.fastq.gz 20190213_54_CGDA6432-3of3_S5_R1_001_report.tsv DN_14N_D 8.820322 10.143147 6.791405 8.714452 8.189546 7.545576 Normal Normal NA NA NA NA NA NA 0.7621622 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14R_B 14R 2 B Progression PDL1+LY 32-36 2018-02-14 2018-05-07 2018-05-23 growing 82 16 98 35.0 growing well differentiated mammary solid adenocarcinoma 6.16 38.8 50.4 NA NA Pos Neg L 3 4 NA 1 2 NA 1 1 No No yes Yes 14R_B_DN NA NA yes NA 20190213_10_CGDA6432-1of3_S8_R1_001.fastq.gz 20190213_10_CGDA6432-1of3_S8_R1_001_report.tsv Ep_14R_B 20190213_56_CGDA6432-3of3_S7_R1_001.fastq.gz 20190213_56_CGDA6432-3of3_S7_R1_001_report.tsv DN_14R_B 10.204521 11.881851 8.644201 10.405372 8.056755 7.073204 Normal LumA NA NA NA NA NA NA 4.3298969 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14R_D 14R NA D Progression PDL1+LY 32-36 2018-02-14 2018-04-02 2018-05-23 stable 47 51 98 1.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 14R PT D-r+p.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating but not many in general Infiltrating -0.1666667 0.0117970 0.4017020 0.0916170 0.1187684 0.3761156 48.85005 0.3375567 1.0789635 45.27498 2.9379310 5.7567568 0.1134790 0.0197123 0.8034234 1.6428080 0.6796239 0.4136965 15L_B 15L 3 B Progression PDL1+LY 32-36 2018-02-14 2018-04-19 2018-05-04 growing 64 15 79 10.0 growing well differentiated mammary solid adenocarcinoma 45.5 32.7 18.7 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No No 15L_B_CD45 20191030_CD45_15LB_CGDA7427_S29_R1_001.fastq.gz 20191030_CD4515LB_report.tsv yes CD45_15LB NA NA NA 20191030_DN_15LB_CGDA7428_S12_R1_001.fastq.gz NA DN_15LB 7.751602 NA 7.813059 NA 7.924340 NA Normal NA 15L PT-R+P.mrxs NA ? Maybe Yes? NA stroma restricted restricted 3.5000000 0.0111370 0.1847646 0.0390109 0.2710420 0.4940455 38.26745 0.3955776 1.8111846 21.12841 0.3194131 0.3286876 0.0397919 0.1210630 0.5137634 0.9076574 0.4808783 0.5298016 15N_C 15N 2 C Progression PDL1+LY 32-36 2018-02-14 2018-05-24 2018-06-06 growing 99 13 112 30.0 growing well differentiated mammary solid adenocarcinoma 14.8 39.9 44 NA NA Mod Neg B 1 2 NA 1 1 NA 2 2 No yes yes Yes 15N_C_CD45 20190213_34_CGDA6432-2of3_S8_R1_001.fastq.gz 20190213_34_CGDA6432-2of3_S8_R1_001_report.tsv yes CD45_15N_C 20190213_11_CGDA6432-1of3_S9_R1_001.fastq.gz 20190213_11_CGDA6432-1of3_S9_R1_001_report.tsv Ep_15N_C 20190213_57_CGDA6432-3of3_S8_R1_001.fastq.gz 20190213_57_CGDA6432-3of3_S8_R1_001_report.tsv DN_15N_C 7.547977 7.900689 6.751697 7.319210 9.623160 9.621462 Basal Basal NA NA NA NA NA NA 5.7142857 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 15N_C-D 15N NA C-D Progression PDL1+LY 32-36 2018-02-14 2018-05-17 2018-06-06 growing 92 20 112 22.0 growing fibroadenoma 7.25 65.1 26.3 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 15N PT C-D 1.mrxs 4channel_23samples YES Most double labeled SMA:EpCAM is really just SMA Very few CD8. Stroma restricted. Fibroadenoma? restricted 2.6857143 0.0103478 0.2080159 0.0000000 0.2845617 0.4970746 50.23737 2.0409443 2.0409443 24.61477 0.2707581 0.2707581 0.0180375 0.0666186 0.9185654 0.9185654 0.5431117 0.5912608 15N_D 15N NA D Progression PDL1+LY 32-36 2018-02-14 2018-05-03 2018-06-06 stable 78 34 112 3.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 15N PT D 7.mrxs 4channel_23samples YES NA infiltrating Infiltrating -0.2285714 0.0099611 0.3821704 0.0524684 0.1032245 0.4521756 16.37622 0.1782979 0.4342034 37.71556 4.1355932 4.5185185 0.1446354 0.0320095 0.4508831 0.9408380 0.6456409 0.6862402 15R_D 15R 3 D Progression PDL1+LY 32-36 2018-02-14 2018-05-03 2018-06-06 growing 78 34 112 17.0 growing well differentiated mammary solid adenocarcinoma 27.4 42 29.8 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No 15R_D_CD45 20191030_CD45_15RD_CGDA7427_S30_R1_001.fastq.gz 20191030_CD4515RD_report.tsv yes CD45_15RD NA NA NA NA NA NA NA NA NA NA NA NA NA NA 15R PT D-R+P.mrxs NA Yes, No SMA cells: is this expected? Its weird but true. Staining probably did work as antibody was prepared in a master mix for all samples and all antibodies. NA stroma restricted restricted 3.5000000 0.0323480 0.1453377 0.0000000 0.0000000 0.8223143 94.84958 NA NA NA NA NA 0.0363265 NA NA NA 0.4108967 NA 16L_A 16L NA A Progression PDL1+LY 32-36 2018-02-14 2018-07-24 2018-07-27 no data 160 3 163 5.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 16L Tumor A-R+P.mrxs 2+3channel_57samples Yes Most double labeled SMA:EpCAM is really just SMA Mostly stroma, few infiltrated Infiltrating NA 0.0166398 0.4115991 0.0000000 0.3636697 0.2080914 31.42735 1.6330629 1.6330629 19.24442 0.6585839 0.6585839 0.0553879 0.0841015 1.0170047 1.0170047 0.4230694 0.4159955 16L_C 16L 2 C Progression PDL1+LY 32-36 2018-02-14 2018-06-26 2018-07-27 stable 132 31 163 7.0 stable well differentiated mammary solid adenocarcinoma 61.7 23.1 13.7 NA NA Mod Neg L 3 3 NA 2 2 NA 1 2 No No yes Yes 16L_C_DN NA NA yes NA 20190213_12_CGDA6432-1of3_S10_R1_001.fastq.gz 20190213_12_CGDA6432-1of3_S10_R1_001_report.tsv Ep_16L_C 20190213_58_CGDA6432-3of3_S9_R1_001.fastq.gz 20190213_58_CGDA6432-3of3_S9_R1_001_report.tsv DN_16L_C 10.091019 10.755017 9.538591 9.806592 8.394353 8.999201 Basal LumB 16L Tumor C 8.mrxs 4channel_23samples YES Most double labeled SMA:EpCAM is really just EpCAM Infiltrating but not many Infiltrating 0.6475410 0.0469600 0.4689090 0.0000000 0.2466732 0.2374578 68.89330 1.0930529 1.0930529 63.02833 2.0740741 2.0740741 0.0580094 0.0279688 1.0344293 1.0344293 0.0707065 0.0683532 16L_D 16L 3 D Progression PDL1+LY 32-36 2018-02-14 2018-05-15 2018-07-27 stable 90 73 163 24.0 stable well differentiated mammary solid adenocarcinoma 40.5 27.1 30.7 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No Yes No No 16L_D_CD45 20191030_CD45_16LD_CGDA7427_S31_R1_001.fastq.gz 20191030_CD45_16LD_report.tsv yes CD45_16LD NA NA NA 20191030_DN_16LD_CGDA7428_S13_R1_001.fastq.gz NA DN_16LD 8.821280 NA 7.921996 NA 8.357876 NA LumB NA 16L Tumor D-P+R.mrxs 2+3channel_57samples Yes Most double labeled SMA:EpCAM is really just SMA Infiltrating Infiltrating 1.9151786 0.0316745 0.3473600 0.0000000 0.4037981 0.2171674 41.66245 2.0765619 2.0765619 20.06319 0.5758169 0.5758169 0.0535965 0.0930790 0.9892534 0.9892534 0.6194852 0.6262148 16N_D 16N NA D Progression PDL1 32-36 2018-02-14 2018-06-21 2018-10-04 stable 127 105 232 25.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 16N D 2.mrxs 4channel_23samples YES NA infiltrating but not many Infiltrating 1.0745763 0.0739084 0.3661758 0.1285033 0.3156246 0.1157879 30.67905 0.4503144 1.1615878 26.41131 1.0666667 1.1207037 0.0490696 0.0437846 0.4746967 0.9025683 0.5277804 0.5847540 16R_C 16R NA C Progression PDL1 32-36 2018-02-14 2018-06-21 2018-08-16 growing 127 56 183 25.0 growing well differentiated mammary solid adenocarcinoma 9.83 47.7 36.3 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 16R TC-R+P.mrxs 2+3channel_57samples Yes Most double labeled SMA:EpCAM is really just EpCAM Infiltrating Infiltrating 2.4571429 0.1170018 0.3159351 0.0000000 0.1917937 0.3752694 221.63698 3.2526256 3.2526256 68.14094 3.5719844 3.5719844 0.0608229 0.0170278 0.6129173 0.6129173 0.0906911 0.1479662 16R_D 16R 3 D Progression PDL1 32-36 2018-02-14 2018-06-21 2018-08-16 stable 127 56 183 3.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA 1 NA NA 1 NA NA 1 NA No No No No 16R_D_DN NA NA yes NA NA NA NA 20191030_DN_16RD_CGDA7428_S14_R1_001.fastq.gz NA DN_16RD 7.072540 NA 6.593111 NA 6.844678 NA Normal NA 16R TD-R+P.mrxs 2+3channel_57samples Yes Most double labeled SMA:EpCAM is really just SMA Infiltrating Infiltrating -0.1027397 0.0286946 0.1882468 0.0000000 0.4877710 0.2952876 82.67478 4.7255313 4.7255313 17.49534 0.2398635 0.2398635 0.0417292 0.1739707 0.7958084 0.7958084 0.4223919 0.5307709 17N_A 17N 3 A Progression Vehicle 32-36 2018-02-14 2018-07-05 2018-08-02 growing 141 28 169 28.0 growing mucinous carcinoma 20.4 29.3 50 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No No 17N_A_CD45 20191030_CD45_17NA_CGDA7427_S32_R1_001.fastq.gz 20191030_CD4517NA_report.tsv yes CD45_17NA NA NA NA 20191030_DN_17NA_CGDA7428_S15_R1_001.fastq.gz NA DN_17NA 8.674888 NA 8.698166 NA 8.616739 NA Her2 NA 17N Tumor A-R+P.mrxs 2+3channel_57samples Yes Most double labeled are just SMA stroma restricted restricted 6.8000000 0.0472524 0.1755227 0.0000000 0.4965940 0.2806309 84.19668 3.6028136 3.6028136 23.36970 0.1795486 0.1795486 0.0130866 0.0728862 0.9607334 0.9607334 0.3762539 0.3916320 17N_B 17N NA B Progression Vehicle 32-36 2018-02-14 2018-05-31 2018-08-02 stable 106 63 169 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 17N_D 17N 2 D Progression Vehicle 32-36 2018-02-14 2018-08-02 2018-08-02 stable 169 0 169 4.0 stable well differentiated mammary solid adenocarcinoma 6.88 46.3 44.8 NA NA Mod Neg L 1 2 NA 1 2 NA 1 1 No No Yes Yes 17N_D_DN NA NA yes NA 20190213_13_CGDA6432-1of3_S11_R1_001.fastq.gz 20190213_13_CGDA6432-1of3_S11_R1_001_report.tsv Ep_17N_D 20190213_59_CGDA6432-3of3_S10_R1_001.fastq.gz 20190213_59_CGDA6432-3of3_S10_R1_001_report.tsv DN_17N_D 7.591882 9.226168 7.962199 9.216738 7.804626 8.113343 Normal LumB 17N Tumor D-R+P.mrxs 2+3channel_57samples Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Tumor infiltrating Infiltrating -0.3846154 0.0777472 0.3783436 0.0021022 0.0201337 0.5216733 20.41543 0.0608049 0.2082690 98.02435 58.5897436 63.4722222 0.1243131 0.0019585 0.9749741 1.6472614 0.8238693 0.5001448 17R_B 17R NA B Progression Vehicle 32-36 2018-02-14 2018-05-31 2018-06-21 growing 106 21 127 35.0 growing well differentiated mammary solid adenocarcinoma 4.35 18.4 67.1 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 17R tumor B 4 HPC18-1274.mrxs 4channel_23samples YES NA infiltrating Infiltrating 8.2142857 0.0420434 0.6431048 0.1132436 0.0512089 0.1503993 16.71597 0.0840295 0.1541792 108.41913 14.2179342 27.9598214 0.1334114 0.0047715 0.7859833 1.7123368 0.5027943 0.2936305 18LN2 NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 18N 2.mrxs 4channel_23samples YES Normal? FIBROADENOMA? MOST DOUBLE LABELED IS EPCAM NA NA NA 0.0053220 0.3526985 0.0000000 0.3067915 0.3351880 21.58353 1.1172725 1.1172725 19.31805 1.5517241 1.5517241 0.2097902 0.1351981 0.9501550 0.9501550 0.4201287 0.4421686 18R4 NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 18R 4.mrxs 4channel_23samples Yes Normal? Fibroadenoma? NA NA NA 0.0115088 0.1597988 0.1223603 0.3364584 0.3698738 41.14848 0.5683999 2.2633170 18.18061 0.3462604 0.3834356 0.0563825 0.1470456 0.5118961 0.9717001 0.4683674 0.4820081 1L_A 1L NA A Progression PDL1+LY 32-36 2018-02-14 2018-08-02 2018-11-29 stable 169 119 288 17.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LA-R+P.mrxs NA Not done. No image found NA NA NA 0.9440338 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1N_A 1N NA A Progression PDL1+LY 32-36 2018-02-14 2018-09-20 2018-10-25 stable 218 35 253 10.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1.0571429 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1N_D 1N NA D Progression PDL1+LY 32-36 2018-02-14 2018-08-02 2018-10-25 growing 169 84 253 29.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1.6774892 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1R_B 1R NA B Progression PDL1+LY 32-36 2018-02-14 2018-08-02 2018-10-13 stable 169 72 241 15.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0.7597403 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 2N_ 2N 2 D Progression Vehicle 32-36 2018-02-14 2018-04-02 2018-05-02 growing 47 30 77 47.0 growing well differentiated mammary solid adenocarcinoma 21.8 61.6 16.6 NA NA Not done Not done B 2 2 NA 1 2 NA 2 2 No yes yes Yes 2N__CD45 20190213_37_CGDA6432-2of3_S10_R1_001.fastq.gz 20190213_37_CGDA6432-2of3_S10_R1_001_report.tsv yes CD45_2N 20190213_14_CGDA6432-1of3_S12_R1_001.fastq.gz 20190213_14_CGDA6432-1of3_S12_R1_001_report.tsv Ep_2N 20190213_60_CGDA6432-3of3_S11_R1_001.fastq.gz 20190213_60_CGDA6432-3of3_S11_R1_001_report.tsv DN_2N 8.066863 9.152129 7.996903 9.590791 9.632986 9.256976 Basal Her2 2N PT-R+P.mrxs 4 parts: pyra, Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Stroma restricted restricted 11.7000000 0.0302046 0.3111043 0.0913614 0.1954502 0.3718795 50.57317 0.3958040 1.3934420 36.29371 1.0607350 1.2720703 0.0808353 0.0635462 0.6639386 1.1954598 0.4691640 0.3924548 2R_A 2R 3 A Progression Vehicle 32-36 2018-02-14 2018-03-29 2018-05-09 growing 43 41 84 20.0 growing well differentiated mammary solid adenocarcinoma 70.7 21.9 6.23 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No No 2R_A_CD45 20191030_CD45_2RA_CGDA7427_S33_R1_001.fastq.gz 20191030_CD452RA_report.tsv yes CD45_2RA NA NA NA 20191030_DN_2RA_CGDA7428_S16_R1_001.fastq.gz NA DN_2RA 8.797113 NA 8.326194 NA 7.149784 NA LumA NA 2R A Tumor-G-R+P.mrxs pyramid Yes Suspicious about SMA-EpCAM switch. Underestimation of whats labeled as “EpCAM” Mostly stroma restricted restricted 3.5428571 0.0792751 0.3913913 0.0023491 0.0461938 0.4807907 46.05918 0.0711163 0.3568518 129.07088 16.0205128 16.1865285 0.1252656 0.0077389 1.6375694 1.8864816 0.6503756 0.3447559 2R_C 2R 3 C Progression Vehicle 32-36 2018-02-14 2018-03-29 2018-05-09 growing 43 41 84 15.0 growing well differentiated mammary solid adenocarcinoma 73.5 19.2 5.23 NA NA Not done Not done NA 3 NA NA 2 NA NA 2 NA No No No No 2R_C_CD45 20191030_CD45_2RC_CGDA7427_S34_R1_001.fastq.gz 20191030_CD452RC_report.tsv yes CD45_2RC NA NA NA 20191030_DN_2RC_CGDA7428_S17_R1_001.fastq.gz NA DN_2RC 9.942308 NA 8.425529 NA 9.122072 NA Normal NA NA NA NA NA NA NA 15.0000000 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 2R_D 2R 3 D Progression Vehicle 32-36 2018-02-14 2018-03-29 2018-05-09 growing 43 41 84 20.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA 1 NA NA 1 NA NA 2 NA No No No No 2R_D_CD45 20191030_CD45_2RD_CGDA7427_S35_R1_001.fastq.gz 20191030_CD452RD_report.tsv yes CD45_2RD NA NA NA 20191030_DN_2RD_CGDA7428_S18_R1_001.fastq.gz NA DN_2RD 5.350711 NA 5.009788 NA 9.397333 NA LumB NA 2R D Tumor-R+P.mrxs 1 Yes NA stroma restricted restricted 20.0000000 0.0679470 0.2390803 0.1098166 0.1748265 0.4083295 44.01575 0.4204195 1.5995029 27.51839 0.5629272 1.0971787 0.0440127 0.0401144 0.6003194 1.0687599 0.6926679 0.6481043 3L_A 3L 3 A Progression Vehicle 32-36 2018-02-14 2018-05-03 2018-05-09 growing 78 6 84 12.0 growing well differentiated mammary solid adenocarcinoma 12.5 80.9 4.21 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No No 3L_A_CD45 20191030_CD45_3LA_CGDA7427_S36_R1_001.fastq.gz 20191030_CD453LA_report.tsv yes CD45_3LA NA NA NA 20191030_DN_3LA_CGDA7428_S19_R1_001.fastq.gz NA DN_3LA 9.096221 NA 8.344281 NA 7.622097 NA LumB NA 3L A Tumor-R+P.mrxs ROItoobig Yes NA stroma restricted restricted 3.0000000 0.0534346 0.3906121 0.1457996 0.0987689 0.3113848 50.81349 0.2904539 0.7622396 66.66341 4.3657787 14.2508361 0.0498829 0.0035004 0.5568064 1.1134545 0.4487909 0.4030617 3L_D 3L 2 D Progression Vehicle 32-36 2018-02-14 2018-04-05 2018-05-09 growing 50 34 84 30.0 growing fibroadenoma 26.2 69.6 2.55 NA NA Not done Not done NA 1 NA NA 1 NA NA 2 NA No yes No Yes 3L_D_CD45 20190213_38_CGDA6432-2of3_S11_R1_001.fastq.gz 20190213_38_CGDA6432-2of3_S11_R1_001_report.tsv yes CD45_3L_D NA NA NA 20190213_61_CGDA6432-3of3_S12_R1_001.fastq.gz 20190213_61_CGDA6432-3of3_S12_R1_001_report.tsv DN_3L_D 5.440199 NA 9.034759 NA 9.112564 NA LumB NA 3L D Tumor-R+P.mrxs 1 Yes weird. Fibroadenoma? stroma restricted restricted 5.8000000 0.1693800 0.0011329 0.0035403 0.0894314 0.7365153 1469.94759 1.0674643 18.5061923 79.43004 0.0000000 0.0000000 0.0000000 0.0021676 0.0560487 0.0631333 0.0299087 0.4737395 3N_B 3N 2 B Progression Vehicle 32-36 2018-02-14 2018-05-03 2018-06-21 stable 78 49 127 6.0 stable well differentiated mammary solid adenocarcinoma 24.4 44.5 25.3 NA NA Mod Positive B 1 3 NA 1 2 NA 1 1 No yes yes Yes 3N_B_CD45 20190213_39_CGDA6432-2of3_S12_R1_001.fastq.gz 20190213_39_CGDA6432-2of3_S12_R1_001_report.tsv yes CD45_3N_B 20190213_16_CGDA6432-1of3_S13_R1_001.fastq.gz 20190213_16_CGDA6432-1of3_S13_R1_001_report.tsv Ep_3N_B 20190213_62_CGDA6432-3of3_S13_R1_001.fastq.gz 20190213_62_CGDA6432-3of3_S13_R1_001_report.tsv DN_3N_B 6.153223 9.699559 6.446680 9.988743 6.908861 8.314425 Normal LumA 3N Tumor B-R+P.mrxs 1 Yes Most double labeled SMA:EpCAM is really just EpCAM Infiltrating Infiltrating 0.0245902 0.2436148 0.4279583 0.0000000 0.0430856 0.2853413 35.85117 0.5736141 0.5736141 62.50051 32.4685714 32.4685714 0.1089340 0.0033551 1.1898543 1.1898543 0.7272775 0.6112324 3N_D 3N NA D Progression Vehicle 32-36 2018-02-14 2018-05-03 2018-06-21 stable 78 49 127 3.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 3N Tumor D 1.mrxs 4channel_23samples Yes NA Tumor infiltrating Infiltrating -0.1516393 0.0275129 0.4057772 0.1214179 0.1169171 0.3283749 14.88177 0.2404611 0.4350742 34.20513 6.7187500 8.6000000 0.1987061 0.0231054 0.6448255 1.4608243 0.8101682 0.5545966 3R_B 3R 3 B Progression Vehicle 32-36 2018-02-14 2018-04-02 2018-05-09 growing 47 37 84 35.0 growing well differentiated mammary solid adenocarcinoma 29.7 65.2 3.17 NA NA Not done Not done NA 2 NA NA 2 NA NA 1 NA No No No No 3R_B_CD45 20191030_CD45_3RB_CGDA7427_S37_R1_001.fastq.gz 20191030_CD453RB_report.tsv yes CD45_3RB NA NA NA 20191030_DN_3RB_CGDA7428_S20_R1_001.fastq.gz NA DN_3RB 9.076911 NA 10.222521 NA 7.726099 NA LumA NA 3R B.mrxs 4channel_23samples Yes Most double labeled SMA:EpCAM is really just SMA Stroma restricted restricted 7.6857143 0.0271596 0.4290121 0.0000000 0.3780280 0.1658003 45.06497 1.5134520 1.5134520 29.77628 0.8008086 0.8008086 0.0650665 0.0812510 0.8697861 0.8697861 0.4830709 0.5553905 3R_C 3R 2 C Progression Vehicle 32-36 2018-02-14 2018-04-02 2018-05-09 growing 47 37 84 32.0 growing well differentiated mammary solid adenocarcinoma 39.4 40.2 17 NA NA Pos Pos L 2 3 NA 2 2 NA 1 1 No yes yes Yes 3R_C_CD45 20190213_40_CGDA6432-2of3_S13_R1_001.fastq.gz 20190213_40_CGDA6432-2of3_S13_R1_001_report.tsv yes CD45_3R_C 20190213_17_CGDA6432-1of3_S14_R1_001.fastq.gz 20190213_17_CGDA6432-1of3_S14_R1_001_report.tsv Ep_3R_C 20190213_63_CGDA6432-3of3_S14_R1_001.fastq.gz 20190213_63_CGDA6432-3of3_S14_R1_001_report.tsv DN_3R_C 9.008625 10.467371 10.300376 12.200748 6.971775 7.061798 LumA LumA 3R C Tumor-r+p.mrxs 4channel_23samples Yes NA Tumor infiltrating but not many in general Infiltrating 5.5428571 0.0213619 0.3557497 0.1060803 0.1396821 0.3771261 34.19778 0.3536028 0.8841226 38.67991 1.3763636 1.7811765 0.0642778 0.0360873 0.4779858 0.8983180 0.5405923 0.6017828 4L2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4L_2.mrxs 4channel_23samples Yes normal? Fibroadenoma? NA NA NA 0.0107261 0.0949610 0.0413567 0.3647135 0.4882427 61.55198 0.3730199 2.8810690 21.36429 0.4808081 0.5207877 0.0827538 0.1589013 0.5017400 0.9985155 0.5085118 0.5092678 4L_B 4L 3 B Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 35.0 growing well differentiated mammary solid adenocarcinoma 1.64 11.5 81.6 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No 4L_B_CD45 20191030_CD45_4LB_CGDA7427_S38_R1_001.fastq.gz 20191030_CD454LB_report.tsv yes CD45_4LB NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4L Tumor-R+P.mrxs Too large Yes NA Infiltrating Infiltrating 6.8783784 0.0231318 0.2915087 0.0843215 0.1479126 0.4531254 64.74914 0.4531535 2.0830003 31.08456 1.0044357 1.2923272 0.0439035 0.0339724 0.5341282 0.9817225 0.5635765 0.5740691 4N_C 4N 3 C Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 15.0 growing well differentiated mammary solid adenocarcinoma 4.86 41.3 51.2 NA NA Not done Not done NA 1 NA NA 1 NA NA 1 NA No No No No 4N_C_DN NA NA yes NA NA NA NA 20191030_DN_4NC_CGDA7428_S21_R1_001.fastq.gz NA DN_4NC 7.450232 NA 6.897643 NA 6.834431 NA Normal NA 4N T C-R+P.mrxs 4channel_23samples Yes Most double labeled SMA:EpCAM is really just EpCAM stroma restricted and very few restricted 3.0000000 0.0082696 0.6904486 0.0000000 0.1998705 0.1014113 17.41818 0.5857194 0.5857194 29.73810 5.6067416 5.6067416 0.1988048 0.0354582 1.1566551 1.1566551 0.1225326 0.1059371 4N_D 4N NA D Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 20.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4N Tumor D-R+P.mrxs 2+3channel_57samples Yes Most double labeled are just SMA Infiltrated but very few Infiltrating 4.3000000 0.0075226 0.3686144 0.0000000 0.4966413 0.1272217 19.31346 1.4696949 1.4696949 13.14114 0.6537143 0.6537143 0.2808740 0.4296587 0.9496026 0.9496026 0.6621314 0.6972721 4R_B 4R NA B Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 40.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4R Tumor B-R+P.mrxs NA Yes NA stroma restricted and very few restricted 7.8108108 0.0264206 0.2628547 0.1375470 0.2123231 0.3608546 77.05475 0.6163713 3.0155708 25.55229 0.3088124 0.3725370 0.0303672 0.0815145 0.4637185 0.7595255 0.3659895 0.4818660 4R_C 4R NA C Progression Vehicle 32-36 2018-02-14 2018-04-09 2018-05-21 growing 54 42 96 15.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4.0000000 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5L_A 5L NA A Progression Vehicle 32-36 2018-02-14 2018-10-03 2018-10-24 no data 231 21 252 6.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA SLA-R+P.pyramid.ome.tif 2+3channel_57samples Yes Most double labeled are just SMA. Use bottom half Infiltrating Infiltrating 0.5000000 0.0499837 0.3211756 0.0000000 0.4594575 0.1693832 88.34088 5.1585539 5.1585539 17.12513 0.3129039 0.3129039 0.0410479 0.1311839 0.7586228 0.7586228 0.3676234 0.4845931 5L_B 5L NA B Progression Vehicle 32-36 2018-02-14 2018-10-17 2018-10-24 no data 245 7 252 4.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA SLB-R+P.pyramid.ome.tif 2+3channel_57samples Yes, No SMA cells: is this expected? Its weird but true. Staining probably did work as antibody was prepared in a master mix for all samples and all antibodies. Use bottom half Stroma restricted restricted 4.0000000 0.0264844 0.4379465 0.0000000 0.0000000 0.5355691 49.82563 NA NA NA NA NA 0.0764733 NA NA NA 0.5132992 NA 5L_C 5L NA C Progression Vehicle 32-36 2018-02-14 2018-10-03 2018-10-24 growing 231 21 252 22.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA SLC-R+P.pyramid.ome.tif 2+3channel_57samples Yes Most double labeled are just SMA. There is potentially bleached area on top third. Best to ignore stroma restricted restricted 3.5000000 0.0534633 0.2774943 0.0000000 0.4679598 0.2010826 69.06072 2.9381168 2.9381168 23.50510 0.2242609 0.2242609 0.0236657 0.1055275 0.5228379 0.5228379 0.2228294 0.4261921 5L_D 5L NA D Progression Vehicle 32-36 2018-02-14 2018-06-06 2018-10-24 stable 112 140 252 15.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA SLD 8.mrxs 4channel_23samples: currently converting Yes Bad fragmentation and classification. Avoid if possible stroma restricted restricted 0.9299769 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5N_A 5N 3 A Progression Vehicle 32-36 2018-02-14 2018-06-07 2018-06-29 growing 113 22 135 26.0 growing mucinous carcinoma 31 24.1 42.2 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No 5N_A_CD45 20191030_CD45_5NA_CGDA7427_S39_R1_001.fastq.gz 20191030_CD455NA_report.tsv yes CD45_5NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5N-A Tumor 4.mrxs 4channel_23samples Yes Most double labeled are just Epcam stroma restricted restricted 5.4285714 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5R_B 5R 3 B Progression Vehicle 32-36 2018-02-14 2018-06-07 2018-06-29 growing 113 22 135 35.0 growing well differentiated mammary solid adenocarcinoma 8.93 20.2 65.3 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No 5R_B_CD45 20191030_CD45_5RB_CGDA7427_S40_R1_001.fastq.gz 20191030_CD455RB_report.tsv yes CD45_5RB NA NA NA NA NA NA NA NA NA NA NA NA NA NA 5R-B tumor 6 HPC18-1644.mrxs 4channel_23samples Yes Most double labeled SMA:EpCAM is really just EpCAM stroma restricted restricted 10.3571429 0.0606622 0.3335444 0.0000000 0.4396765 0.1661169 42.71834 1.8873247 1.8873247 22.63434 0.2646211 0.2646211 0.0250896 0.0948132 0.8555603 0.8555603 0.4794061 0.5603418 6L_DL 6L NA DL Progression Vehicle 32-36 2018-02-14 2018-03-29 2018-06-29 stable 43 92 135 0.0 stable NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA -0.2374720 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 6L_DU 6L NA DU Progression LY 32-36 2018-02-14 2018-03-29 2018-06-29 growing 43 92 135 32.0 growing well differentiated mammary solid adenocarcinoma 12.3 34.1 46.6 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 6L-D Tumor-R+P.mrxs NA Yes? Maybe? Most double labeled SMA:EpCAM is really just EpCAM stroma restricted restricted 2.1974522 0.0564756 0.2536569 0.0000000 0.6390098 0.0508577 113.21745 5.2279784 5.2279784 21.65607 0.1039889 0.1039889 0.0228854 0.2200758 0.5244385 0.5244385 0.2875550 0.5483102 6N_D 6N 2 D Progression LY 32-36 2018-02-14 2018-04-02 2018-04-10 growing 47 8 55 40.0 growing well differentiated mammary solid adenocarcinoma 6.85 41 54.1 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No yes No No 6N_D_CD45 20190213_41_CGDA6432-2of3_S14_R1_001.fastq.gz 20190213_41_CGDA6432-2of3_S14_R1_001_report.tsv yes CD45_6N_D NA NA NA NA NA NA NA NA NA NA NA NA NA NA 6N tumor 4 HPC18-0751.mrxs 4channel_23samples Done. Raw matrix saved NA stroma restricted NA 30.0000000 0.0993318 0.4011496 0.0890823 0.2404363 0.1700000 121.66730 0.4694938 2.8771741 42.28708 1.4519153 1.5049422 0.0355995 0.0236551 0.4830465 0.9118512 0.3459035 0.3793420 6R_B 6R 2 B Progression LY 32-36 2018-02-14 2018-03-29 2018-05-04 stable 43 36 79 18.0 growing well differentiated mammary solid adenocarcinoma 61.1 31.1 6.12 NA NA Pos Pos B 3 3 NA 2 2 NA 1 1 No No yes Yes 6R_B_DN NA NA yes NA 20190213_20_CGDA6432-1of3_S15_R1_001.fastq.gz 20190213_20_CGDA6432-1of3_S15_R1_001_report.tsv Ep_6R_B 20190213_66_CGDA6432-3of3_S15_R1_001.fastq.gz 20190213_66_CGDA6432-3of3_S15_R1_001_report.tsv DN_6R_B 10.169492 10.344437 8.781685 8.969722 7.522004 6.177675 LumA LumA 6R PT B-G.mrxs extract error? Yes, did this matrix disappear? Resaved Most double labeled are just Epcam inflitrating Infiltrating 2.8000000 0.1333593 0.1493153 0.0000000 0.4420708 0.2752545 91.50034 5.5053405 5.5053405 16.62029 0.1220465 0.1220465 0.0299516 0.2454114 0.7830649 0.7830649 0.6100782 0.7790902 6R_C 6R 2 C Progression LY 32-36 2018-02-14 2018-04-19 2018-05-04 growing 64 15 79 40.0 growing well differentiated mammary solid adenocarcinoma 27.2 63.7 11.9 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No yes No No 6R_C_CD45 20190213_42_CGDA6432-2of3_S15_R1_001.fastq.gz 20190213_42_CGDA6432-2of3_S15_R1_001_report.tsv yes CD45_6R_C NA NA NA NA NA NA NA NA NA NA NA NA NA NA 6R PT C 5.mrxs 4channel_23samples YES NA Stroma restricted restricted 8.2142857 0.0864989 0.2319101 0.1109560 0.3706485 0.1999864 72.49339 0.6029672 2.4881180 29.13583 0.2374418 0.2434573 0.0258498 0.1061780 0.4298154 0.7701881 0.5206863 0.6760508 6R_D 6R 3 D Progression LY 32-36 2018-02-14 2018-04-20 2018-05-04 stable 65 14 79 6.0 stable well differentiated mammary solid adenocarcinoma 80.8 11.1 6.61 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No Yes No Yes 6R_D_CD45 20191030_CD45_6RD_CGDA7427_S41_R1_001.fastq.gz 20191030_CD456RD_report.tsv yes CD45_6RD NA NA NA 20191030_DN_6RD_CGDA7428_S22_R1_001.fastq.gz NA DN_6RD 8.417325 NA 7.236626 NA 6.312630 NA Normal NA NA NA NA NA NA NA 1.2857143 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7L_C 7L NA C Progression LY 32-36 2018-02-14 2018-06-14 2018-10-10 growing 120 118 238 40.0 growing fibroadenoma 4.66 72.3 20.7 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 4.7750000 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7L_D 7L NA D Progression LY 32-36 2018-02-14 2018-04-05 2018-10-10 stable 50 188 238 1.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA -0.1235236 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N_A 7N 2 A Progression LY 32-36 2018-02-14 2018-06-14 2018-07-27 stable 120 43 163 30.0 growing well differentiated mammary solid adenocarcinoma 23.7 33.2 40 NA NA Mod Neg B NA 3 NA NA 2 NA NA 1 No yes yes No 7N_A_CD45 20190213_44_CGDA6432-2of3_S16_R1_001.fastq.gz 20190213_44_CGDA6432-2of3_S16_R1_001_report.tsv yes CD45_7N_A 20190213_21_CGDA6432-1of3_S16_R1_001.fastq.gz 20190213_21_CGDA6432-1of3_S16_R1_001_report.tsv Ep_7N_A NA NA NA NA 9.661717 NA 10.411145 NA 7.660148 NA Her2 NA NA NA NA NA NA 2.3555556 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N_B 7N 3 B Progression LY 32-36 2018-02-14 2018-06-14 2018-07-27 growing 120 43 163 31.0 growing well differentiated mammary solid adenocarcinoma 30.4 49.4 14.9 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No Yes No No 7N_B_CD45 20191030_CD45_7NB_CGDA7427_S42_R1_001.fastq.gz 20191030_CD457NB_report.tsv yes CD45_7NB NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N tumor B-P+R.mrxs ROItoobig Yes Most double labeled are SMA stroma restricted restricted 2.8878505 0.0197097 0.2490162 0.0000000 0.3294001 0.4018740 84.92436 3.6566527 3.6566527 23.22462 0.1224769 0.1224769 0.0107935 0.0881271 0.5880665 0.5880665 0.2129967 0.3621983 7N_C 7N NA C Progression LY 32-36 2018-02-14 2018-06-14 2018-07-27 growing 120 43 163 40.0 growing well differentiated mammary solid adenocarcinoma 13.2 40 43.5 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N tumor C-R+P.mrxs NA Yes Most double labeled are SMA stroma restricted restricted 3.4444444 0.0463236 0.1346398 0.0000000 0.7110174 0.1080192 92.31737 4.9228872 4.9228872 18.75269 0.0537130 0.0537130 0.0072339 0.1346774 0.6417327 0.6417327 0.2326071 0.3624673 7N_D 7N NA D Progression LY 32-36 2018-02-14 2018-05-03 2018-07-27 stable 78 85 163 0.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7N Tumor D-R+P.mrxs NA QC fail Poor fragmentation. No matrix. Fibroadenoma? NA NA -0.4041667 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7R_A 7R NA A Progression LY 32-36 2018-02-14 2018-09-06 2018-10-04 stable 204 28 232 8.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7RA 1.mrxs 4channel_23samples YES NA Stroma restricted. restricted 1.1153846 0.0317495 0.2214839 0.1816895 0.3343786 0.2306985 39.38134 0.6286412 2.2497090 17.50508 0.2502672 0.2841323 0.0233445 0.0821607 0.4579687 0.8736315 0.4487517 0.5136625 7R_B 7R NA B Progression LY 32-36 2018-02-14 2018-09-06 2018-10-04 growing 204 28 232 20.0 growing well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7RB-R+P.mrxs NA Yes NA No leukocytes NA 3.9615385 0.0166350 0.1950950 0.5054210 0.1375849 0.1452641 43.57347 0.9030164 1.5733647 27.69445 0.0894722 0.7731707 0.0130378 0.0168627 0.5098294 1.1129001 0.7558650 0.6791850 7R_D 7R NA D Progression LY 32-36 2018-02-14 2018-04-26 2018-10-04 stable 71 161 232 20.0 stable well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 7RD-R+P.mrxs NA Yes Most double labeled SMA:EpCAM is really just SMA Infiltrating Infiltrating 0.9966997 0.0323655 0.2446566 0.0000000 0.5631544 0.1598235 50.83112 3.5481404 3.5481404 14.32613 0.2462187 0.2462187 0.0444639 0.1805868 0.7886489 0.7886489 0.4171900 0.5289933 8L_D 8L 2 D Progression LY 32-36 2018-02-14 2018-05-03 2018-06-21 stable 78 49 127 6.0 stable well differentiated mammary solid adenocarcinoma 34.6 43.4 16.5 NA NA Pos Pos B NA 3 NA NA 2 NA NA 1 No yes yes No 8L_D_CD45 20190213_45_CGDA6432-2of3_S17_R1_001.fastq.gz 20190213_45_CGDA6432-2of3_S17_R1_001_report.tsv yes CD45_8L_D 20190213_22_CGDA6432-1of3_S17_R1_001.fastq.gz 20190213_22_CGDA6432-1of3_S17_R1_001_report.tsv Ep_8L_D NA NA NA NA 10.122925 NA 9.544170 NA 3.153971 NA LumA 8L Tumor D-R+P.mrxs extract error? Yes USE bottom half Infiltrating Infiltrating 0.2418033 0.0538574 0.5599011 0.0020168 0.0043954 0.3798293 17.23622 0.0274629 0.0602517 286.07024 749.5000000 749.5000000 0.1864892 0.0002488 1.4730487 2.9839286 0.7792160 0.2611376 8R_CL 8R 3 CL Progression LY 32-36 2018-02-14 2018-06-20 2018-06-21 growing 126 1 127 12.0 growing well differentiated mammary solid adenocarcinoma 31.8 32.3 29.8 NA NA Not done Not done NA 1 NA NA 1 NA NA 1 NA No Yes No Yes 8R_CL_CD45 20191030_CD45_8RCL_CGDA7427_S43_R1_001.fastq.gz 20191030_CD458RCL_report.tsv yes CD45_8RCL NA NA NA 20191030_DN_8RCL_CGDA7428_S23_R1_001.fastq.gz NA DN_8RCL 7.489866 NA 6.690138 NA 7.658753 NA Normal NA 8R Tumor CL-1 5.mrxs 4channel_23samples YES Most double labeled SMA:EpCAM is really just SMA stroma restricted restricted 12.0000000 0.0161679 0.5067175 0.0000000 0.2719489 0.2051657 15.61440 0.4269370 0.4269370 36.57309 1.7398649 1.7398649 0.1124700 0.0646429 1.3216443 1.3216443 0.8006283 0.6057820 8R_CU 8R 2 CU Progression LY 32-36 2018-02-14 2018-05-14 2018-06-21 growing 89 38 127 27.0 growing well differentiated mammary solid adenocarcinoma 9.79 29.7 55.7 NA NA Pos Pos B 2 2 NA 1 1 NA 2 2 No yes yes Yes 8R_CU_CD45 20190213_46_CGDA6432-2of3_S18_R1_001.fastq.gz 20190213_46_CGDA6432-2of3_S18_R1_001_report.tsv yes CD45_8R_CU 20190213_23_CGDA6432-1of3_S18_R1_001.fastq.gz 20190213_23_CGDA6432-1of3_S18_R1_001_report.tsv Ep_8R_CU 20190213_69_CGDA6432-3of3_S16_R1_001.fastq.gz 20190213_69_CGDA6432-3of3_S16_R1_001_report.tsv DN_8R_CU 8.636364 9.218367 7.482100 8.499153 9.396025 9.515202 Basal Basal 8R Tumor CU-R+P.mrxs ROItoobig Yes Most double labeled SMA:EpCAM is really just SMA stroma restricted restricted 5.5142857 0.0285043 0.2510430 0.0000000 0.5074442 0.2130085 57.96393 2.3659458 2.3659458 24.49926 0.3686127 0.3686127 0.0355496 0.0964415 1.0299044 1.0299044 0.5045609 0.4899104 9N NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 9N-R+P.pyramid.ome.tif 2+3channel_57samples Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples infiltrating Infiltrating NA 0.0281318 0.0527279 0.2718778 0.3041077 0.3431548 122.14151 1.6230379 4.6141243 26.47122 0.0257210 0.0633397 0.0045181 0.0713308 0.3342252 0.6758403 0.2248600 0.3327118 9R NA NA NA NA NA NA NA NA NA no data NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 9R-R+P.pyramid.ome.tif 2+3channel_57samples Yes Normal? Fibroadenoma? Poor fragmentation. Best to ignore samples stroma NA NA 0.0264824 0.1126289 0.0427425 0.0579105 0.7602357 116.40815 0.6781596 1.8294927 63.62865 2.5185185 3.6266667 0.0790009 0.0217833 0.4442082 0.7932739 0.4431065 0.5585794 9L_A 9L 3 A Progression PDL1+LY 32-36 2018-02-14 2018-08-29 2018-10-10 growing 196 42 238 45.0 growing well differentiated mammary solid adenocarcinoma 13 21 61.1 NA NA Not done Not done NA 2 NA NA 1 NA NA 1 NA No No No Yes 9L_A_DN NA NA yes NA NA NA NA 20191030_DN_9LA_CGDA7428_S24_R1_001.fastq.gz NA DN_9LA 8.216490 NA 8.028715 NA 8.016124 NA Basal NA NA NA NA NA NA NA 5.8504673 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 9L_B 9L 3 B Progression PDL1+LY 32-36 2018-02-14 2018-08-15 2018-10-10 growing 182 56 238 35.0 growing well differentiated mammary solid adenocarcinoma 15.8 15.7 57.4 NA NA Not done Not done NA NA NA NA NA NA NA NA NA No Yes No No 9L_B_CD45 20191030_CD45_9LB_CGDA7427_S44_R1_001.fastq.gz 20191030_CD45_9LB_CGDA7427_S44_R1_001_report.tsv yes CD45_9LB NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 3.2597403 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C1R_ C1R NA NA Prevention Vehicle 32-36 2017-05-26 NA NA no data NA NA NA 6.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C1R-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2N_ C2N 1 NA Prevention Vehicle 32-36 2017-05-26 NA NA no data NA NA NA 19.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 1 C2N-tumor.final.bam Yes Yes No C2N__CD45 20180119_C2N_Tumor_CD45plus_LD5110-5of6_S16_R1_001.fastq.gz 20180119_C2N_Tumor_CD45plus_LD5110-5of6_S16_R1_001_report.tsv yes C2N_Tumor_CD45plus 20180119_C2N_Tumor_Epcamplus_LD5110-5of6_S4_R1_001.fastq.gz 20180119_C2N_Tumor_Epcamplus_LD5110-5of6_S4_R1_001_report.tsv C2N_Tumor_Epcamplus NA NA NA NA 7.043804 NA 6.648735 NA 6.648735 NA Normal NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2R_ C2R 1 NA Prevention Vehicle 32-36 2017-05-26 NA NA no data NA NA NA 21.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 1 No Yes Yes No C2R__CD45 20180119_C2R_Tumor_CD45plus_LD5110-5of6_S17_R1_001.fastq.gz 20180119_C2R_Tumor_CD45plus_LD5110-5of6_S17_R1_001_report.tsv yes C2R_Tumor_CD45plus 20180119_C2R_Tumor_Epcamplus_LD5110-5of6_S5_R1_001.fastq.gz 20180119_C2R_Tumor_Epcamplus_LD5110-5of6_S5_R1_001_report.tsv C2R_Tumor_Epcamplus NA NA NA NA 7.541335 NA 7.367312 NA 5.727280 NA Normal NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2R1_ C2R1 NA NA Prevention Vehicle 32-36 2017-05-26 NA NA no data NA NA NA 15.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C2R1-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2R2_ C2R2 NA NA Prevention Vehicle 32-36 2017-05-26 NA NA no data NA NA NA 7.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C2R2-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C2R3_ C2R3 NA NA Prevention Vehicle 32-36 2017-05-26 NA NA no data NA NA NA 3.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C2R3-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C4P_ C4P NA NA Prevention Vehicle 32-36 2017-05-26 NA NA no data NA NA NA 25.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA C4P-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA C5R_ C5R 1 NA Prevention Vehicle 32-36 2017-05-26 NA NA no data NA NA NA 9.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 2 NA NA 1 NA NA 1 No Yes Yes No C5R__CD45 20180119_C5R_Tumor_CD45plus_LD5110-5of6_S18_R1_001.fastq.gz 20180119_C5R_Tumor_CD45plus_LD5110-5of6_S18_R1_001_report.tsv yes C5R_Tumor_CD45plus 20180119_C5R_Tumor_Epcamplus_LD5110-5of6_S6_R1_001.fastq.gz 20180119_C5R_Tumor_Epcamplus_LD5110-5of6_S6_R1_001_report.tsv C5R_Tumor_Epcamplus NA NA NA NA 8.606440 NA 8.355635 NA 8.470766 NA LumA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Control1_ Control1 NA NA Characterisation Untreated 49 2016-10-11 NA 2017-01-07 no data NA NA NA NA NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Control2_ Control2 NA NA Characterisation Untreated 49 2016-10-11 NA 2017-01-10 no data NA NA NA NA NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Control3_ Control3 NA NA Characterisation Untreated 35 2017-01-06 NA NA no data NA NA NA NA NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Control4_ Control4 1 NA Characterisation Untreated 35 2017-01-06 NA NA no data NA NA NA NA NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA control4-liver.final.bam Yes Yes No control__Ep NA NA yes Mammarygland_leukocyte_control 20170125_Control4_Mammarygland__EpCAM_CGDA5146_S16_R1_001.fastq.gz NA Mammarygland_epithelial_control NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU1_LL NMU1 3 LL Characterisation Vehicle 49 2016-10-11 NA 2017-01-07 no data NA NA 88 10.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU1-tumor.final.bam No Yes No NMU1_LL_Ep NA NA yes NA 20191030_Ep_NMU1_CGDA7428_S1_R1_001.fastq.gz NA Ep_NMU1 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU10_LL NMU10 1 LL Characterisation Vehicle 35 2017-01-06 NA 2017-03-08 no data NA NA 61 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 2 NA NA 1 NA NA 2 No Yes Yes No NMU10_LL_Ep 20170125_NMU10_Tumor_LL_CD45_CGDA5146_S2_R1_001.fastq.gz 20170125_NMU10_Tumor_LL_CD45_CGDA5146_S2_R1_001_report.tsv yes Tumor_leukocyte_NMU10_LL 20170125_NMU10_Tumor_LL_EpCAM_CGDA5146_S10_R1_001.fastq.gz NA Tumor_epithelial_NMU10_LL NA NA NA NA 8.493266 NA 7.983543 NA 9.754247 NA LumB NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU11_LA NMU11 NA LA Characterisation Vehicle 49 2016-10-11 NA 2017-04-26 no data NA NA 197 10.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU12_LA NMU12 1 LA Characterisation Vehicle 35 2017-01-06 NA 2017-04-26 no data NA NA 110 12.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 2 NA NA 1 NA NA 2 NMU12-tumor-LA.final.bam Yes Yes No NMU12_LA_Ep 20170125_NMU12_Tumor_LA_CD45_CGDA5146_S3_R1_001.fastq.gz 20170125_NMU12_Tumor_LA_CD45_CGDA5146_S3_R1_001_report.tsv yes Tumor_leukocyte_NMU12_LA 20170125_NMU12_Tumor_LA_EpCAM_CGDA5146_S11_R1_001.fastq.gz NA Tumor_epithelial_NMU12_LA NA NA NA NA 8.811266 NA 9.083968 NA 9.537113 NA Her2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU12_RL NMU12 3 RL Characterisation Vehicle 35 2017-01-06 NA 2017-03-08 no data NA NA 61 6.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 3 NA NA 2 NA NA 2 NMU12-tumor-RL.final.bam No Yes No NMU12_RL_Ep NA NA yes NA 20191030_Ep_NMU12RL_CGDA7428_S2_R1_001.fastq.gz NA Ep_NMU12RL NA NA NA NA 9.963973 NA 9.911103 NA 9.937780 NA Her2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_LAL NMU13 NA LAL Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 8.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU13-tumor-LAL.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_LAU NMU13 1 LAU Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 14.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 1 No Yes Yes No NMU13_LAU_Ep 20170125_NMU13_Tumor_LAU_CD45_CGDA5146_S5_R1_001.fastq.gz 20170125_NMU13_Tumor_LAU_CD45_CGDA5146_S5_R1_001_report.tsv yes Tumor_leukocyte_NMU13_LAU 20170125_NMU13_Tumor_LAU_EpCAM_CGDA5146_S13_R1_001.fastq.gz NA Tumor_epithelial_NMU13_LAU NA NA NA NA 3.153971 NA 10.644107 NA 4.569700 NA Her2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_LLL NMU13 NA LLL Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 5.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_LLU NMU13 1 LLU Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 2 No Yes Yes No NMU13_LLU_Ep 20170125_NMU13_Tumor_LLU_CD45_CGDA5146_S4_R1_001.fastq.gz 20170125_NMU13_Tumor_LLU_CD45_CGDA5146_S4_R1_001_report.tsv yes Tumor_leukocyte_NMU13_LLU 20170125_NMU13_Tumor_LLU_EpCAM_CGDA5146_S12_R1_001.fastq.gz NA Tumor_epithelial_NMU13_LLU NA NA NA NA 8.086132 NA 8.643148 NA 9.408074 NA Basal NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_RAL NMU13 NA RAL Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 20.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_RAU NMU13 1 RAU Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 8.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU13-tumor-RAU.final.bam Yes Yes No NMU13_RAU_Ep 20170125_NMU13_Tumor_RAU_CD45_CGDA5146_S6_R1_001.fastq.gz 20170125_NMU13_Tumor_RAU_CD45_CGDA5146_S6_R1_001_report.tsv yes Tumor_leukocyte_NMU13_RAU 20170125_NMU13_Tumor_RAU_EpCAM_CGDA5146_S14_R1_001.fastq.gz NA Tumor_epithelial_NMU13_RAU NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_RLL NMU13 NA RLL Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 7.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU13-tumor-RLL.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU13_RLU NMU13 NA RLU Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 20.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU14_ NMU14 1 NA Characterisation Vehicle 35 2017-01-06 NA 2017-06-15 no data NA NA 160 6.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 3 NA NA 1 NA NA 1 NMU14-tumor.final.bam Yes Yes No NMU14__Ep 20170125_NMU14_Tumor__CD45_CGDA5146_S7_R1_001.fastq.gz 20170125_NMU14_Tumor__CD45_CGDA5146_S7_R1_001_report.tsv yes Tumor_leukocyte_NMU14 20170125_NMU14_Tumor__EpCAM_CGDA5146_S15_R1_001.fastq.gz NA Tumor_epithelial_NMU14 NA NA NA NA 11.059146 NA 9.399838 NA 8.236589 NA LumA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU2_RL NMU2 NA RL Characterisation Vehicle 49 2016-10-11 NA 2017-01-07 no data NA NA 88 10.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU2-tumor.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU3_LA NMU3 NA LA Characterisation Vehicle 49 2016-10-11 NA 2017-01-10 no data NA NA 91 10.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU4_RA NMU4 NA RA Characterisation Vehicle 35 2017-01-06 NA 2017-03-01 no data NA NA 54 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU4_RL NMU4 NA RL Characterisation Vehicle 35 2017-01-06 NA 2017-03-01 no data NA NA 54 1.5 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU5_LA NMU5 3 LA Characterisation Vehicle 35 2017-01-06 NA 2017-03-01 no data NA NA 54 3.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU5-tumor-LA.final.bam No Yes No NMU5_LA_Ep NA NA yes NA 20191030_Ep_NMU5LA_CGDA7428_S3_R1_001.fastq.gz NA Ep_NMU5LA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU5_LL NMU5 NA LL Characterisation Vehicle 35 2017-01-06 NA 2017-03-01 no data NA NA 54 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU6_LA NMU6 NA LA Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 1.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU6_RL NMU6 NA RL Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 6.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU7_LA NMU7 NA LA Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 2.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU7_LL NMU7 NA LL Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 1.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU7_RL lower x2 NMU7 NA RL lower x2 Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 2.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU7_RLU NMU7 1 RLU Characterisation Vehicle 35 2017-01-06 NA 2017-03-02 no data NA NA 55 4.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA 1 NA NA 1 NA NA 1 No Yes Yes No NMU7_RLU_Ep 20170125_NMU7_Tumor_RLU_CD45_CGDA5146_S1_R1_001.fastq.gz 20170125_NMU7_Tumor_RLU_CD45_CGDA5146_S1_R1_001_report.tsv yes Tumor_leukocyte_NMU7_RLU 20170125_NMU7_Tumor_RLU_EpCAM_CGDA5146_S9_R1_001.fastq.gz NA Tumor_epithelial_NMU7_RLU NA NA NA NA 6.746370 NA 3.561978 NA 8.172066 NA Basal NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU8_RA NMU8 NA RA Characterisation Vehicle 35 2017-01-06 NA 2017-03-06 no data NA NA 59 1.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU8_RL NMU8 NA RL Characterisation Vehicle 35 2017-01-06 NA 2017-03-06 no data NA NA 59 5.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA No No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NMU9_LL NMU9 NA LL Characterisation Vehicle 35 2017-01-06 NA 2017-03-06 no data NA NA 59 5.0 NA well differentiated mammary solid adenocarcinoma NA NA NA NA NA Not done Not done NA NA NA NA NA NA NA NA NA NMU9-tumor-LL.final.bam No No No NA NA NA no NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LB2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LB 2.mrxs 4channel_23samples: NOT CONVERTED NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LD2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1LD 2.mrxs 4channel_23samples: NOT CONVERTED NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10N_3 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 10N_3.mrxs 4channel_23samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12N NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12N-R+P.pyramid.ome.tif 2+3channel_57samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12R NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 12R-R+P.pyramid.ome.tif 2+3channel_57samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13L NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13L-P+R.pyramid.ome.tif 2+3channel_57samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13R NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 13R-R+P.pyramid.ome.tif 2+3channel_57samples NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 2.1 Size information We have two cohorts, the characterisation and progression cohorts. Below is a plot of the size distribution in these two cohorts: Note that in the characterisation cohort, samples are selected for SAC at different time points: 2.2 Calculating growth rates In this section, we estimate the growth rates of the samples: Below is a plot of the tumor size per week for each recorded tumor, color-coded according to treatment. Time is measured at the first time point at which a tumor is palpated. Spontaneous large tumors are assumed to have a tumor size of 0 or 1 one week prior to palpating. These tumors doesn’t have growth rate data: 17N_B. We can then compute the growth rate for the above samples by considering the change in size over a given period of time using a linear regression model. Below is the histogram of growth rates: Based on the above distribution, a cut-off of 2mm/week may be an optimal cut-off to separate growing and stable tumors. Below are growth rates of tumors under different treatments: We can calculate the p.values below, using a t.test. The growth rates comparing the treatment to the controls are: ## [1] &quot;LY samples&quot; ## ## Wilcoxon rank sum test with continuity correction ## ## data: d1$growthrate[d1$treatment == &quot;LY&quot;] and d1$growthrate[d1$treatment == &quot;Vehicle&quot;] ## W = 165.5, p-value = 0.1718 ## alternative hypothesis: true location shift is not equal to 0 ## [1] &quot;PDL1 samples&quot; ## ## Wilcoxon rank sum test with continuity correction ## ## data: d1$growthrate[d1$treatment == &quot;PDL1&quot;] and d1$growthrate[d1$treatment == &quot;Vehicle&quot;] ## W = 103, p-value = 0.051 ## alternative hypothesis: true location shift is not equal to 0 ## [1] &quot;PDL1+LY samples&quot; ## ## Wilcoxon rank sum test with continuity correction ## ## data: d1$growthrate[d1$treatment == &quot;PDL1+LY&quot;] and d1$growthrate[d1$treatment == &quot;Vehicle&quot;] ## W = 154.5, p-value = 0.006713 ## alternative hypothesis: true location shift is not equal to 0 This shows a smaller growth-rate in PDL1 single and double treated cases compared to the vehicles. Overall the distribution of growing vs stable tumors is shown below: ## ## grow stable ## 47 31 We can replot the previous graphs according to growth, and color code according to whether it is a fast or slow growing tumor As a sanity check, compare these growth rates with differences in tumour size at different time points: comparing the growth rate according to classifications (growing, stable) tumor size at time of sacrifice rate of tumor development from the time of NMU injection ## Warning in wilcox.test.default(x = c(3.54285714285714, 15, 20, 11.7, 5.8, : ## cannot compute exact p-value with ties ## Warning in wilcox.test.default(x = c(20, 15, 20, 47, 30, 12, 32, 35, 4, : cannot ## compute exact p-value with ties ## Warning in wilcox.test.default(x = c(0.238095238095238, 0.178571428571429, : ## cannot compute exact p-value with ties Is there an association with treatment? Calculate below using chi-squared test: ## ## Pearson&#39;s Chi-squared test ## ## data: table(factor(d1$treatment), d1$growthrate_cutoff2) ## X-squared = 6.8181, df = 3, p-value = 0.07793 Overall, it appears that there is an association between growth rate and treatment 2.3 FACS data The immune (CD45) fractions from a number of samples were collected, and assessed using FACs. The major cell types detected are: Leukocytes: Tregs CD8 T cells Thelper cells B cells NK T cells gamma delta T cells Myeloid cells: Macrophages M1 Macrophages M2 Dendritic cells Monocytes Neutrophils We can look at the: types of cells distributions Note that in a number of samples the leukocyte population could not be inferred with confidence, and proportions are normalised to the myeloid population type 11ND 8LD 8RCU 12LD 6RB 11RD 14ND 14NC 3NB 3RC 10LC 10RB 11LB 11RC 15LB 15NC 15RD 16LD 2RA 2RC 5NA 6RD 8RCL Leukocytes 913.8400000 379.5600000 829.5700000 298.8300000 NA NA 291.4300000 576.7400000 1118.8200000 616.3800000 414.7500000 899.6000000 1243.7900000 204.8900000 NA NA NA NA NA NA NA NA NA leukocytes NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Th 0.1823733 0.1223259 0.1239799 0.0542784 NA NA 0.1503277 0.1370462 0.0964141 0.0980077 0.0832309 0.1489996 0.0910604 0.0454390 NA NA NA NA NA NA NA NA NA Tregs 0.1020748 0.3822584 0.0570175 0.0703075 NA NA 0.0703085 0.0438673 0.1722261 0.1392972 0.1607233 0.1387394 0.0263389 0.0292352 NA NA NA NA NA NA NA NA NA CD8 T cells 0.0558632 0.0329329 0.0248804 0.0239936 NA NA 0.0681124 0.0403648 0.0628966 0.0438204 0.0201326 0.0435749 0.0088681 0.0188394 NA NA NA NA NA NA NA NA NA gd T cells 0.0057231 0.0029508 0.0048338 0.0051869 NA NA 0.0052843 0.0034851 0.0054343 0.0099614 0.0108981 0.0039573 0.0023155 0.0078091 NA NA NA NA NA NA NA NA NA NK cells 0.0081852 0.0023975 0.0086430 0.0082321 NA NA 0.0024706 0.0033984 0.0057471 0.0130277 0.0073056 0.0078924 0.0047355 0.0009273 NA NA NA NA NA NA NA NA NA B cells 0.0320297 0.0259774 0.1150958 0.3691731 NA NA 0.0552105 0.1627076 0.1690978 0.1648821 0.0852803 0.1415963 0.1131783 0.5891942 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA DC 0.0847253 0.0099781 0.0240649 0.0937623 0.0796767 0.0904331 0.0210829 0.0866281 0.1246231 0.2439219 0.0338069 0.0087373 0.0787654 0.0441001 0.0782997 0.1614173 0.0582119 0.0529557 0.0371143 0.0034515 0.0605741 0.0224583 0.0656124 Monocytes 0.0869640 0.0992694 0.1052141 0.1075509 0.0750577 0.0896695 0.1671775 0.0227902 0.0658291 0.0406536 0.0388811 0.0573525 0.0550409 0.0607867 0.0630813 0.0921618 0.1345743 0.2219148 0.0818758 0.0326953 0.1337320 0.0871336 0.0882122 Neutrophils 0.1195109 0.0713534 0.0989646 0.0961261 0.1039261 0.0484346 0.0821956 0.0795769 0.1165829 0.0390594 0.2022707 0.0442465 0.1378131 0.0369487 0.0839361 0.0629921 0.1058862 0.0959791 0.1177103 0.0213367 0.1875633 0.0681735 0.0702109 MHCII-hi Macro 0.0079215 0.0188760 0.0327395 0.0978332 0.0254042 0.1052689 0.1015139 0.0328633 0.0341709 0.0462336 0.0260688 0.0224593 0.0856493 0.0309893 0.0660404 0.0758769 0.0283632 0.1103736 0.0456621 0.0460621 0.0757107 0.1725741 0.0463399 MHCII-lo Macro 0.0451180 0.2975240 0.2654603 0.1099146 0.0542725 0.0976328 0.1608619 0.0690003 0.0894472 0.0278996 0.0253711 0.2559019 0.0511094 0.0536353 0.0862846 0.0606657 0.0647108 0.1009692 0.2576354 0.2502040 0.0721728 0.1834358 0.0866607 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Total 0.7304889 1.0658438 0.8608938 1.0363587 0.3383372 0.4314389 0.8845458 0.6817281 0.9424693 0.8667644 0.6939694 0.8734574 0.6548747 0.9179043 0.3776421 0.4531138 0.3917464 0.5821924 0.5399978 0.3537496 0.5297529 0.5337753 0.3570360 Lin- 0.2695111 -0.0658438 0.1391062 -0.0363587 0.6616628 0.5685611 0.1154542 0.3182719 0.0575307 0.1332356 0.3060306 0.1265426 0.3451253 0.0820957 0.6223579 0.5468862 0.6082536 0.4178076 0.4600022 0.6462504 0.4702471 0.4662247 0.6429640 We can look solely at the myeloid population (and normalise to this total), and color according to growth Similarly, we can look at the leukocyte population. Note that the Treg population in some of these samples is very high. 2.4 Summary Table Firstly, look at the total number of samples: Feature Levels N Total No Tumors All 143 - Characterisation 33 - Prevention 8 - Progression 84 Total No Rats All 69 - Characterisation 18 - Prevention 8 - Progression 42 No tumours per rat 1.84 ( 1, 3) 2.4.1 Compare the characterisation vs progression cohort Feature Levels Characterisation Progression Total No tumours 59 102 Treatments Vehicle 64 27 - Untreated 4 - LY 17 - PDL1 17 - PDL1+LY 23 - NA 18 18 Histology diff. adenocarcinomas 41 76 - mucinous carcinoma 0 3 - Fibroadenoma 0 4 - NA 18 19 Age Injection 32-36 8 84 - 35 27 0 - 49 6 0 - NA 18 18 Time (days) NMU 2 Sac 98.59 (54, 160) 149.37 (79, 248.7) - Cases with NA 30 18 - NMU 2 Tumor 100.62 (44.2, 182.7) - Cases with NA 59 18 - Tum Spec Surv 48.75 (9.5, 92) - Cases with NA 59 18 Growth Rate/Size (mm) overall size @ sac 8.07 (1.8, 19.4) 19.52 (3, 40) - Growing No. 47 - Growing size @ sac 27.7 15, 28, 40 - Stable 31 - Stable size @ sac 9.58 (1, 6, 24) - NA 59 24 Spatial Pattern - Infiltrating 0 26 - Restricted 0 33 - NA 59 43 RNA samples any fraction 14 46 - Ep 14 21 - DN 0 33 - CD45 10 36 Imaging Data No tumors 64 - No tumors with RNA 38 FACS data Comprehensive 22 - EpCAM/CD45 0 82 TO INCLUDE: - trichrome data? 2.4.2 Summary of the RNA data Below is a table of the samples with RNA information Feature Levels Characterisation Progression RNA samples any fraction 14 46 - Ep 14 21 - DN 0 33 - CD45 10 36 Treatments Char/Prev Vehicle 13 15 - Untreat (char) 1 - LY 9 - PDL1 11 - PDL1+LY 11 - NA 0 0 Time NMU 2 Sac 106.9 (54.9, 160) 113.85 (79, 166) Growth Rate/Size (mm) overall size @ sac 9.23 (4, 18) 21.96 (6, 37.5) - Growing No. 33 - Growing size @ sac 27.64 15, 28, 40 - Stable 12 - Stable size @ sac 7.17 (3.1, 6, 9.7) - NA 14 1 Growth and Treatment: comparing small/stable vs large/growing Vehicle N s/l 2, 13 LY N s/l 2, 7 PDL1 and Treatment N s/l 4, 6 PDL1+LY N s/l 4, 7 "],["whole-slide-imaging.html", "Chapter 3 Whole-slide imaging 3.1 Associate the frequencies with other data types 3.2 Cellular composition 3.3 Associate composition with other covariates 3.4 Estimate tumor size 3.5 Correlations between different subpopulations 3.6 Associations between CD8 counts with other clinical variables", " Chapter 3 Whole-slide imaging In this section, we will be looking at the composition and spatial distribution of cells in whole slide images. These sections have previously been assessed using an external script. Save this somewhere The following markers have been used: EpCAM (tumor cells) SMA (fibroblasts or myeopithelial cells) CD8 (T cells) Note that in some images a double positive EpCAM+/SMA+ population exists. Some CD8 cells have Epcam+ or SMA+ staining, however, we consider all of these to be simply CD8+ 3.1 Associate the frequencies with other data types Note there are 47 samples with imaging data. 33 of these samples have FACS data, manual counts and TIMER scores Correlate the following information: “CD8.WSI”: CD8 total counts “CD8Frac.WSI”: CD8 fraction (normalised by cell count) “CD8_EPorSMARatio.WSI”: CD8/EP+SMA ratio (any EpCAM or SMA + cell) “CD8_AnySMARatio.WSI”: CD8/Any EPcam+ cell “CD8_EPRatio.WSI”: CD8 to EpCAM+SMA- ratio “CD8normTumSize”: normalised CD8 counts per mm of tumor size at sac “CD8.EpBoundingBox”: approx area per CD8 cell (density) UPDATE THE CIBERSORT INFORMATION. Below are heatmaps which show the correlation between two variables (red is correlated and blue is anti-correlated), and the p.value is indicated in the middle of the square. It appears that CD8 whole-slide imaging associates well with: FACS data (both CD8 and CD45) Manual scoring (Fig 4) of CD8 cells Some CD8 gene signature scores (mainly in EPC, TIMER) 3.2 Cellular composition Here, we look at the raw distributions of the different cell types and see if there are associations with: tumor size growth rate growth rate (categorical) treatment stromal restricted or infiltrating Below are the total cell counts: Here, the same data is shown and normalised according to total cell count: 3.3 Associate composition with other covariates We can collapse the above data into boxplots to see if there is an association with treatments, performed using non-parametric wilcoxon test. Compared to the vehicle, LY treated samples have a lower “stromal” fraction (unclassed DAPI+ cells) and PDL1 treated samples are more likely to have a EpCAM+SMA+ double positive fraction When comparing these fractions to growth, there is no association: ## Warning in wilcox.test.default(Cdata[Cdata$Growth2 == &quot;growing&quot;, i], ## Cdata[Cdata$Growth2 == : cannot compute exact p-value with ties ## Warning in wilcox.test.default(Cdata[Cdata$Growth2 == &quot;growing&quot;, i], ## Cdata[Cdata$Growth2 == : cannot compute exact p-value with ties Nor is there any association with whether a sample is “immune infiltrated” or not (by manual inspection) ## Warning in wilcox.test.default(Cdata[Cdata$InfiltratingVsRestricted == ## &quot;Infiltrating&quot;, : cannot compute exact p-value with ties ## Warning in wilcox.test.default(Cdata[Cdata$InfiltratingVsRestricted == ## &quot;Infiltrating&quot;, : cannot compute exact p-value with ties We can also use linear regression models to assess: correlation between growth rate and cell fractions (no associations) correlation between final tumor size and cell fractions (no association) 3.4 Estimate tumor size Using WSI data, we can estimate a tumor size for each tissue sample and compare to the final tumor sizes. This will be based on the distribution of EpCAM+ cells. This estimate is also used to normalise CD8 counts earlier on. ## ## Pearson&#39;s product-moment correlation ## ## data: TareaSum and Tdiameter ## t = 1.6859, df = 54, p-value = 0.09759 ## alternative hypothesis: true correlation is not equal to 0 ## 95 percent confidence interval: ## -0.04174574 0.45949702 ## sample estimates: ## cor ## 0.2236089 3.5 Correlations between different subpopulations Look for correlates between different subpopulations: Naturally, we would expect a negative correlation since this should sum to 1. Below are heatmaps showing correlations between different cell types, and significant associations are linearly shown. Note the following negative correlations: epcam and SMA SMA+ and Unclass ## CD8 EpCAM EpCAM: SMA SMA Unclass ## CD8 1.0000000 -0.1780975 -0.1268947 -0.0344095 -0.1107879 ## EpCAM -0.1780975 1.0000000 -0.1595219 -0.5597908 -0.1898428 ## EpCAM: SMA -0.1268947 -0.1595219 1.0000000 -0.2171477 -0.1783030 ## SMA -0.0344095 -0.5597908 -0.2171477 1.0000000 -0.4946850 ## Unclass -0.1107879 -0.1898428 -0.1783030 -0.4946850 1.0000000 ## [,1] [,2] [,3] [,4] [,5] ## [1,] 0.0000000 1.891064e-01 0.3513624 8.012235e-01 0.416293560 ## [2,] 0.1891064 0.000000e+00 0.2402481 7.272201e-06 0.161096722 ## [3,] 0.3513624 2.402481e-01 0.0000000 1.079270e-01 0.188588161 ## [4,] 0.8012235 7.272201e-06 0.1079270 0.000000e+00 0.000106427 ## [5,] 0.4162936 1.610967e-01 0.1885882 1.064270e-04 0.000000000 3.6 Associations between CD8 counts with other clinical variables Below we assess whether any of the CD8-variables described in section 3.1 is associated with treatment growth spatial pattern Note that CD8 normalised by tumor size is associated with growth (but this could a reflection of the size of the tumor), and there is a borderline difference once normalised by epithelial content. In addition the CD8 total count is associated with pdl1+ly treatment. Note that p=0.05 is designated by a value of 1.3 "],["spatial-statistics.html", "Chapter 4 Spatial statistics 4.1 knn-Distances: 4.2 The interacting fraction 4.3 M-H distances 4.4 Comparison between metrics 4.5 Other cell types", " Chapter 4 Spatial statistics Below, we use three different metrics to compare spatial distributions: k-nearest neighbour distances the interacting fraction morisita-horn distances These are compared to manual inspection of the result 4.1 knn-Distances: The k-nearest neighbour distances looks at the average distance from a given cell type of class A to a cell type of class B. In this section, the reference class A is the CD8 T cell, and we will look at the mean distance to SMA, Epcam, double positive and unclassified cells in each image. To account for potential fluctuations due to misclassified cells, or isolated single cells, k values of 1, 3, 5 will be used. I.e. for each cell, we will compute the mean distance from each Cd8Tcell to its 1, 3, and 5 nearest neighbours. 4.1.1 Comparison to manual classification, treatment, growth Overall, we see that the differences in infiltrating vs restricted are similar. We see statistical differences (using anova followed by Tukey’s test) between: epcam and SMA-epcam in both cases (higher distances to EpCAM on average) SMA-Epcam to SMA (CD8s are closer to SMA+) Unclass to Epcam-SMA (CD8s closer to unclass) In the infiltrating case: Unclass to Epcam (CD8s closer to unclass, borderline significant) In the restricted cases, we see: Unclass to SMA (higher distance to unclass in the restricted case) SMA to epcam (CD8s are closer to the SMA) This last result is consistent with what we expect for a CD8+ cell which is stroma-restricted. 4.1.2 Associations with outcome We can also see if there is an association between these distances with growth and treatment Treatment: CD8 cells in PDL1 sample are further away to SMA+ cells and EpCAM+ (compared to vehicle or double agent) CD8 cells in LY treated samples are further away from unclassified cells (compared to any of the other treatments) 4.1.3 Growth All 95% confidence lines cross 0, but it appears that stable cases have a closer unclass-CD8 interaction distance compared to growing. Based on the above distributions, knn1, knn3, and knn5 analyses give similar results. In the following section, we will make comparisons using knn3 results. 4.1.4 Association between distance and content The spatial differences could be influenced by CD8 content. Here, we test if the distances from CD8Tcells to celltype B could be influenced by this. We see that there is a correlation between CD8 fraction and the SMA proportion (both SMA and double positive). But we don’t see an association with epcam+ cells or unclassified stromal cells CD8-Epcam distances are looked at in greater detail below. Here, we look at whether there is an association with CD8 fraction in a growing and stable tumors. In growing or spatially restricted tumors, there is an association between the CD8-epcam distances with the CD8 fraction, but not in infiltrating or stable tumours. Do any of the below metrics correlate with manual scoring: We can assess the distances from CD8 cells which come automatically: Ep-distance SMA distance Ep:SMA distance SMA distance. EpMIN: distance to any Epcam expressing cell (includes EP+SMA+) Ratios between Epcam and SMA: There are different values depending on whether the double positive fraction is used or not (Ratio 1): Ep/any SMA (Ratio 2): EP/SMA (Ratio 3): Any Ep / Any SMA (Ratio 4): Any Ep/ SMA Whilst the manual scorings associate strongly with CD8-EPcam distances, there is no association with any other cell type. 4.2 The interacting fraction The interacting fraction uses the knn-distances and determines the proportion of CD8 cells which are within a proximity of r um from celltype B. 4.2.1 Comparison to manual &amp; select optimal r Below are plots of the proportion of CD8 cells within an “interacting distance” as we increase r. This looks at both the interacting fraction of CD8 cells with Epcam+ and SMA+ cells. Lines are color coded according to the manual spatial-infiltration annotation. We notice from the line plots for each single sample that the restricted samples generally have low interacting fractins with EpCAM and SMA compared to the infiltrating samples. In addition, there is a statistical difference in EpCAM measurements compared to SMA. Using the boxplots as a guide, we can determine optimal “interacting distances” at which to perform downstream analysis. The best separation between restricted and infiltrating for EpCAM appears at: 1-nn: 10-15 um 3-nn: 15 um 5-nn: 20 um The interacting fraction does not distinguish SMA fractions (all restricted boxplots overlap with the infiltrating boxplots) The following plots use 3NN analysis with an interacting distance of 15um. We can firstly check if there is an association between different “interacting fraction” types and manual scoring, similar to what was performed for knn-analysis. Only CD8-EpCAM interacting distances is associated with manual scoring. All other metrics are not significant. Again, association between CD8 content and interacting fraction was observed ONLY in the growing samples or restricted cases. 4.2.2 Growth Here, we check if there is an association between the spatial pattern and tumor growth. None of the above metrics associate with growth. (P value by wilcox test shown) 4.2.3 Treatment Similarly, compare the distances with treatment: There appears to be a difference in CD8-unclass interactions in LY treated samples (LY, PDL1+LY), but not in the other cases 4.3 M-H distances The M-H distance (or Morisita Horn index) can be considered as a correlation coefficient in spatial distribution between cell type A and cell type B. To calculate this metric, the whole slide image is divided into grids of size 50 to 500um. Within each grid, the total number of cells A and B are determined. The M-H index is thus determined as: \\[ \\frac{2\\sum_{i=1}^n a_ib_i}{(D_a+D_b)AB} \\] where \\(a_i\\) and \\(b_i\\) are the number of cells in grid \\(i\\), \\[A\\] and \\[B\\] the total number of cells, and \\[D_x\\] is the Simpson’s index. 4.3.1 Comparison to Manual Scoring Similar to the interacting fraction, we plot the MH index for increasing values of gridsize to determine an optimal metric to compare spatial patterns. Ideally, we would pick a metric has the following properties: good separation of the different values a reasonable number of cells within each grid (avoid too small grids which give counts of 0) avoid plateauing of MH values because the grid size is too large With increasing grid size, optimal differences between infiltrating and restricted appear at the following sizes: epCAML 100um+ epcam:SMA most significant at 350+ SMA: 150+ Unclass:200+ We probably want to use a metric/gridsize of 250 um as the expected/mean number of cells in each grid is 10 here. Other notes: double positive cells (EpCAM+SMA+) appear in predominantly the restricted cases? higher SMA- stromal cells in restricted Below, we check whether these metrics can differentiate between infiltrating and restricted tumors: The above analysis shows that the MH-index shows differences in mixing between CD8 cells and mixing with most cell types. However MH-CD8-to-Epcam to MH-CD8-to-stroma ratios do not support this difference. 4.3.2 Growth Below are the MH indices with increasing grid-size for individual samples. In general, there is a subset of stable samples which have very high intermixing Although the MH values for growing vs stable are not different, we can compare the mixing in epcam vs stroma in matched samples: 4.3.3 Treatment There is no difference between the different spatial metrics compared to the vehicle, however, we can compare for a given treatment if there is a difference between the epcam and the stromal interaction scores. It appears that there is a difference only in the control, where SMA mixing is higher than EPcam mixing: 4.4 Comparison between metrics After assessing optimal parameters for each metric, in this section we assess which metric could be the best for spatial analysis. Below is a table of the different metrics and their values for each sample knn.EpCAM IF.EpCAM MH.EpCAM Treatment Growth Infil CD8frac TumSize 10LB 39.96193 0.2236555 0.4598790 PDL1 growing Infiltrating 0.0228977 35 10LC 17.87345 0.4768745 0.5432610 PDL1 growing Infiltrating 0.0100341 25 10LD 34.33110 0.2944373 0.6867357 PDL1 stable Infiltrating 0.0681088 10 10NA 23.80977 0.4808547 0.4764461 PDL1 NA restricted 0.0465627 12 10ND 26.20801 0.4408878 0.4181843 PDL1 stable restricted 0.0227195 15 10RBL 44.92703 0.2213380 0.5857603 PDL1 growing restricted 0.0202715 40 10RBU 87.12901 0.0816202 0.3840030 PDL1 NA restricted 0.0670641 12 11LB 69.10296 0.2080105 0.2992537 PDL1 growing NA 0.1521777 25 11ND 92.98237 0.0079816 0.5643066 PDL1 stable Infiltrating 0.3800672 3 11RC 153.33513 0.0386688 0.0388372 PDL1 growing restricted 0.0504186 19 11RD 73.82461 0.2323507 0.3847338 PDL1 growing restricted 0.0224452 25 12LD 355.94915 0.0002809 0.1642608 PDL1 stable Infiltrating 0.0223693 6 13NA 70.80101 0.1279338 0.3039013 Vehicle growing restricted 0.0355811 35 14NB 49.22243 0.2540062 0.4353436 PDL1+LY growing restricted 0.1061520 23 14NC 44.46686 0.1239597 0.3670808 PDL1+LY stable restricted 0.0541298 6 14RD 31.50346 0.1681860 0.6214897 PDL1+LY stable Infiltrating 0.0103371 1 15LB 32.69579 0.2226772 0.4642353 PDL1+LY growing restricted 0.0129612 10 15NC-D 39.22818 0.1299775 0.4756601 PDL1+LY growing restricted 0.0107875 22 15ND 15.54429 0.6025030 0.6063571 PDL1+LY stable Infiltrating 0.0104721 3 15RD 91.07517 0.1578969 0.3729870 PDL1+LY growing restricted 0.0328312 17 16LA 31.26867 0.2750368 0.3355138 PDL1+LY NA Infiltrating 0.0171528 5 16LC 71.64542 0.2411490 0.0623470 PDL1+LY stable Infiltrating 0.0476926 7 16LD 38.85862 0.3001624 0.5734648 PDL1+LY stable Infiltrating 0.0316168 24 16ND 29.84045 0.2842939 0.5094333 PDL1 stable Infiltrating 0.0753308 25 16RD 56.31604 0.2354937 0.3920871 PDL1 stable Infiltrating 0.0306486 3 17NA 61.86642 0.0907525 0.3510232 Vehicle growing restricted 0.0472687 28 17ND 111.85371 0.0029328 0.6112631 Vehicle stable Infiltrating 0.1115267 4 17RB 16.70828 0.6275561 0.4630693 Vehicle growing Infiltrating 0.0411074 35 2N 35.15413 0.2448721 0.3766073 Vehicle growing restricted 0.0301041 47 2RA 132.80795 0.0452766 0.3252085 Vehicle growing restricted 0.0858192 20 2RD 38.61221 0.1979009 0.6791816 Vehicle growing restricted 0.0742195 20 3LA 46.09601 0.2865240 0.4162200 Vehicle growing restricted 0.0531246 12 3NB 32.31159 0.4377911 0.7061056 Vehicle stable Infiltrating 0.2768299 6 3RB 42.63162 0.2910751 0.4645950 Vehicle growing restricted 0.0266554 35 3RC 32.11938 0.2962108 0.4965437 Vehicle growing Infiltrating 0.0232139 32 4LB 30.99117 0.2903294 0.5447258 Vehicle growing Infiltrating 0.0244474 35 4NC 15.33106 0.6851436 0.0901870 Vehicle growing restricted 0.0081388 15 4ND 20.75556 0.4768080 0.5809047 Vehicle growing Infiltrating 0.0076245 20 4RB 53.31478 0.1765476 0.3445324 Vehicle growing restricted 0.0280096 40 5LA 41.12871 0.2471295 0.3724930 Vehicle stable Infiltrating 0.0453952 6 5LB 41.91177 0.2807178 0.4690510 Vehicle growing restricted 0.0257830 4 5LC 82.68448 0.1168545 0.1980203 Vehicle growing restricted 0.0515055 22 5LD 91.41539 0.0735101 0.2028472 Vehicle stable restricted 0.0348108 15 5RB 39.00602 0.1934315 0.4479302 Vehicle growing restricted 0.0596672 35 6LDU 111.44785 0.1092889 0.2738092 LY growing restricted 0.0556253 32 6ND 28.41556 0.2756628 0.4251078 LY growing NA 0.0815901 40 6RB 76.37955 0.1446840 0.5947703 LY growing Infiltrating 0.1554804 18 6RC 50.21453 0.1966022 0.5496400 LY growing restricted 0.0788010 40 7NB 80.17580 0.0728176 0.1877309 LY growing restricted 0.0206734 31 7NC 89.34399 0.0531233 0.2103338 LY growing restricted 0.0479457 40 7RA 33.35958 0.2251296 0.4269972 LY stable restricted 0.0319310 8 7RB 34.39737 0.1917334 0.7110689 LY growing NA 0.0169469 20 7RD 44.13770 0.2386457 0.4019270 LY stable Infiltrating 0.0321690 20 8LD 16.36623 0.6508906 0.7532812 LY stable Infiltrating 0.0562336 6 8RCL 15.12966 0.6186366 0.7536385 LY growing restricted 0.0176691 12 8RCU 50.00101 0.2347423 0.4676640 LY growing restricted 0.0287668 27 knn.EpCAM knn.EpCAM..SMA knn.SMA knn.Unclass knn.EpMIN knn.EpStrRatio1 knn.EpStrRatio2 knn.EpStrRatio3 knn.EpStrRatio4 IF.CD8 IF.EpCAM IF.EpCAM..SMA IF.SMA IF.Unclass IF.EpMIN IF.EpStrRatio1 IF.EpStrRatio2 IF.EpStrRatio3 IF.EpStrRatio4 MH.EpCAM MH.EpCAM..SMA MH.SMA MH.Unclass MH.EpMIN MH.EpStrRatio1 MH.EpStrRatio2 MH.EpStrRatio3 MH.EpStrRatio4 Treatment Growth Infil CD8frac GrowthRate TumSize knn.EpCAMcut MH.EpCAMcut IF.EpCAMcut CD8Fraccut CD8 EpCAM EpCAM: SMA SMA Unclass 10LB 39.96193 52.72253 16.94935 28.07623 39.96193 0.5735732 2.3577258 1.3302993 5.4683183 0.2053826 0.2236555 0.0803884 0.5905018 0.3010823 0.0803884 3.333713e-01 3.787550e-01 4.531947e-01 5.148906e-01 0.4598790 0.4523963 0.6129639 0.5544075 0.4523963 0.4316653 0.7502546 0.8563069 1.4883019 PDL1 growing Infiltrating 0.0228977 6.2285714 35 high high low low 0.0228977 0.2663149 0.1200304 0.3936498 0.1971072 10LC 17.87345 34.57734 32.12258 24.28626 17.87345 0.2679682 0.5564141 0.7863697 1.6328326 0.0784257 0.4768745 0.2375754 0.3168630 0.3714450 0.2375754 8.601036e-01 1.504986e+00 1.288601e+00 2.254760e+00 0.5432610 0.5212001 0.4755447 0.5727582 0.5212001 0.5450352 1.1423973 1.0679374 2.2384038 PDL1 growing Infiltrating 0.0100341 5.3571429 25 high high high low 0.0100341 0.3081967 0.1672355 0.2960411 0.2184926 10LD 34.33110 30.18133 15.97086 35.99495 30.18133 0.7438671 2.1496080 1.3978193 4.0393825 0.2816222 0.2944373 0.2563779 0.5786730 0.1450209 0.2563779 3.525981e-01 5.088147e-01 6.596187e-01 9.518592e-01 0.6867357 0.6212434 0.7215931 0.6164435 0.6212434 0.5114068 0.9516938 0.9740419 1.8126268 PDL1 stable Infiltrating 0.0681088 1.9729730 10 high high high high 0.0681088 0.1948931 0.2063845 0.4066703 0.1239434 10NA 23.80977 NA 27.49276 48.19205 23.80977 0.8660376 0.8660376 0.8660376 0.8660376 0.3591542 0.4808547 NA 0.3207166 0.1112743 0.4808547 1.499313e+00 1.499313e+00 1.499313e+00 1.499313e+00 0.4764461 NA 0.5082689 0.4033893 0.4764461 0.9373898 0.9373898 0.9373898 0.9373898 PDL1 NA restricted 0.0465627 NA 12 high high high high 0.0465627 0.5554448 0.0000000 0.2855199 0.1124726 10ND 26.20801 NA 30.06210 40.01762 26.20801 0.8717958 0.8717958 0.8717958 0.8717958 0.3008666 0.4408878 NA 0.1738438 0.1426298 0.4408878 2.536114e+00 2.536114e+00 2.536114e+00 2.536114e+00 0.4181843 NA 0.3506799 0.3206394 0.4181843 1.1924959 1.1924959 1.1924959 1.1924959 PDL1 stable restricted 0.0227195 0.3930533 15 high low high low 0.0227195 0.4651478 0.0000000 0.2837204 0.2284123 10RBL 44.92703 67.36295 18.22774 26.07893 44.92703 0.5249056 2.4647619 1.3119416 6.1603904 0.1279104 0.2213380 0.2039493 0.5758915 0.4544651 0.2039493 2.838246e-01 3.843398e-01 5.453515e-01 7.384852e-01 0.5857603 0.5360503 0.6881028 0.5917978 0.5360503 0.4785025 0.8512686 0.9163973 1.6302950 PDL1 growing restricted 0.0202715 4.9761905 40 NA high low low 0.0202715 0.3478534 0.1505455 0.2547647 0.2265650 10RBU 87.12901 76.12121 20.78384 35.23226 76.12121 0.8991173 4.1921519 1.6846410 7.8546713 0.4317687 0.0816202 0.3119480 0.4723411 0.2877489 0.0816202 1.040690e-01 1.727993e-01 5.018152e-01 8.332287e-01 0.3840030 0.4336137 0.6001987 0.5692091 0.3840030 0.3714435 0.6397930 0.7908753 1.3622433 PDL1 NA restricted 0.0670641 NA 12 NA low low high 0.0670641 0.1639585 0.3359050 0.2865291 0.1465433 11LB 69.10296 7919.73815 6967.17455 17.47761 69.10296 0.0046419 0.0099184 0.5366352 1.1466400 0.6929437 0.2080105 0.0000000 0.0000102 0.5774735 0.0000000 2.041550e+04 2.041550e+04 2.041550e+04 2.041550e+04 0.2992537 0.0009305 0.0014195 0.6153063 0.0009305 127.3411644 210.8113890 127.7371118 211.4668740 PDL1 growing NA 0.1521777 3.7857143 25 NA low low high 0.1521777 0.4554672 0.0000101 0.0000364 0.3923085 11ND 92.98237 115.53783 26.89773 27.03077 92.98237 0.6528030 3.4568846 1.4639616 7.7523330 0.8951232 0.0079816 0.0146566 0.4326199 0.2765993 0.0079816 1.784480e-02 1.844940e-02 5.061340e-02 5.232810e-02 0.5643066 0.4637951 0.7401398 0.7604776 0.4637951 0.4687186 0.7624325 0.8539513 1.3890643 PDL1 stable Infiltrating 0.3800672 0.1065574 3 NA high low high 0.3800672 0.0140030 0.0185443 0.4231776 0.1642079 11RC 153.33513 178.57028 70.26468 25.53931 153.33513 0.6162122 2.1822504 1.3338375 4.7236450 0.7894172 0.0386688 0.0222283 0.0532631 0.4286498 0.0222283 5.122274e-01 7.259953e-01 8.066755e-01 1.143325e+00 0.0388372 0.0400059 0.0547144 0.2349901 0.0388372 0.4100202 0.7098171 0.8323782 1.4409931 PDL1 growing restricted 0.0504186 2.6785714 19 NA low low high 0.0504186 0.3112585 0.1730174 0.2084050 0.2569004 11RD 73.82461 68.89859 24.26948 26.26985 68.89859 0.7923810 3.0418697 1.5318895 5.8807677 0.2660563 0.2323507 0.1251300 0.3447698 0.4433712 0.1251300 4.944686e-01 6.739300e-01 7.607594e-01 1.036868e+00 0.3847338 0.3672279 0.4221137 0.5481637 0.3672279 0.4874111 0.9114460 0.9526443 1.7814199 PDL1 growing restricted 0.0224452 3.6428571 25 NA low high low 0.0224452 0.2650348 0.1493557 0.2823673 0.2807970 12LD 355.94915 285.85343 12.74758 26.97636 285.85343 1.1920561 27.9228787 2.1493650 50.3470110 0.1078652 0.0002809 0.0230337 0.8362360 0.3896067 0.0002809 3.269000e-04 3.359000e-04 2.713310e-02 2.788040e-02 0.1642608 0.1721016 0.8136763 0.7564140 0.1642608 0.1666306 0.2018748 0.3412152 0.4133860 PDL1 stable Infiltrating 0.0223693 0.7702703 6 NA low low low 0.0223693 0.0019856 0.0110841 0.7397626 0.2247985 13NA 70.80101 NA 22.21206 41.36664 70.80101 3.1875036 3.1875036 3.1875036 3.1875036 0.4678459 0.1279338 NA 0.4849838 0.2605385 0.1279338 2.637897e-01 2.637897e-01 2.637897e-01 2.637897e-01 0.3039013 NA 0.4030033 0.2985239 0.3039013 0.7540913 0.7540913 0.7540913 0.7540913 Vehicle growing restricted 0.0355811 6.2000000 35 NA low low high 0.0355811 0.3384585 0.0000000 0.3573896 0.2685709 14NB 49.22243 100.58773 30.48163 18.51350 49.22243 0.3755449 1.6148228 1.1429838 4.9147687 0.5053671 0.2540062 0.0380039 0.2488995 0.5430442 0.0380039 8.853369e-01 1.020517e+00 1.017799e+00 1.173205e+00 0.4353436 0.3003687 0.4807218 0.6659649 0.3003687 0.5573537 0.9056041 0.9419041 1.5304326 PDL1+LY growing restricted 0.1061520 3.3150685 23 NA low high high 0.1061520 0.3688850 0.0639930 0.1816036 0.2793663 14NC 44.46686 76.76388 45.49485 19.26432 44.46686 0.3637111 0.9774042 0.9915917 2.6647132 0.4206746 0.1239597 0.1186159 0.3935173 0.4955760 0.1186159 2.420458e-01 3.150045e-01 4.736572e-01 6.164292e-01 0.3670808 0.2510773 0.3189692 0.6342029 0.2510773 0.6439488 1.1508345 1.0843994 1.9379867 PDL1+LY stable restricted 0.0541298 0.5595238 6 NA low low high 0.0541298 0.0814721 0.1262934 0.5460494 0.1920553 14RD 31.50346 43.27617 22.18326 22.40920 31.50346 0.4812669 1.4201454 1.1423813 3.3709930 0.1216955 0.1681860 0.1927985 0.5000000 0.4799453 0.1681860 2.427632e-01 3.363719e-01 5.210526e-01 7.219690e-01 0.6214897 0.5437266 0.6250649 0.6154319 0.5437266 0.5317370 0.9942802 0.9969411 1.8641523 PDL1+LY stable Infiltrating 0.0103371 -0.1666667 1 high high low low 0.0103371 0.0890900 0.1325255 0.5077127 0.2603347 15LB 32.69579 70.46882 20.89178 15.83206 32.69579 0.3578762 1.5650073 1.1292024 4.9380478 0.1064567 0.2226772 0.0332283 0.4615748 0.6502362 0.0332283 4.500318e-01 4.824292e-01 5.171865e-01 5.544183e-01 0.4642353 0.4020065 0.5474241 0.5488986 0.4020065 0.4889618 0.8480358 0.9123802 1.5823959 PDL1+LY growing restricted 0.0129612 3.5000000 10 high high low low 0.0129612 0.2153910 0.0414453 0.2667501 0.4634524 15NC-D 39.22818 NA 23.06369 22.18943 39.22818 1.7008635 1.7008635 1.7008635 1.7008635 0.1344853 0.1299775 NA 0.3683947 0.3005259 0.1299775 3.528212e-01 3.528212e-01 3.528212e-01 3.528212e-01 0.4756601 NA 0.5696919 0.4691125 0.4756601 0.8349427 0.8349427 0.8349427 0.8349427 PDL1+LY growing restricted 0.0107875 2.6857143 22 high high low low 0.0107875 0.2245321 0.0000000 0.2679737 0.4967068 15ND 15.54429 53.43276 37.28968 17.33598 15.54429 0.1713390 0.4168524 0.7603086 1.8497622 0.0286055 0.6025030 0.0643623 0.1877235 0.4928486 0.0643623 2.390071e+00 3.209524e+00 2.645390e+00 3.552381e+00 0.6063571 0.6982168 0.6574648 0.5594791 0.6063571 0.4472710 0.9222654 0.9623011 1.9842489 PDL1+LY stable Infiltrating 0.0104721 -0.2285714 3 high high high low 0.0104721 0.4017761 0.0548254 0.1042150 0.4287114 15RD 91.07517 NA NA 11.52589 91.07517 NA NA NA NA 0.2216630 0.1578969 NA NA 0.8819101 0.1578969 NA NA NA NA 0.3729870 NA NA 0.5004661 0.3729870 NA NA NA NA PDL1+LY growing restricted 0.0328312 3.5000000 17 NA low low low 0.0328312 0.1499809 0.0000000 0.0000000 0.8171879 16LA 31.26867 NA 19.19006 27.79750 31.26867 1.6294199 1.6294199 1.6294199 1.6294199 0.3536187 0.2750368 NA 0.4480477 0.3018298 0.2750368 6.138560e-01 6.138560e-01 6.138560e-01 6.138560e-01 0.3355138 NA 0.3365390 0.5012026 0.3355138 0.9969537 0.9969537 0.9969537 0.9969537 PDL1+LY NA Infiltrating 0.0171528 NA 5 high low high low 0.0171528 0.4248684 0.0000000 0.3742464 0.1837324 16LC 71.64542 NA 65.51353 21.56242 71.64542 1.0935973 1.0935973 1.0935973 1.0935973 0.6542978 0.2411490 NA 0.1293491 0.3635133 0.2411490 1.864327e+00 1.864327e+00 1.864327e+00 1.864327e+00 0.0623470 NA 0.0566396 0.1755563 0.0623470 1.1007664 1.1007664 1.1007664 1.1007664 PDL1+LY stable Infiltrating 0.0476926 0.6475410 7 NA low high high 0.0476926 0.4774508 0.0000000 0.2398580 0.2349986 16LD 38.85862 NA 19.42446 22.61613 38.85862 2.0004993 2.0004993 2.0004993 2.0004993 0.2420006 0.3001624 NA 0.4920473 0.3806520 0.3001624 6.100274e-01 6.100274e-01 6.100274e-01 6.100274e-01 0.5734648 NA 0.5863769 0.7224551 0.5734648 0.9779799 0.9779799 0.9779799 0.9779799 PDL1+LY stable Infiltrating 0.0316168 1.9151786 24 high high high low 0.0316168 0.3541756 0.0000000 0.4114572 0.2027504 16ND 29.84045 40.34701 26.33421 47.06903 29.84045 0.4475090 1.1331438 1.0525821 2.6652576 0.4492659 0.2842939 0.0509409 0.3098188 0.0600419 0.0509409 7.880422e-01 9.176134e-01 9.292468e-01 1.082035e+00 0.5094333 0.5063105 0.5696619 0.4611237 0.5063105 0.4734632 0.8942731 0.9440241 1.7830645 PDL1 stable Infiltrating 0.0753308 1.0745763 25 high high high high 0.0753308 0.3759357 0.1326910 0.3128979 0.1031446 16RD 56.31604 NA 16.51236 34.65626 56.31604 3.4105390 3.4105390 3.4105390 3.4105390 0.2959863 0.2354937 NA 0.6114905 0.2825043 0.2354937 3.851142e-01 3.851142e-01 3.851142e-01 3.851142e-01 0.3920871 NA 0.5091869 0.5001361 0.3920871 0.7700258 0.7700258 0.7700258 0.7700258 PDL1 stable Infiltrating 0.0306486 -0.1027397 3 NA low high low 0.0306486 0.2428567 0.0000000 0.5034447 0.2230500 17NA 61.86642 NA 22.48160 21.57101 61.86642 2.7518686 2.7518686 2.7518686 2.7518686 0.3757123 0.0907525 NA 0.3861962 0.5524496 0.0907525 2.349907e-01 2.349907e-01 2.349907e-01 2.349907e-01 0.3510232 NA 0.3711945 0.6450455 0.3510232 0.9456584 0.9456584 0.9456584 0.9456584 Vehicle growing restricted 0.0472687 6.8000000 28 NA low low high 0.0472687 0.1826840 0.0000000 0.5151503 0.2548971 17ND 111.85371 232.02438 15.06388 18.01790 111.85371 0.4526873 7.4252921 1.3917217 22.8279895 0.3246353 0.0029328 0.0003008 0.6664160 0.4851857 0.0003008 4.398800e-03 4.400800e-03 4.850000e-03 4.852200e-03 0.6112631 0.3687613 0.8549621 0.8295674 0.3687613 0.4995108 0.7149593 0.8008545 1.1462782 Vehicle stable Infiltrating 0.1115267 -0.3846154 4 NA high low high 0.1115267 0.0111711 0.0017025 0.5278356 0.3477641 17RB 16.70828 88.48121 95.13230 35.71473 16.70828 0.0909970 0.1756320 0.5728853 1.1057178 0.3890573 0.6275561 0.0788001 0.0414694 0.2133747 0.0788001 5.217914e+00 1.513298e+01 5.873110e+00 1.703317e+01 0.4630693 0.3330522 0.2863570 0.5250959 0.3330522 0.7475982 1.6171046 1.2852916 2.7801709 Vehicle growing Infiltrating 0.0411074 8.2142857 35 high high high high 0.0411074 0.6606120 0.1202333 0.0539738 0.1240735 2N 35.15413 87.60001 47.77260 19.20262 35.15413 0.2596842 0.7358639 0.9067871 2.5695512 0.3846518 0.2448721 0.0808522 0.2826408 0.5902966 0.0808522 6.736639e-01 8.663721e-01 8.960951e-01 1.152432e+00 0.3766073 0.2983787 0.4403993 0.5295795 0.2983787 0.5097705 0.8551496 0.9136520 1.5326682 Vehicle growing restricted 0.0301041 11.7000000 47 high low high low 0.0301041 0.1961374 0.0921483 0.3136859 0.3679243 2RA 132.80795 534.05443 44.80857 15.31048 132.80795 0.2294290 2.9638960 1.1520211 14.8824729 0.3464678 0.0452766 0.0009580 0.4371043 0.6856881 0.0009580 1.033565e-01 1.035830e-01 1.055434e-01 1.057747e-01 0.3252085 0.0428215 0.6315026 0.7958075 0.0428215 0.4822734 0.5149758 0.5457762 0.5827846 Vehicle growing restricted 0.0858192 3.5428571 20 NA low low high 0.0858192 0.0391991 0.0016908 0.4304185 0.4428724 2RD 38.61221 73.15221 27.66634 21.62384 38.61221 0.3829872 1.3956389 1.1085701 4.0397263 0.3219793 0.1979009 0.1740124 0.2492193 0.5216188 0.1740124 4.675947e-01 7.940835e-01 8.787464e-01 1.492314e+00 0.6791816 0.5025059 0.6306731 0.6470092 0.5025059 0.5993594 1.0769154 1.0428074 1.8736925 Vehicle growing restricted 0.0742195 20.0000000 20 high high low high 0.0742195 0.2659629 0.1222001 0.1820660 0.3555515 3LA 46.09601 104.05573 65.98973 41.88896 46.09601 0.2710805 0.6985331 0.8830094 2.2753805 0.4243628 0.2865240 0.0929863 0.0477520 0.2387958 0.0929863 2.035863e+00 6.000250e+00 2.696566e+00 7.947526e+00 0.4162200 0.3804293 0.3760026 0.3828019 0.3804293 0.5502412 1.1069606 1.0531673 2.1187337 Vehicle growing restricted 0.0531246 3.0000000 12 NA low high high 0.0531246 0.3953915 0.1475608 0.0995967 0.3043263 3NB 32.31159 NA 62.64161 29.70786 32.31159 0.5158168 0.5158168 0.5158168 0.5158168 0.7233868 0.4377911 NA 0.0275246 0.2218779 0.4377911 1.590545e+01 1.590545e+01 1.590545e+01 1.590545e+01 0.7061056 NA 0.6013878 0.6956147 0.7061056 1.1741270 1.1741270 1.1741270 1.1741270 Vehicle stable Infiltrating 0.2768299 0.0245902 6 high high high high 0.2768299 0.4731210 0.0000000 0.0426761 0.2073729 3RB 42.63162 NA 29.99254 46.16097 42.63162 1.4214077 1.4214077 1.4214077 1.4214077 0.1779959 0.2910751 NA 0.3592331 0.2055695 0.2910751 8.102681e-01 8.102681e-01 8.102681e-01 8.102681e-01 0.4645950 NA 0.5255821 0.5058014 0.4645950 0.8839629 0.8839629 0.8839629 0.8839629 Vehicle growing restricted 0.0266554 7.6857143 35 NA high high low 0.0266554 0.4366082 0.0000000 0.3803764 0.1563600 3RC 32.11938 55.92834 37.32758 27.31100 32.11938 0.3444219 0.8604733 0.9441516 2.3587846 0.2039175 0.2962108 0.0879309 0.2004961 0.3165683 0.0879309 1.026987e+00 1.477389e+00 1.331851e+00 1.915956e+00 0.4965437 0.4931253 0.5659050 0.4892378 0.4931253 0.4688663 0.8774329 0.9345049 1.7488254 Vehicle growing Infiltrating 0.0232139 5.5428571 32 high high high low 0.0232139 0.3885529 0.1160041 0.1513443 0.3208848 4LB 30.99117 57.04930 28.06937 16.66993 30.99117 0.3640937 1.1040920 1.0343262 3.1365315 0.2172720 0.2903294 0.1223870 0.2381757 0.5714738 0.1223870 8.052119e-01 1.218972e+00 1.144645e+00 1.732824e+00 0.5447258 0.4889290 0.6094964 0.6457394 0.4889290 0.4959152 0.8937309 0.9410332 1.6959161 Vehicle growing Infiltrating 0.0244474 6.8783784 35 high high high low 0.0244474 0.3498723 0.1053868 0.1496622 0.3706314 4NC 15.33106 NA 30.68159 155.44956 15.33106 0.4996826 0.4996826 0.4996826 0.4996826 0.2675045 0.6851436 NA 0.2188061 0.0832585 0.6851436 3.131282e+00 3.131282e+00 3.131282e+00 3.131282e+00 0.0901870 NA 0.0833893 0.0617270 0.0901870 1.0815175 1.0815175 1.0815175 1.0815175 Vehicle growing restricted 0.0081388 3.0000000 15 high low high low 0.0081388 0.7235846 0.0000000 0.1765309 0.0917458 4ND 20.75556 NA 14.30657 39.67271 20.75556 1.4507707 1.4507707 1.4507707 1.4507707 0.0356608 0.4768080 NA 0.7169576 0.1271820 0.4768080 6.650435e-01 6.650435e-01 6.650435e-01 6.650435e-01 0.5809047 NA 0.6145949 0.4747809 0.5809047 0.9451830 0.9451830 0.9451830 0.9451830 Vehicle growing Infiltrating 0.0076245 4.3000000 20 high high high low 0.0076245 0.3776893 0.0000000 0.5044369 0.1102494 4RB 53.31478 62.79761 25.09420 28.66758 53.31478 0.6065954 2.1245853 1.3210831 4.6270602 0.3672294 0.1765476 0.1182837 0.3346431 0.3210703 0.1182837 3.897928e-01 5.275699e-01 6.509470e-01 8.810323e-01 0.3445324 0.2962686 0.4664550 0.4612347 0.2962686 0.4517134 0.7386188 0.8401484 1.3737682 Vehicle growing restricted 0.0280096 7.8108108 40 NA low low low 0.0280096 0.3031804 0.1644440 0.2243090 0.2800569 5LA 41.12871 NA 15.84267 35.17202 41.12871 2.5960728 2.5960728 2.5960728 2.5960728 0.3901975 0.2471295 NA 0.5824421 0.1998228 0.2471295 4.242987e-01 4.242987e-01 4.242987e-01 4.242987e-01 0.3724930 NA 0.4774657 0.5347450 0.3724930 0.7801461 0.7801461 0.7801461 0.7801461 Vehicle stable Infiltrating 0.0453952 0.5000000 6 high low high high 0.0453952 0.3487738 0.0000000 0.4772540 0.1285770 5LB 41.91177 NA NA 15.05867 41.91177 NA NA NA NA 0.3379618 0.2807178 NA NA 0.6502489 0.2807178 NA NA NA NA 0.4690510 NA NA 0.5768777 0.4690510 NA NA NA NA Vehicle growing restricted 0.0257830 4.0000000 4 high high high low 0.0257830 0.4705880 0.0000000 0.0000000 0.5036290 5LC 82.68448 NA 23.56636 61.02936 82.68448 3.5085804 3.5085804 3.5085804 3.5085804 0.5297032 0.1168545 NA 0.4516540 0.1066662 0.1168545 2.587257e-01 2.587257e-01 2.587257e-01 2.587257e-01 0.1980203 NA 0.3895202 0.2387265 0.1980203 0.5083697 0.5083697 0.5083697 0.5083697 Vehicle growing restricted 0.0515055 3.5000000 22 NA low low high 0.0515055 0.2846330 0.0000000 0.4592795 0.2045821 5LD 91.41539 174.12079 36.47074 28.68030 91.41539 0.4340886 2.5065407 1.2609063 7.2808006 0.4943721 0.0735101 0.0027369 0.1400046 0.2530645 0.0027369 5.149878e-01 5.250551e-01 5.341615e-01 5.446035e-01 0.2028472 0.2788666 0.4802003 0.2621711 0.2028472 0.2672323 0.4224220 0.6346131 1.0031517 Vehicle stable restricted 0.0348108 0.9299769 15 NA low low high 0.0348108 0.2374921 0.0095635 0.0727253 0.6454083 5RB 39.00602 NA 20.88804 28.66510 39.00602 1.8673849 1.8673849 1.8673849 1.8673849 0.4820815 0.1934315 NA 0.5213079 0.2945054 0.1934315 3.710503e-01 3.710503e-01 3.710503e-01 3.710503e-01 0.4479302 NA 0.5374927 0.6768886 0.4479302 0.8333697 0.8333697 0.8333697 0.8333697 Vehicle growing restricted 0.0596672 10.3571429 35 high high low high 0.0596672 0.3435375 0.0000000 0.4625612 0.1342341 6LDU 111.44785 NA 21.09500 421.71225 111.44785 5.2831411 5.2831411 5.2831411 5.2831411 0.4110641 0.1092889 NA 0.6222455 0.0145634 0.1092889 1.756363e-01 1.756363e-01 1.756363e-01 1.756363e-01 0.2738092 NA 0.5283543 0.1477985 0.2738092 0.5182302 0.5182302 0.5182302 0.5182302 LY growing restricted 0.0556253 2.1974522 32 NA low low high 0.0556253 0.2676477 0.0000000 0.6471339 0.0295931 6ND 28.41556 47.86891 30.70313 51.92693 28.41556 0.3616497 0.9254938 0.9708856 2.4845825 0.5991449 0.2756628 0.0305404 0.2129080 0.0798398 0.0305404 1.132325e+00 1.294750e+00 1.257774e+00 1.438195e+00 0.4251078 0.4268267 0.4635154 0.3522267 0.4251078 0.4774657 0.9171386 0.9568620 1.8379855 LY growing NA 0.0815901 30.0000000 40 high low high high 0.0815901 0.4698473 0.1070807 0.2534581 0.0880237 6RB 76.37955 NA 15.75336 43.30215 76.37955 4.8484602 4.8484602 4.8484602 4.8484602 0.5258014 0.1446840 NA 0.6712516 0.2653502 0.1446840 2.155435e-01 2.155435e-01 2.155435e-01 2.155435e-01 0.5947703 NA 0.7777489 0.5992406 0.5947703 0.7647331 0.7647331 0.7647331 0.7647331 LY growing Infiltrating 0.1554804 2.8000000 18 NA high low high 0.1554804 0.1771439 0.0000000 0.4830327 0.1843430 6RC 50.21453 66.49674 18.16188 34.81308 50.21453 0.5931413 2.7648305 1.3786105 6.4261656 0.3830618 0.1966022 0.0674351 0.5424852 0.2411991 0.0674351 3.223408e-01 3.624103e-01 4.329047e-01 4.867181e-01 0.5496400 0.5658702 0.7159182 0.5999896 0.5496400 0.4288071 0.7677413 0.8702764 1.5581531 LY growing restricted 0.0788010 8.2142857 40 NA high low high 0.0788010 0.2478878 0.1192287 0.3914362 0.1626462 7NB 80.17580 NA 23.02340 30.71527 80.17580 3.4823613 3.4823613 3.4823613 3.4823613 0.3887826 0.0728176 NA 0.3846771 0.3060872 0.0728176 1.892955e-01 1.892955e-01 1.892955e-01 1.892955e-01 0.1877309 NA 0.3301680 0.3085962 0.1877309 0.5685921 0.5685921 0.5685921 0.5685921 LY growing restricted 0.0206734 2.8878505 31 NA low low low 0.0206734 0.2664928 0.0000000 0.3467436 0.3660903 7NC 89.34399 NA 18.52427 73.48726 89.34399 4.8230787 4.8230787 4.8230787 4.8230787 0.5526142 0.0531233 NA 0.5233799 0.0517752 0.0531233 1.015004e-01 1.015004e-01 1.015004e-01 1.015004e-01 0.2103338 NA 0.3281735 0.3093273 0.2103338 0.6409224 0.6409224 0.6409224 0.6409224 LY growing restricted 0.0479457 3.4444444 40 NA low low high 0.0479457 0.1405509 0.0000000 0.7359455 0.0755580 7RA 33.35958 39.17649 17.01392 25.12197 33.35958 0.5936880 1.9607221 1.2908975 4.2633357 0.2951535 0.2251296 0.1866754 0.4992183 0.1908445 0.1866754 3.282281e-01 4.509642e-01 6.003919e-01 8.248997e-01 0.4269972 0.4450687 0.4880454 0.4605433 0.4269972 0.4576045 0.8749129 0.9345759 1.7868541 LY stable restricted 0.0319310 1.1153846 8 high low low low 0.0319310 0.2323095 0.1931934 0.3383713 0.2041948 7RB 34.39737 14.99604 27.35225 37.09141 14.99604 0.8122495 1.2575703 1.1663616 1.8058266 0.0670603 0.1917334 0.6787431 0.1155631 0.1097005 0.1917334 2.413848e-01 1.659124e+00 1.095895e+00 7.532482e+00 0.7110689 0.7542676 0.7243839 0.6983881 0.7110689 0.4808902 0.9816189 0.9909952 2.0228729 LY growing NA 0.0169469 3.9615385 20 high high low low 0.0169469 0.2035659 0.5256130 0.1194875 0.1343866 7RD 44.13770 NA 14.33429 38.10895 44.13770 3.0791694 3.0791694 3.0791694 3.0791694 0.3013841 0.2386457 NA 0.6842436 0.1745901 0.2386457 3.487731e-01 3.487731e-01 3.487731e-01 3.487731e-01 0.4019270 NA 0.5112804 0.4716179 0.4019270 0.7861186 0.7861186 0.7861186 0.7861186 LY stable Infiltrating 0.0321690 0.9966997 20 NA low high low 0.0321690 0.2553332 0.0000000 0.5606542 0.1518436 8LD 16.36623 350.73208 292.95079 22.72937 16.36623 0.0254259 0.0558668 0.5703093 1.2531057 0.3456743 0.6508906 0.0008906 0.0035623 0.3871501 0.0008906 1.461714e+02 1.827143e+02 1.463714e+02 1.829643e+02 0.7532812 0.2276701 0.2459080 0.6704011 0.2276701 1.5906168 3.0632648 2.0713614 3.9890994 LY stable Infiltrating 0.0562336 0.2418033 6 high high high high 0.0562336 0.5936154 0.0018530 0.0036344 0.3446635 8RCL 15.12966 NA 36.87314 33.12931 15.12966 0.4103167 0.4103167 0.4103167 0.4103167 0.1051350 0.6186366 NA 0.3669765 0.2673749 0.6186366 1.685766e+00 1.685766e+00 1.685766e+00 1.685766e+00 0.7536385 NA 0.6632300 0.5347990 0.7536385 1.1363156 1.1363156 1.1363156 1.1363156 LY growing restricted 0.0176691 12.0000000 12 high high high low 0.0176691 0.5536036 0.0000000 0.2486459 0.1800814 8RCU 50.00101 NA 24.56317 37.07321 50.00101 2.0356094 2.0356094 2.0356094 2.0356094 0.2746806 0.2347423 NA 0.4697355 0.2889853 0.2347423 4.997329e-01 4.997329e-01 4.997329e-01 4.997329e-01 0.4676640 NA 0.4583922 0.5419777 0.4676640 1.0202267 1.0202267 1.0202267 1.0202267 LY growing restricted 0.0287668 5.5142857 27 NA high high low 0.0287668 0.2578575 0.0000000 0.5074018 0.2059739 Firstly, we can compare the different metrics to determine how similar or different they are: Do any of these metrics associate with growth or treatments? ## ## Wilcoxon rank sum exact test ## ## data: df.Spatial$CD8frac by df.Spatial$Growth ## W = 258, p-value = 0.2917 ## alternative hypothesis: true location shift is not equal to 0 We can also compare this to raw tumor size or growth rate data as well: 4.5 Other cell types We noted that the proportion of Unclassified cells seemed to be different between the treatments. Assess here whether the MH index for this cell type is associated with growth or treatment here: "],["expression-data.html", "Chapter 5 Expression data 5.1 Running alignment 5.2 RNA Initial QC 5.3 Normalisation 5.4 Processing files for external software", " Chapter 5 Expression data This file looks at loading and pre-processing data for: differential gene expression analysis PAM50 subtyping uploading into CIBERSORT/TIMER 5.1 Running alignment Samples were mapped in star using the following parameters. Note that the first two batches of samples run had shorter read lengths (~75 bp) whereas batch 3 had lengths of ~150bp ## Not run here STAR \\ --readFilesCommand zcat \\ --genomeDir /n/scratch2/at268/rn6_v2 \\ --sjdbGTFfile /n/scratch2/at268/rn6_v2/rn6.refGene.gtf \\ --runThreadN 10 \\ --runMode alignReads \\ --genomeLoad NoSharedMemory\\ --outSAMattributes NH HI AS nM NM\\ --outSAMstrandField intronMotif\\ --outFilterMultimapNmax 20\\ --alignSJoverhangMin 8\\ --readFilesIn $1 $2 \\ --alignSJDBoverhangMin 1\\ --outFilterMismatchNmax 999\\ --outFilterMismatchNoverLmax 0.1\\ --alignIntronMin 20\\ --alignIntronMax 1000000\\ --alignMatesGapMax 1000000\\ --outFilterType BySJout\\ --outFilterScoreMinOverLread 0.33 \\ --outFilterMatchNminOverLread 0.33 \\ --limitSjdbInsertNsj 1200000 \\ --outFilterIntronMotifs None \\ --alignSoftClipAtReferenceEnds Yes\\ --outSAMattrRGline ID:$4 SM:$4 \\ --chimSegmentMin 15 \\ --chimJunctionOverhangMin 15\\ --limitBAMsortRAM 0\\ --outSAMtype BAM SortedByCoordinate\\ --outSAMunmapped Within \\ --quantMode GeneCounts transcriptomeSAM \\ --quantTranscriptomeBan IndelSoftclipSingleend \\ --outFileNamePrefix $3 \\ --twopassMode Basic In addition, RSEM was run to obtain TPM, rsem and FPKM counts. Note: rn6.refGene.gtf.gz was used to generate the RSEM library!(This is the may version) 5.2 RNA Initial QC Default output from R showing the number of unique reads compared to multimapped, unmapped etc. This is shown for each batch. Note that batch 3 has differences (high percentage of unmapped) compared to the other batches, possibly due to DNA contamination. Below we check for three measures: mapped million reads (ideally, 10M+ reads) Gene Sparsity: This is a measurement of the number of genes which have non-zero values. Ideally, would be greater than 10K, but values which are too high may also suggest contamination from DNA (unexpressed genes are also counted) Varability: standard deviation of the transcriptomic counts. If this value is too low, would suggest that high DNA contamination, non-representative transcriptome. Samples to remove from analysis: The thresholds indicated below are based on the above density plots, and removes cases which are &lt;1.5 SD of the mean low total number of mapped reads (under 1.5M) sparsity: less than 8K genes variability : threshold under 500 The omitted samples are: MappedReadsM GeneSparsityK Batch GeneVariabilityCounts Type names 6R_C_CD45 2.287110 5.585 2 1063.38925 CD45 6R_C_CD45 10L_B_DN 0.864838 3.308 2 559.30659 DN 10L_B_DN NMU1_LL_Ep 1.032440 16.708 3 69.82645 Ep NMU1_LL_Ep NMU5_LA_Ep 0.500429 15.707 3 35.56084 Ep NMU5_LA_Ep Control1__Ep 8.224593 5.800 1 3164.00515 Ep Control1__Ep NMU13_RAU_Ep 3.049733 7.242 1 1069.99912 Ep NMU13_RAU_Ep We are left with 110 samples. There are 47, 32, 31 samples in the CD45, Ep, DN fractions. There are 20, 49, 41 samples from batches 1, 2 and 3 respectively. 5.3 Normalisation Run through DESEq and normalise the library. Using all samples, we run the model: expression ~ Celltype + factor (Batch) and keep the genes which have a total count of at least half the number of samples. ie. $ sum(gene_i) &gt; N_{samples}/2 $ 5.3.1 preliminary visualisation (to remove outliers) Below are PCA plots based on: Batch CellType Batches in general separate out well, however, some samples appear to be outliers in comparison to the main group. We look in closer detail the CD45, DN and EpCAM populations. In the CD45 population, narrow down to only immune related genes to see if there is a difference. Based on the above plots, we remove the following outliers and re-run the normalisation: 2R_D_DN 4L_B_CD45 5.4 Processing files for external software We also process these files for external software: Software RNA-data PAM50 rsem data after quantile normalised, genes converted to human TIMER TPM values, retain rat ids xcell rsem data, genes converted ti human cibersort tpm?? convert to rat genes and use lm22 rat ## named integer(0) ## named integer(0) Save the mouse names for TIMER cistrome: check that this is actually required for TIMER "],["rna-data-preliminary-plots.html", "Chapter 6 RNA data: preliminary plots 6.1 PCA plots 6.2 Expression patterns by cell type", " Chapter 6 RNA data: preliminary plots Prior to doing any comparative analysis, we will look at the following plots to get an overview of the data. 6.1 PCA plots We can check the new PCA plots, and overlay parameters of interest including treatment, growth, tumor size, CD8 fraction, spatial distribution. In addition, we can look at the CD45 population and the distributions based on CD8 content and spatial infiltration 6.2 Expression patterns by cell type Below, we check whether the different fractions are expressing expected markers The cell types are: Red: Cd45 Epcam: green DN:blue Reference Genes: purple: immune blue: epithelial green: stroma orange: myoepithelial red: endothelial Below, we see that the CD45 cells separate from the Ep/DN populations have high expression of immune related genes including CD3, CD4, IFNG. However, the DN/Ep fractions are more intermixed. The DN fraction has expression of keratins, as well as fibroblast markers (Acta1), and myeoepithelial markers (Tp63) "],["deseq-analysis.html", "Chapter 7 DESeq analysis 7.1 DN vs Ep 7.2 No. samples in comparisons 7.3 Set-up cell-type specifoc the comparisons 7.4 PCA plots 7.5 Collating results and running GSEA", " Chapter 7 DESeq analysis This document sets up DESeq runs to compare: DN vs Ep samples growing vs stable samples (all 3 fractions) treatments (all 3 fractions) spatial patterns (all 3 fractions) The outputs of these analyses will be used for Gene Set Enrichment Analysis, using MSigDB databases (c2, c5, hallmark), alongside pathways from Metacore (Process Networks, Pathway Maps) 7.1 DN vs Ep In section 6.2, we have noticed that some DN samples had expression of epithelial markers. Here, we perform a differential gene expression analysis to find genes which are different between these two fractions. Below is a summary of the number of differential genes, using p value cut off of 0.05 and log2 fold change of 1.5 and base expression of 100+. ## ## out of 15301 with nonzero total read count ## adjusted p-value &lt; 0.1 ## LFC &gt; 0 (up) : 2172, 14% ## LFC &lt; 0 (down) : 1188, 7.8% ## outliers [1] : 463, 3% ## low counts [2] : 779, 5.1% ## (mean count &lt; 2) ## [1] see &#39;cooksCutoff&#39; argument of ?results ## [2] see &#39;independentFiltering&#39; argument of ?results ## [1] &quot;significant differential genes&quot; baseMean log2FoldChange lfcSE stat pvalue padj CellMarker Col1a1 35939.3836 4.962384 0.7227443 6.866031 0.0000000 0.0000000 1 Fap 147.5058 3.791943 0.6564706 5.776257 0.0000000 0.0000009 1 Mme 214.6225 2.418161 0.5763311 4.195784 0.0000272 0.0005517 1 Itgam 289.8078 -2.251148 0.5564127 -4.045824 0.0000521 0.0009532 1 Tp63 145.5968 2.047668 0.4768123 4.294494 0.0000175 0.0003907 1 Cdh5 114.3639 1.899697 0.6674752 2.846093 0.0044259 0.0302941 1 Cd38 370.4184 1.897076 0.4719555 4.019608 0.0000583 0.0010370 1 Krt14 949.2009 1.834436 0.4774425 3.842214 0.0001219 0.0018837 1 Vim 13706.1725 1.832658 0.3361022 5.452680 0.0000000 0.0000035 1 Cdh3 100.1030 1.705776 0.4293903 3.972553 0.0000711 0.0012132 1 Acta2 489.5164 1.678424 0.4013367 4.182086 0.0000289 0.0005810 1 Cnn1 618.4035 1.572872 0.4698537 3.347578 0.0008152 0.0081399 1 Has1 1055.8193 5.225993 0.9169187 5.699517 0.0000000 0.0000012 0 Kcnj8 150.2479 5.106866 0.9198897 5.551607 0.0000000 0.0000024 0 Tnfaip6 1367.6191 4.884208 0.7501757 6.510752 0.0000000 0.0000000 0 Col3a1 49552.9325 4.760600 0.7012094 6.789128 0.0000000 0.0000000 0 Efemp1 881.5097 4.683106 0.7438751 6.295555 0.0000000 0.0000001 0 Tfpi2 596.7720 4.521006 0.9041932 5.000045 0.0000006 0.0000243 0 Mrgprf 104.0202 4.484916 0.9635078 4.654779 0.0000032 0.0000981 0 Mmp2 7528.7484 4.481987 0.6701775 6.687761 0.0000000 0.0000000 0 Igfbp6 2578.1365 4.465397 0.6658507 6.706304 0.0000000 0.0000000 0 Hbb 1278.4319 4.431234 0.7667745 5.779058 0.0000000 0.0000009 0 Apod 552.7689 4.374624 0.7240692 6.041721 0.0000000 0.0000003 0 Spib 174.1913 4.374116 0.6287682 6.956643 0.0000000 0.0000000 0 Cpz 290.8653 4.325378 0.9187742 4.707770 0.0000025 0.0000793 0 Tspan11 172.1873 4.288019 0.7804044 5.494612 0.0000000 0.0000029 0 LOC100134871 436.1531 4.234204 0.7568248 5.594696 0.0000000 0.0000019 0 Sparcl1 1520.9808 4.233548 0.7343076 5.765360 0.0000000 0.0000009 0 Pdgfra 495.7998 4.190576 0.7179601 5.836782 0.0000000 0.0000007 0 Col5a1 1752.5889 4.155583 0.6259314 6.639039 0.0000000 0.0000000 0 Dpt 583.3697 4.147208 0.6559286 6.322652 0.0000000 0.0000001 0 Fbn1 921.7115 4.125401 0.5615089 7.346992 0.0000000 0.0000000 0 Col15a1 828.4627 4.124258 0.6593330 6.255197 0.0000000 0.0000001 0 Dcn 10892.6969 4.117527 0.6250693 6.587313 0.0000000 0.0000000 0 Fxyd1 174.1726 4.106043 0.6962028 5.897768 0.0000000 0.0000005 0 Postn 12740.6036 4.096853 0.6938254 5.904732 0.0000000 0.0000005 0 Itgbl1 223.0312 4.053286 0.8615332 4.704735 0.0000025 0.0000801 0 Ccl22 1262.4011 -4.048056 0.5944758 -6.809453 0.0000000 0.0000000 0 Islr 445.7657 4.041353 0.6851470 5.898519 0.0000000 0.0000005 0 Gldn 394.0635 4.040732 0.8432221 4.792014 0.0000017 0.0000575 0 Olfml1 101.7302 4.039497 0.8714107 4.635583 0.0000036 0.0001056 0 Galnt16 235.8797 4.029000 0.7805832 5.161526 0.0000002 0.0000120 0 Itm2a 1424.0267 4.019341 0.5205803 7.720886 0.0000000 0.0000000 0 Thbs2 1680.5753 3.997895 0.7430007 5.380743 0.0000001 0.0000047 0 Scara5 224.8668 3.996331 0.7415814 5.388930 0.0000001 0.0000046 0 Crabp1 1258.6359 3.995252 0.6104762 6.544485 0.0000000 0.0000000 0 Pdgfrb 899.2339 3.990568 0.7270536 5.488684 0.0000000 0.0000030 0 Gfpt2 1672.4921 3.990263 0.5355044 7.451410 0.0000000 0.0000000 0 Ccl21 643.8399 3.985334 0.6767897 5.888585 0.0000000 0.0000005 0 RGD1566401 114.7767 3.962035 0.7965527 4.973977 0.0000007 0.0000269 0 Eln 5425.0544 3.943520 0.7444350 5.297334 0.0000001 0.0000067 0 Col6a2 5387.6668 3.942080 0.6932033 5.686758 0.0000000 0.0000013 0 Cpxm1 1585.0603 3.939259 0.6515195 6.046264 0.0000000 0.0000003 0 Adcyap1r1 133.3374 3.925702 0.8368514 4.691039 0.0000027 0.0000851 0 PCOLCE2 117.6909 3.921190 0.6696112 5.855920 0.0000000 0.0000006 0 Aoc3 343.2626 3.905368 0.7833824 4.985265 0.0000006 0.0000258 0 Col5a3 1013.1137 3.898067 0.6018566 6.476737 0.0000000 0.0000000 0 Pdgfrl 188.5097 3.888176 0.6219678 6.251410 0.0000000 0.0000001 0 Ackr3 750.1550 3.887427 0.6112644 6.359648 0.0000000 0.0000001 0 Abcc9 113.4290 3.887186 0.8540347 4.551556 0.0000053 0.0001468 0 Col13a1 172.4789 3.879389 0.7149660 5.425977 0.0000001 0.0000039 0 Gpc3 293.2851 3.876982 0.7374236 5.257469 0.0000001 0.0000077 0 Bgn 1353.8364 3.843048 0.5484879 7.006624 0.0000000 0.0000000 0 Twist2 122.7245 3.828633 0.6948534 5.509986 0.0000000 0.0000028 0 Mmp23 153.3978 3.817112 0.8035153 4.750515 0.0000020 0.0000671 0 Lum 2996.3591 3.808064 0.7535869 5.053251 0.0000004 0.0000198 0 Col5a2 1987.2832 3.806475 0.5944438 6.403424 0.0000000 0.0000000 0 Mfap2 708.5328 3.764531 0.6990823 5.384962 0.0000001 0.0000046 0 Clec14a 213.1095 3.762077 0.7577298 4.964933 0.0000007 0.0000278 0 Aebp1 2400.6551 3.761392 0.5572265 6.750203 0.0000000 0.0000000 0 Cpxm2 189.4602 3.751737 0.7498173 5.003535 0.0000006 0.0000241 0 Alas2 117.5090 3.751124 0.7688976 4.878575 0.0000011 0.0000403 0 Loxl1 2793.2778 3.733739 0.6722600 5.554011 0.0000000 0.0000024 0 Rarres2 395.4666 3.712135 0.6645458 5.585973 0.0000000 0.0000020 0 Sparc 16599.5599 3.698458 0.5551124 6.662539 0.0000000 0.0000000 0 Tmeff2 140.8363 3.695953 0.7468236 4.948896 0.0000007 0.0000298 0 Rn5-8s 337.1775 3.695742 0.8313426 4.445511 0.0000088 0.0002221 0 Srpx 874.7754 3.689491 0.6004505 6.144537 0.0000000 0.0000002 0 C1qtnf5 228.0348 3.676580 0.7843584 4.687373 0.0000028 0.0000863 0 Prss23 724.0416 3.671800 0.6468671 5.676283 0.0000000 0.0000014 0 Mfap5 685.2607 3.668213 0.6620112 5.541013 0.0000000 0.0000025 0 Ccdc80 1829.8179 3.645264 0.5482910 6.648412 0.0000000 0.0000000 0 Cpe 2628.2092 3.641322 0.4887377 7.450461 0.0000000 0.0000000 0 Enpep 135.7973 3.627904 0.7184404 5.049694 0.0000004 0.0000200 0 Rem1 171.7637 3.616636 0.7462768 4.846239 0.0000013 0.0000455 0 Ccn4 146.5475 3.604087 0.6045394 5.961707 0.0000000 0.0000004 0 Adamts2 569.0533 3.598100 0.7003446 5.137613 0.0000003 0.0000133 0 Ctsk 1004.5330 3.586386 0.5769632 6.215970 0.0000000 0.0000001 0 Thy1 1639.9832 3.585712 0.5555107 6.454804 0.0000000 0.0000000 0 Fndc1 653.4144 3.583788 0.6517777 5.498482 0.0000000 0.0000029 0 Ednra 214.7011 3.571042 0.6918549 5.161548 0.0000002 0.0000120 0 Cd19 300.3735 3.566912 0.7591247 4.698716 0.0000026 0.0000822 0 Cilp 767.8307 3.558115 0.8654277 4.111396 0.0000393 0.0007442 0 Cdh11 303.1402 3.553893 0.6881904 5.164112 0.0000002 0.0000120 0 Adam33 218.2169 3.529658 0.7313335 4.826332 0.0000014 0.0000494 0 Srpx2 147.1139 3.526927 0.8243701 4.278330 0.0000188 0.0004162 0 Igf2 107.1462 -3.524473 0.6396803 -5.509741 0.0000000 0.0000028 0 Gpx7 283.5994 3.507575 0.5984975 5.860634 0.0000000 0.0000006 0 Sod3 773.2443 3.498057 0.6224266 5.620032 0.0000000 0.0000017 0 Ccl11 449.9654 3.487867 0.7399373 4.713734 0.0000024 0.0000775 0 Fbln5 329.1670 3.473358 0.6305254 5.508672 0.0000000 0.0000028 0 Lrrc15 160.6559 3.465589 0.6896151 5.025396 0.0000005 0.0000222 0 Igfbp4 6868.9260 3.449300 0.5317118 6.487160 0.0000000 0.0000000 0 Ccl17 3117.8792 -3.441018 0.5784371 -5.948819 0.0000000 0.0000004 0 Frzb 335.9461 3.439346 0.7246032 4.746524 0.0000021 0.0000678 0 C1s 3234.7963 3.432168 0.5636997 6.088645 0.0000000 0.0000002 0 Olfml2b 293.5409 3.428133 0.7345340 4.667086 0.0000031 0.0000928 0 Loxl2 494.6941 3.420520 0.5158520 6.630815 0.0000000 0.0000000 0 Fbln1 652.1221 3.414300 0.4889470 6.982967 0.0000000 0.0000000 0 Egflam 351.8968 3.411422 0.6319873 5.397928 0.0000001 0.0000044 0 Htra3 1126.9497 3.410652 0.5461941 6.244396 0.0000000 0.0000001 0 Gpr153 157.3531 3.370957 0.5778828 5.833288 0.0000000 0.0000007 0 Fn1 4381.3125 3.363465 0.5333507 6.306292 0.0000000 0.0000001 0 Aqp1 342.5305 3.357604 0.6858442 4.895578 0.0000010 0.0000373 0 Cygb 194.7823 3.352873 0.5415572 6.191169 0.0000000 0.0000001 0 Col4a1 4913.9207 3.351806 0.4175209 8.027876 0.0000000 0.0000000 0 Igsf10 125.4202 3.350222 0.6831169 4.904317 0.0000009 0.0000363 0 Serpinf1 4732.2516 3.346877 0.5542602 6.038457 0.0000000 0.0000003 0 Olfml3 354.2830 3.338585 0.6408231 5.209838 0.0000002 0.0000096 0 Lox 310.8568 3.333985 0.7054371 4.726126 0.0000023 0.0000741 0 Colec12 287.2502 3.328795 0.6597500 5.045540 0.0000005 0.0000202 0 Plac9 137.8345 3.325018 0.6254486 5.316213 0.0000001 0.0000061 0 Pla1a 293.2981 3.292023 0.5477565 6.010012 0.0000000 0.0000003 0 LOC691995 230.8211 3.270834 0.5669424 5.769254 0.0000000 0.0000009 0 Nid2 275.2809 3.266345 0.5258189 6.211920 0.0000000 0.0000001 0 Ror2 221.1602 3.252701 0.5544133 5.866924 0.0000000 0.0000006 0 Sfrp4 614.7835 3.245150 0.7690096 4.219908 0.0000244 0.0005098 0 Procr 422.2953 3.241370 0.5116031 6.335713 0.0000000 0.0000001 0 Col26a1 203.7522 3.238487 0.9226826 3.509860 0.0004483 0.0052093 0 Pth1r 203.6533 3.224445 0.6928759 4.653712 0.0000033 0.0000982 0 Mxra8 1106.5546 3.221917 0.5417717 5.947000 0.0000000 0.0000004 0 Ntrk2 162.6233 3.218944 0.8043974 4.001684 0.0000629 0.0011011 0 Itga11 156.1783 3.217376 0.7328500 4.390225 0.0000113 0.0002769 0 Plxdc1 129.4791 3.203484 0.6441583 4.973132 0.0000007 0.0000269 0 Cxcl12 1329.1667 3.199417 0.4770814 6.706228 0.0000000 0.0000000 0 Igfbp7 1613.4633 3.196600 0.5026930 6.358950 0.0000000 0.0000001 0 Col18a1 1782.4361 3.193957 0.4689439 6.810958 0.0000000 0.0000000 0 Ptprn 550.2988 3.183959 0.6479817 4.913656 0.0000009 0.0000347 0 Tmem119 478.0750 3.164194 0.6615473 4.783021 0.0000017 0.0000594 0 Rcn3 745.8986 3.155310 0.4892169 6.449717 0.0000000 0.0000000 0 Aldh1a2 770.4939 3.141025 0.6416706 4.895073 0.0000010 0.0000373 0 C1qtnf2 110.6790 3.138506 0.8151385 3.850273 0.0001180 0.0018410 0 Crlf1 170.8953 3.136556 0.6503800 4.822652 0.0000014 0.0000500 0 Sfrp2 419.4813 3.135111 0.6458889 4.853947 0.0000012 0.0000440 0 Mest 108.6908 3.133469 0.5449935 5.749554 0.0000000 0.0000009 0 Sema5a 336.9651 3.123662 0.5521207 5.657571 0.0000000 0.0000015 0 Prrx2 207.9948 3.104235 0.7152915 4.339818 0.0000143 0.0003336 0 Gdf10 308.3986 3.070474 0.8339944 3.681649 0.0002317 0.0030910 0 Serpine1 1698.5002 3.060692 0.4948773 6.184749 0.0000000 0.0000001 0 Cxcl14 531.1343 3.060009 0.5173575 5.914690 0.0000000 0.0000005 0 Art3 125.4455 3.059212 0.5381400 5.684789 0.0000000 0.0000013 0 F5 332.5615 3.049476 0.4464786 6.830061 0.0000000 0.0000000 0 Pdpn 364.2568 3.030787 0.5390622 5.622332 0.0000000 0.0000017 0 LOC100909539 169.7553 3.010776 0.5585051 5.390775 0.0000001 0.0000045 0 Angpt2 201.8915 3.002538 0.6244514 4.808282 0.0000015 0.0000532 0 Clmp 340.4767 2.999023 0.5209771 5.756535 0.0000000 0.0000009 0 Ddr2 298.4212 2.998915 0.6192823 4.842565 0.0000013 0.0000462 0 Dkk3 664.5565 2.990207 0.4783266 6.251393 0.0000000 0.0000001 0 Cthrc1 865.9902 2.986193 0.5470008 5.459212 0.0000000 0.0000034 0 Pcdh18 177.4891 2.984432 0.7089265 4.209791 0.0000256 0.0005256 0 Cd79b 308.2109 2.980007 0.6062223 4.915700 0.0000009 0.0000345 0 Ebf1 152.8504 2.977847 0.5928732 5.022738 0.0000005 0.0000224 0 Pcsk5 185.0072 2.970241 0.6957095 4.269369 0.0000196 0.0004273 0 Col7a1 388.1235 2.928671 0.5240962 5.588041 0.0000000 0.0000020 0 Lgals1 3162.6255 2.921244 0.4830130 6.047960 0.0000000 0.0000003 0 Dact3 122.8208 2.915181 0.6039315 4.827006 0.0000014 0.0000493 0 Mgp 5586.2963 2.913536 0.5159668 5.646751 0.0000000 0.0000015 0 Serpine2 1847.1176 2.910431 0.4861802 5.986321 0.0000000 0.0000004 0 Dchs1 150.0491 2.909508 0.6620094 4.394964 0.0000111 0.0002723 0 Gpr176 157.3434 2.905958 0.6979777 4.163397 0.0000314 0.0006179 0 Tspan18 109.9649 2.894857 0.5438674 5.322725 0.0000001 0.0000060 0 Fhl1 100.0144 2.894404 0.7088432 4.083279 0.0000444 0.0008291 0 Zeb1 687.3436 2.888971 0.4564160 6.329688 0.0000000 0.0000001 0 Spon1 1549.9136 2.888666 0.5786447 4.992124 0.0000006 0.0000251 0 Ptn 1471.7408 2.886369 0.3667629 7.869851 0.0000000 0.0000000 0 Clec11a 347.8725 2.867538 0.6526878 4.393429 0.0000112 0.0002738 0 Lrrn4cl 263.9826 2.862207 0.5884124 4.864287 0.0000011 0.0000426 0 Enpp2 271.0467 2.852701 0.5843194 4.882091 0.0000010 0.0000397 0 Vcam1 103.3172 2.847069 0.4926157 5.779494 0.0000000 0.0000009 0 Igfbp3 1112.3975 2.831892 0.6360159 4.452548 0.0000085 0.0002165 0 Gpx8 338.0409 2.820505 0.4716752 5.979762 0.0000000 0.0000004 0 Tnc 1036.5953 2.816061 0.6119118 4.602070 0.0000042 0.0001210 0 Gjc1 135.2396 2.808647 0.7316139 3.838975 0.0001235 0.0019004 0 Dnm1 259.7699 2.805204 0.5143616 5.453758 0.0000000 0.0000034 0 Ccn5 121.7561 2.800896 0.6882458 4.069616 0.0000471 0.0008725 0 F2r 1275.7316 2.799342 0.4152079 6.742024 0.0000000 0.0000000 0 Chrd 100.5599 2.797132 0.6603563 4.235792 0.0000228 0.0004772 0 Gpihbp1 108.5640 2.790033 0.9113183 3.061535 0.0022021 0.0178026 0 Nkd2 621.3418 2.788870 0.4347884 6.414316 0.0000000 0.0000000 0 Ptgis 147.3581 2.786126 0.5958481 4.675901 0.0000029 0.0000896 0 Cd86 362.9962 -2.782396 0.5568040 -4.997084 0.0000006 0.0000246 0 Slc41a2 152.2474 2.777581 0.4907141 5.660283 0.0000000 0.0000015 0 Ednrb 258.5797 2.776462 0.5552799 5.000112 0.0000006 0.0000243 0 Vcan 403.5607 2.771671 0.5223230 5.306432 0.0000001 0.0000064 0 Fzd1 315.2015 2.768743 0.4969659 5.571295 0.0000000 0.0000022 0 Smoc2 1825.8370 2.758326 0.5697965 4.840897 0.0000013 0.0000465 0 Bcat1 530.6735 2.740230 0.4803200 5.705008 0.0000000 0.0000012 0 Gypc 116.9778 2.723421 0.4312477 6.315213 0.0000000 0.0000001 0 C1qtnf1 562.5344 2.713356 0.4942579 5.489757 0.0000000 0.0000030 0 Il6 252.6444 2.686174 0.7007907 3.833062 0.0001266 0.0019340 0 Cst7 1576.3782 -2.669137 0.4995658 -5.342913 0.0000001 0.0000055 0 Acvrl1 339.3948 2.665439 0.4922901 5.414366 0.0000001 0.0000041 0 Flnc 140.3515 2.659266 0.7214758 3.685870 0.0002279 0.0030547 0 Cdh13 254.5316 2.655742 0.4896650 5.423590 0.0000001 0.0000039 0 Thbd 350.6080 2.646872 0.5486791 4.824080 0.0000014 0.0000498 0 Numbl 181.5281 2.645062 0.5030532 5.258018 0.0000001 0.0000077 0 Twist1 208.8353 2.634759 0.4730718 5.569469 0.0000000 0.0000022 0 Col8a1 402.9575 2.634058 0.6495240 4.055367 0.0000501 0.0009187 0 Col14a1 1586.4906 2.633108 0.4209208 6.255591 0.0000000 0.0000001 0 Exoc3l4 107.4459 2.631149 0.6180609 4.257103 0.0000207 0.0004454 0 Hmcn1 173.3986 2.629982 0.6504115 4.043567 0.0000526 0.0009587 0 Col2a1 414.8509 2.613374 0.5963046 4.382615 0.0000117 0.0002850 0 Wfdc1 185.7754 2.601518 0.7956184 3.269806 0.0010762 0.0101280 0 Tril 375.6907 2.593674 0.5492580 4.722141 0.0000023 0.0000749 0 Jam3 368.8751 2.585481 0.4273591 6.049902 0.0000000 0.0000003 0 Abca8a 220.8641 2.570620 0.4998636 5.142643 0.0000003 0.0000130 0 Loxl3 175.7537 2.557596 0.5742389 4.453890 0.0000084 0.0002163 0 Serping1 3124.8259 2.554953 0.4662772 5.479472 0.0000000 0.0000031 0 Sema3b 563.8680 2.552686 0.4677679 5.457163 0.0000000 0.0000034 0 Htra1 1935.9280 2.549874 0.5625072 4.533052 0.0000058 0.0001586 0 Fkbp9 945.7921 2.541668 0.5103939 4.979816 0.0000006 0.0000265 0 Pcsk6 116.6193 2.537736 0.7116839 3.565819 0.0003627 0.0043923 0 Antxr1 126.5270 2.531293 0.5344436 4.736314 0.0000022 0.0000710 0 Cxcl13 256.7606 2.527823 0.6335594 3.989876 0.0000661 0.0011446 0 Plvap 604.4919 2.526245 0.5346152 4.725352 0.0000023 0.0000741 0 Pi16 740.0833 2.525300 0.4830969 5.227314 0.0000002 0.0000089 0 Fst 363.7192 2.522049 0.4555631 5.536113 0.0000000 0.0000025 0 Atp10a 184.7413 2.504687 0.4738484 5.285840 0.0000001 0.0000070 0 Mdk 334.3622 2.501171 0.4977607 5.024847 0.0000005 0.0000222 0 Kazald1 118.4031 2.500609 0.5597252 4.467566 0.0000079 0.0002052 0 Gpx3 3749.5948 2.496370 0.5282970 4.725317 0.0000023 0.0000741 0 Lpar1 348.3481 2.493532 0.4649751 5.362722 0.0000001 0.0000051 0 Itga1 134.7696 2.488265 0.4425356 5.622744 0.0000000 0.0000017 0 Snai1 420.3549 2.480138 0.4429747 5.598825 0.0000000 0.0000019 0 Lhfpl6 232.3414 2.478510 0.4318699 5.739021 0.0000000 0.0000010 0 Xylt1 128.6021 2.459414 0.4574647 5.376184 0.0000001 0.0000047 0 Dlc1 239.7062 2.458324 0.4226957 5.815824 0.0000000 0.0000007 0 Rgs5 236.4488 2.440618 0.5879615 4.150983 0.0000331 0.0006455 0 Bicc1 105.1785 2.435512 0.4783037 5.091979 0.0000004 0.0000166 0 Fbn2 115.3602 2.420348 0.6058808 3.994759 0.0000648 0.0011240 0 Adamts18 148.1927 2.412497 0.5196188 4.642821 0.0000034 0.0001024 0 Col17a1 359.4849 2.409958 0.4112134 5.860601 0.0000000 0.0000006 0 Rn45s 226.6173 2.409292 0.6120201 3.936623 0.0000826 0.0013716 0 Tbx2 124.9535 2.406942 0.5525690 4.355913 0.0000133 0.0003152 0 Smim38 4504.3872 -2.398364 0.4364530 -5.495126 0.0000000 0.0000029 0 Qprt 320.2798 2.390969 0.5126281 4.664140 0.0000031 0.0000939 0 Gpm6b 532.7433 2.385382 0.3517124 6.782193 0.0000000 0.0000000 0 Zcchc24 224.4545 2.385131 0.4972716 4.796435 0.0000016 0.0000563 0 Upk1b 171.9449 2.384468 0.4891124 4.875092 0.0000011 0.0000408 0 Tgfbr3 230.1156 2.379145 0.2937532 8.099127 0.0000000 0.0000000 0 Mnda 372.8592 2.378656 0.5194046 4.579581 0.0000047 0.0001315 0 Plpp3 908.5545 2.374274 0.3744052 6.341455 0.0000000 0.0000001 0 Tnfrsf11b 280.8867 2.356415 0.6596593 3.572170 0.0003540 0.0043206 0 Tspan5 262.2276 2.350072 0.4194301 5.603012 0.0000000 0.0000019 0 Lrp1 1711.4543 2.345939 0.4146000 5.658319 0.0000000 0.0000015 0 Selenom 721.5583 2.343650 0.4332915 5.408945 0.0000001 0.0000042 0 Cav1 1433.9170 2.343621 0.4291187 5.461475 0.0000000 0.0000034 0 C1r 3131.7457 2.338808 0.4278118 5.466909 0.0000000 0.0000033 0 Igfbp2 1851.8729 2.336686 0.4686510 4.985983 0.0000006 0.0000258 0 S1pr3 354.3758 2.330204 0.4799157 4.855444 0.0000012 0.0000440 0 Reln 209.5097 2.320254 0.4954112 4.683491 0.0000028 0.0000873 0 Osr1 234.1777 2.318824 0.5114754 4.533597 0.0000058 0.0001586 0 Lefty1 311.3851 -2.313146 0.5065149 -4.566788 0.0000050 0.0001384 0 Ltbp4 906.2458 2.310865 0.4390268 5.263609 0.0000001 0.0000076 0 Atp1b2 114.9793 2.310429 0.5358680 4.311564 0.0000162 0.0003676 0 Entpd1 103.7150 2.309862 0.5167928 4.469610 0.0000078 0.0002044 0 Angptl2 604.3971 2.295360 0.5953528 3.855462 0.0001155 0.0018105 0 Fgl2 12212.4256 2.291036 0.5454709 4.200107 0.0000267 0.0005438 0 Rgs16 259.1222 2.286640 0.5388128 4.243849 0.0000220 0.0004630 0 Rspo3 118.3061 -2.282611 0.5117722 -4.460209 0.0000082 0.0002108 0 Apold1 227.6434 2.280206 0.6042568 3.773570 0.0001609 0.0023277 0 RGD1564664 1319.1210 2.276683 0.4287354 5.310228 0.0000001 0.0000063 0 Fam102b 445.2780 2.269383 0.3717222 6.105051 0.0000000 0.0000002 0 Emp1 2353.1990 2.267667 0.4045808 5.604981 0.0000000 0.0000019 0 Reck 329.2438 2.258867 0.3799789 5.944717 0.0000000 0.0000004 0 Penk 1540.3959 2.257745 0.4382863 5.151303 0.0000003 0.0000126 0 Ptx3 141.1111 2.249389 0.5402212 4.163830 0.0000313 0.0006179 0 Chst12 436.3871 2.242175 0.3475078 6.452158 0.0000000 0.0000000 0 Nrgn 217.2343 2.240100 0.5588430 4.008460 0.0000611 0.0010765 0 Serpinh1 4143.7490 2.239801 0.4295706 5.214045 0.0000002 0.0000094 0 Ccr7 2037.2987 -2.236902 0.5544875 -4.034180 0.0000548 0.0009889 0 Jam2 120.3868 2.236089 0.5188831 4.309428 0.0000164 0.0003706 0 Nt5e 383.6789 2.228104 0.3784698 5.887139 0.0000000 0.0000005 0 Esam 191.2952 2.227735 0.6043154 3.686379 0.0002275 0.0030515 0 Bst1 140.9215 2.222008 0.5039923 4.408813 0.0000104 0.0002586 0 Anpep 427.4652 2.217710 0.4804716 4.615695 0.0000039 0.0001148 0 Il16 879.1841 2.216921 0.4574305 4.846464 0.0000013 0.0000455 0 Crispld2 844.0229 2.216355 0.3729991 5.941985 0.0000000 0.0000004 0 Cercam 317.4455 2.207242 0.4128150 5.346807 0.0000001 0.0000054 0 Il34 244.5412 2.205054 0.5161618 4.272021 0.0000194 0.0004235 0 Flrt2 114.0168 2.204248 0.6165463 3.575155 0.0003500 0.0042903 0 Cybrd1 447.7854 2.200948 0.4301581 5.116603 0.0000003 0.0000147 0 Slc12a4 448.9469 2.197499 0.3888353 5.651490 0.0000000 0.0000015 0 Gpr65 233.6045 -2.187224 0.6128266 -3.569075 0.0003582 0.0043531 0 Enc1 229.2900 2.186206 0.4161157 5.253841 0.0000001 0.0000078 0 Ccl9 233.5549 -2.178536 0.5866708 -3.713389 0.0002045 0.0028110 0 Fcrla 166.7805 2.169365 0.5382100 4.030703 0.0000556 0.0009985 0 Fscn1 737.0013 2.167616 0.4768007 4.546168 0.0000055 0.0001500 0 Mmp19 645.7798 2.167097 0.5024528 4.313037 0.0000161 0.0003657 0 Krt17 1884.0749 2.164489 0.4743453 4.563109 0.0000050 0.0001403 0 Il1rl1 3784.5982 2.162841 0.5560058 3.889961 0.0001003 0.0016036 0 Smpd3 178.9258 2.159543 0.4116496 5.246070 0.0000002 0.0000082 0 Gramd1b 163.0315 2.151154 0.4341533 4.954825 0.0000007 0.0000290 0 Adamts1 1757.5864 2.146730 0.4202645 5.108046 0.0000003 0.0000153 0 Hpgd 489.9263 -2.144492 0.5450246 -3.934671 0.0000833 0.0013780 0 Ptprv 161.4638 2.135871 0.4532611 4.712230 0.0000025 0.0000779 0 Grb10 101.4931 2.133588 0.5284274 4.037618 0.0000540 0.0009795 0 Egr2 739.9914 2.127505 0.3686815 5.770579 0.0000000 0.0000009 0 Fmod 136.9541 2.115261 0.6573172 3.218021 0.0012908 0.0116322 0 Gpnmb 1703.4913 2.112824 0.4871702 4.336932 0.0000144 0.0003374 0 Cd72 302.5215 2.112040 0.4858108 4.347455 0.0000138 0.0003254 0 Tpsb2 593.5598 2.110619 0.7893911 2.673731 0.0075013 0.0444765 0 Pcdhgc3 233.7452 2.109003 0.3981033 5.297626 0.0000001 0.0000067 0 Tpst1 338.9386 2.107755 0.4221425 4.992994 0.0000006 0.0000250 0 Dse 555.1690 2.107540 0.4206702 5.009960 0.0000005 0.0000235 0 Spats2l 120.3372 2.104586 0.4590032 4.585122 0.0000045 0.0001285 0 Ca4 208.0065 2.094648 0.6572557 3.186961 0.0014378 0.0127289 0 Rnase4 971.6501 2.089620 0.4302504 4.856754 0.0000012 0.0000438 0 Myh11 475.3686 2.086043 0.4483121 4.653104 0.0000033 0.0000982 0 Lrrc32 852.1014 2.075154 0.4554558 4.556214 0.0000052 0.0001447 0 Slc7a5 1803.6608 2.075151 0.3757376 5.522873 0.0000000 0.0000027 0 Mark1 200.4608 2.069547 0.4064892 5.091270 0.0000004 0.0000166 0 Calcrl 138.4676 2.068618 0.4622890 4.474730 0.0000077 0.0002003 0 Plod2 105.1379 2.066244 0.4980889 4.148344 0.0000335 0.0006494 0 Adamts12 211.9791 2.064721 0.5574499 3.703869 0.0002123 0.0028983 0 Jag2 263.7754 2.059162 0.3416715 6.026731 0.0000000 0.0000003 0 Spef2 231.7931 -2.047257 0.3474386 -5.892427 0.0000000 0.0000005 0 Tie1 319.9769 2.046796 0.5366856 3.813771 0.0001369 0.0020535 0 Itga4 997.0015 2.046091 0.4858247 4.211583 0.0000254 0.0005235 0 Clec4e 207.6632 -2.044018 0.5575570 -3.666024 0.0002464 0.0032490 0 Gulp1 139.6368 2.038964 0.5492316 3.712394 0.0002053 0.0028160 0 Septin5 131.7907 2.033865 0.5028013 4.045067 0.0000523 0.0009551 0 Oaf 2181.8975 2.030784 0.4198118 4.837369 0.0000013 0.0000471 0 Gng2 1119.1447 2.030253 0.4015689 5.055802 0.0000004 0.0000196 0 Zbtb40 1077.5801 -2.027441 0.4017095 -5.047033 0.0000004 0.0000201 0 Emp3 3941.5983 2.024880 0.4324765 4.682057 0.0000028 0.0000874 0 Zeb2 385.2744 2.021275 0.4867873 4.152275 0.0000329 0.0006437 0 Gja1 2550.1918 2.012062 0.4308272 4.670230 0.0000030 0.0000916 0 Lix1l 128.8913 2.009983 0.4625160 4.345758 0.0000139 0.0003269 0 Havcr2 300.5183 -2.006718 0.5398209 -3.717377 0.0002013 0.0027773 0 Bco2 1491.8857 -1.999702 0.2797820 -7.147359 0.0000000 0.0000000 0 Aadat 101.5507 -1.998804 0.5412698 -3.692805 0.0002218 0.0029954 0 Il1r1 112.2660 1.994843 0.4144325 4.813432 0.0000015 0.0000521 0 Mmd 2288.9790 1.991969 0.3961048 5.028893 0.0000005 0.0000219 0 Cdr2 183.9220 1.991143 0.3453108 5.766235 0.0000000 0.0000009 0 Nfatc4 115.5429 1.989880 0.4682547 4.249568 0.0000214 0.0004528 0 Tph1 1224.6705 -1.988458 0.4006382 -4.963225 0.0000007 0.0000279 0 Napsa 1927.4859 -1.986069 0.4963492 -4.001355 0.0000630 0.0011013 0 Il9r 164.0984 -1.979120 0.6916802 -2.861322 0.0042188 0.0291602 0 Septin4 316.8378 1.977934 0.3974436 4.976639 0.0000006 0.0000267 0 Fkbp7 210.7457 1.977329 0.3435197 5.756087 0.0000000 0.0000009 0 Clec7a 921.1302 -1.976820 0.5263490 -3.755720 0.0001728 0.0024595 0 Ppic 1223.3450 1.974598 0.5092597 3.877388 0.0001056 0.0016735 0 S100a4 5939.0874 1.966305 0.3977831 4.943160 0.0000008 0.0000305 0 Plagl1 119.8296 1.963112 0.5047560 3.889229 0.0001006 0.0016056 0 Gsn 21229.9871 1.958623 0.3649656 5.366596 0.0000001 0.0000050 0 Nrg2 121.4362 1.958544 0.3707566 5.282560 0.0000001 0.0000071 0 Il17b 168.5649 1.952653 0.5230121 3.733476 0.0001889 0.0026472 0 Cdo1 2539.9828 -1.948737 0.3785039 -5.148527 0.0000003 0.0000127 0 Adora2b 120.2112 1.944527 0.5233267 3.715703 0.0002026 0.0027903 0 LOC310926 3065.7080 1.943524 0.4525129 4.294958 0.0000175 0.0003905 0 Fstl1 2928.0675 1.940305 0.4085014 4.749811 0.0000020 0.0000672 0 Rgl1 143.6425 1.939954 0.4858323 3.993053 0.0000652 0.0011308 0 Lyc2 857.2614 -1.937423 0.5201090 -3.725032 0.0001953 0.0027104 0 Bcl2a1 3786.3405 -1.933919 0.4230839 -4.571005 0.0000049 0.0001365 0 Unc5b 223.4973 1.930223 0.3381409 5.708338 0.0000000 0.0000012 0 Rnase1l1 174.9596 -1.929827 0.5768677 -3.345354 0.0008218 0.0081880 0 Rftn1 1215.3651 1.924466 0.4455383 4.319417 0.0000156 0.0003588 0 Runx2 471.8028 1.922405 0.3159568 6.084391 0.0000000 0.0000002 0 Rbp7 480.1474 -1.921581 0.4302511 -4.466186 0.0000080 0.0002059 0 LOC361346 121.7652 1.920722 0.3830946 5.013701 0.0000005 0.0000231 0 Akap12 213.7561 1.918247 0.4691473 4.088795 0.0000434 0.0008118 0 Lef1 184.3474 1.916056 0.3795404 5.048357 0.0000004 0.0000200 0 Fbp1 331.1460 -1.906706 0.5519375 -3.454569 0.0005512 0.0060824 0 Bdkrb2 132.0112 1.904959 0.6237563 3.054011 0.0022580 0.0181612 0 Susd2 183.1380 1.904708 0.5360100 3.553494 0.0003801 0.0045484 0 Robo1 110.9296 1.901541 0.6040660 3.147903 0.0016445 0.0142012 0 Rgma 393.9521 1.891122 0.3786517 4.994356 0.0000006 0.0000249 0 Ch25h 110.0212 1.887806 0.5110277 3.694136 0.0002206 0.0029856 0 Sgce 211.1257 1.884961 0.4961342 3.799295 0.0001451 0.0021429 0 Adcy7 865.2872 1.880226 0.3453261 5.444784 0.0000001 0.0000036 0 Ramp2 160.7973 1.879907 0.4273419 4.399070 0.0000109 0.0002691 0 Tgfbi 874.4704 1.875558 0.4312061 4.349564 0.0000136 0.0003233 0 Ccl7 1563.8042 1.861674 0.6251454 2.977985 0.0029015 0.0219313 0 Ndrg4 175.7857 1.858193 0.4022644 4.619333 0.0000038 0.0001132 0 Papss2 142.1093 1.855157 0.4989255 3.718304 0.0002006 0.0027699 0 Akap2 590.9492 1.852774 0.3930252 4.714134 0.0000024 0.0000775 0 Eng 550.9289 1.851888 0.3698651 5.006928 0.0000006 0.0000238 0 Mitf 232.0786 1.848871 0.3899704 4.741054 0.0000021 0.0000695 0 Prnp 5001.9730 1.829442 0.3167321 5.775992 0.0000000 0.0000009 0 Mylk 178.0554 1.828806 0.4621694 3.957003 0.0000759 0.0012809 0 Spdef 262.5472 -1.824240 0.4243007 -4.299403 0.0000171 0.0003840 0 Selp 109.1368 1.818810 0.5940214 3.061860 0.0021997 0.0177952 0 Rps4y2 110.1568 1.817091 0.4207861 4.318324 0.0000157 0.0003600 0 Pcolce 1567.3340 1.814585 0.5064272 3.583111 0.0003395 0.0041835 0 Lhfpl2 459.6401 1.810530 0.4903840 3.692066 0.0002224 0.0029993 0 Cyp2s1 707.2856 1.807160 0.4746702 3.807191 0.0001406 0.0021022 0 Tmprss6 169.0051 -1.806669 0.4205949 -4.295508 0.0000174 0.0003902 0 Pecam1 259.5646 1.803637 0.4047088 4.456628 0.0000083 0.0002140 0 Tmem47 654.8932 1.790057 0.4312821 4.150547 0.0000332 0.0006459 0 Prlr 1038.4200 -1.789469 0.3380740 -5.293127 0.0000001 0.0000068 0 Mfsd2a 157.3265 1.781935 0.3850442 4.627872 0.0000037 0.0001093 0 Bmp3 268.3157 -1.779925 0.4684137 -3.799899 0.0001448 0.0021400 0 Axl 1540.3909 1.778598 0.4818414 3.691251 0.0002232 0.0030022 0 Pgr 553.8533 -1.778007 0.4174838 -4.258865 0.0000205 0.0004451 0 Igf1 453.6448 1.777963 0.5172704 3.437203 0.0005878 0.0063858 0 Gas7 621.4026 1.777329 0.3613375 4.918751 0.0000009 0.0000341 0 Emilin1 858.2433 1.777025 0.3976511 4.468806 0.0000079 0.0002048 0 Csrp2 122.0930 1.773860 0.3788562 4.682144 0.0000028 0.0000874 0 Shc2 169.5342 1.770604 0.4129739 4.287449 0.0000181 0.0004018 0 Mmrn2 117.9529 1.768113 0.5147693 3.434769 0.0005931 0.0064335 0 Cited1 4874.4124 -1.763999 0.4351835 -4.053460 0.0000505 0.0009250 0 Nbl1 1846.7788 1.763501 0.4475333 3.940490 0.0000813 0.0013513 0 Abcc8 176.7389 -1.760148 0.5427708 -3.242894 0.0011832 0.0108796 0 Dclk1 360.2840 1.757166 0.3303263 5.319486 0.0000001 0.0000061 0 Chsy1 546.0574 1.755178 0.3257964 5.387346 0.0000001 0.0000046 0 Blk 139.8965 1.753627 0.5773214 3.037523 0.0023853 0.0189893 0 Ptprm 169.5719 1.749849 0.2972451 5.886890 0.0000000 0.0000005 0 Nav3 107.8021 1.749617 0.5300042 3.301139 0.0009629 0.0092662 0 Actg2 319.0454 1.748692 0.5211526 3.355431 0.0007924 0.0079803 0 Acsm3 364.8452 -1.747477 0.3532533 -4.946810 0.0000008 0.0000300 0 Flna 3143.6337 1.747214 0.2726283 6.408777 0.0000000 0.0000000 0 Efemp2 808.4068 1.745307 0.3351773 5.207115 0.0000002 0.0000097 0 Adamts7 115.4126 1.741746 0.5883998 2.960141 0.0030750 0.0229465 0 Vill 391.1768 -1.739503 0.3871273 -4.493361 0.0000070 0.0001853 0 Gem 1400.7636 1.737091 0.4139451 4.196427 0.0000271 0.0005509 0 Krt15 994.1953 1.733449 0.4195517 4.131670 0.0000360 0.0006926 0 Phlda3 425.8693 1.733230 0.3955968 4.381304 0.0000118 0.0002860 0 Nnat 189.4333 1.729796 0.4046546 4.274747 0.0000191 0.0004197 0 Rab3il1 143.5864 1.729302 0.5337276 3.240046 0.0011951 0.0109602 0 Mex3b 141.6301 1.725431 0.3162860 5.455288 0.0000000 0.0000034 0 Abcc5 677.2999 1.724119 0.3242449 5.317336 0.0000001 0.0000061 0 Gask1b 398.6166 1.722921 0.4624421 3.725701 0.0001948 0.0027058 0 Tent5a 709.8951 1.722197 0.2941224 5.855375 0.0000000 0.0000006 0 Shisa8 282.5511 -1.717869 0.4680178 -3.670520 0.0002421 0.0032014 0 Fgfrl1 144.8710 1.711684 0.3511148 4.874999 0.0000011 0.0000408 0 Cited4 1273.0814 -1.711186 0.3056412 -5.598677 0.0000000 0.0000019 0 Cbs 570.9305 -1.706962 0.4429111 -3.853962 0.0001162 0.0018196 0 Fbp2 100.9160 -1.703870 0.4001664 -4.257904 0.0000206 0.0004454 0 Foxa1 537.7609 -1.697933 0.3800476 -4.467686 0.0000079 0.0002052 0 Il1b 3574.7588 -1.695613 0.5317013 -3.189033 0.0014275 0.0126460 0 Tcf4 861.9130 1.695051 0.3350309 5.059389 0.0000004 0.0000194 0 Prex2 120.8571 1.693675 0.4587660 3.691806 0.0002227 0.0029993 0 Tpm2 1865.6893 1.691841 0.3547151 4.769578 0.0000018 0.0000626 0 Hdgfl3 286.8142 1.688904 0.3208874 5.263230 0.0000001 0.0000076 0 Arhgap31 129.6162 1.677005 0.4091900 4.098353 0.0000416 0.0007821 0 Col16a1 1951.5428 1.674836 0.4213475 3.974953 0.0000704 0.0012040 0 Palm 311.4550 1.673663 0.4038504 4.144266 0.0000341 0.0006602 0 Pde8a 110.0276 1.672023 0.3824267 4.372140 0.0000123 0.0002947 0 P2ry14 118.9237 -1.669713 0.5112920 -3.265675 0.0010920 0.0102421 0 Areg 3374.7754 -1.669107 0.3356301 -4.973056 0.0000007 0.0000269 0 Plpp1 284.8529 1.668880 0.2936385 5.683452 0.0000000 0.0000013 0 Nectin1 232.9211 1.662334 0.3340302 4.976598 0.0000006 0.0000267 0 Nlrp3 348.0204 -1.662011 0.5320888 -3.123560 0.0017868 0.0151509 0 Slc39a2 190.8223 -1.661511 0.4952125 -3.355147 0.0007932 0.0079828 0 Ntng2 105.5954 1.660486 0.4581374 3.624428 0.0002896 0.0037115 0 Ghr 211.4815 1.652280 0.4548143 3.632867 0.0002803 0.0036020 0 Adamts4 616.4569 1.652100 0.4856100 3.402112 0.0006687 0.0070156 0 Tmem156 165.0585 -1.651383 0.5124065 -3.222799 0.0012694 0.0114921 0 Ntm 274.2325 -1.651341 0.3987414 -4.141385 0.0000345 0.0006665 0 Scarf1 102.4250 1.648939 0.5201642 3.170035 0.0015242 0.0133680 0 Apoe 30877.9129 1.648500 0.4088444 4.032095 0.0000553 0.0009951 0 Clca1 16700.5682 -1.647375 0.4855261 -3.392968 0.0006914 0.0071368 0 Hs3st1 255.3184 1.641778 0.3062554 5.360813 0.0000001 0.0000051 0 P3h3 527.1631 1.641196 0.2981758 5.504123 0.0000000 0.0000028 0 Epdr1 228.0653 -1.639757 0.4324078 -3.792153 0.0001493 0.0021917 0 Tmem150c 536.1353 -1.632309 0.3417937 -4.775715 0.0000018 0.0000613 0 Sulf1 152.7828 1.630183 0.5179972 3.147088 0.0016491 0.0142321 0 Mmp12 1407.0981 -1.630139 0.4870348 -3.347069 0.0008167 0.0081491 0 Tns1 226.6551 1.626172 0.3817017 4.260322 0.0000204 0.0004432 0 Cd226 125.5658 -1.622772 0.5904819 -2.748217 0.0059920 0.0380562 0 Slamf6 498.3312 -1.622449 0.5331203 -3.043308 0.0023399 0.0187021 0 Evc 108.9292 1.619116 0.5686263 2.847417 0.0044076 0.0301830 0 Car2 568.4271 1.615463 0.3963277 4.076079 0.0000458 0.0008529 0 Cd300lf 134.2303 -1.607553 0.5138731 -3.128307 0.0017582 0.0149988 0 Aqp5 2758.9669 -1.607128 0.4103911 -3.916088 0.0000900 0.0014764 0 Adm 319.5167 1.607125 0.3265104 4.922124 0.0000009 0.0000336 0 Ccl4 1108.5357 -1.605529 0.5271857 -3.045472 0.0023232 0.0185892 0 Lrg1 554.4698 1.604111 0.4796284 3.344488 0.0008243 0.0081962 0 Art4 143.3735 1.602183 0.4238262 3.780284 0.0001566 0.0022751 0 Cmtm3 449.6897 1.601825 0.3362425 4.763898 0.0000019 0.0000640 0 Itgb7 2471.2300 -1.592028 0.4935656 -3.225564 0.0012572 0.0114036 0 Tmem204 127.5390 1.591124 0.4849385 3.281084 0.0010341 0.0098216 0 Ccl3 2482.6547 -1.587844 0.4961453 -3.200361 0.0013726 0.0122364 0 Wnt4 720.6999 -1.584608 0.3182657 -4.978885 0.0000006 0.0000265 0 Ptprz1 125.4763 1.580747 0.4516521 3.499920 0.0004654 0.0053346 0 Slpi 6548.3851 -1.578460 0.4551713 -3.467838 0.0005247 0.0058602 0 Rarres1 622.1153 1.578229 0.5990843 2.634402 0.0084286 0.0482874 0 Fbxo27 167.8075 1.574968 0.4143658 3.800912 0.0001442 0.0021357 0 Myl9 1326.7436 1.574082 0.3907314 4.028553 0.0000561 0.0010025 0 Spp1 1254.8622 1.573638 0.5000601 3.146898 0.0016501 0.0142326 0 Phldb1 338.0246 1.569592 0.3612348 4.345073 0.0000139 0.0003273 0 Prdm1 1304.2794 1.569166 0.4553747 3.445879 0.0005692 0.0062324 0 Cd48 3183.8392 1.568575 0.3689768 4.251148 0.0000213 0.0004503 0 Ptp4a3 460.9780 1.568134 0.3799839 4.126844 0.0000368 0.0007044 0 Kdr 203.9429 1.566194 0.5535153 2.829540 0.0046615 0.0314623 0 Il18 1205.2386 -1.565126 0.2651402 -5.903014 0.0000000 0.0000005 0 Col9a2 354.2581 1.561271 0.4339736 3.597617 0.0003211 0.0040241 0 Zbtb46 105.5504 1.559646 0.3914134 3.984652 0.0000676 0.0011686 0 Alox15 109.5051 1.558519 0.5671441 2.748013 0.0059958 0.0380562 0 Fzd7 109.3312 1.558485 0.3700445 4.211614 0.0000254 0.0005235 0 Il21r 3001.3664 -1.556061 0.5211345 -2.985909 0.0028274 0.0215097 0 Pde2a 547.3440 1.555375 0.3657252 4.252853 0.0000211 0.0004491 0 Timp2 5214.7280 1.549576 0.3958332 3.914721 0.0000905 0.0014831 0 Serpinb9 2201.9583 -1.549197 0.2447923 -6.328619 0.0000000 0.0000001 0 Daglb 580.2591 1.543155 0.3622276 4.260181 0.0000204 0.0004432 0 Ctse 1486.9626 -1.541442 0.2587217 -5.957916 0.0000000 0.0000004 0 Cd93 209.7660 1.535139 0.5262280 2.917252 0.0035313 0.0253088 0 Fcrlb 204.5203 -1.535048 0.5081493 -3.020859 0.0025206 0.0196544 0 Tgfbr2 749.2769 1.534223 0.3190563 4.808629 0.0000015 0.0000532 0 Gsta4 225.6188 -1.529211 0.3788303 -4.036665 0.0000542 0.0009823 0 Folr2 349.4547 -1.527816 0.5142778 -2.970799 0.0029703 0.0223669 0 Nrp2 209.7190 1.525764 0.3327332 4.585546 0.0000045 0.0001285 0 Scara3 397.2718 1.518208 0.5266509 2.882759 0.0039421 0.0275456 0 Msx2 235.8917 -1.517463 0.4702880 -3.226667 0.0012524 0.0113785 0 Chst8 161.5705 -1.515934 0.5133025 -2.953297 0.0031440 0.0233376 0 Afap1l2 130.5068 1.514096 0.5170662 2.928245 0.0034088 0.0248175 0 Vldlr 154.3150 1.513696 0.3907625 3.873699 0.0001072 0.0016952 0 Id3 2308.8781 1.513594 0.3301188 4.584998 0.0000045 0.0001285 0 Wnk4 239.9166 -1.510658 0.3350633 -4.508574 0.0000065 0.0001744 0 Scpep1 3925.6741 1.510387 0.2584617 5.843756 0.0000000 0.0000006 0 Cpq 594.2496 1.507902 0.4148402 3.634899 0.0002781 0.0035868 0 Timp3 1855.0802 1.507625 0.3961868 3.805340 0.0001416 0.0021112 0 Csf1 431.1994 1.507064 0.3898543 3.865712 0.0001108 0.0017399 0 Pkd2 292.3461 1.506404 0.3918875 3.843971 0.0001211 0.0018744 0 Fabp4 248.2869 1.506139 0.4967936 3.031720 0.0024316 0.0192275 0 Tmem263 133.8049 1.504077 0.2494754 6.028961 0.0000000 0.0000003 0 Cbfa2t3 169.0738 1.503354 0.4225581 3.557745 0.0003741 0.0044942 0 Pam 947.5924 1.500654 0.4356275 3.444810 0.0005715 0.0062425 0 Note that there seems to be two main groups of Ep cells: The first one is enriched for canonical tumour progression pathways: eg. expression of wnt, fox1a etc. The second one doesn’t seem to have as high expression of these genes, but have high immune related signalling pathways. We can append this information into the overall data file and determine whether there is an association with growth or treatment ## C2N__Ep C2R__Ep C5R__Ep 10L_D_Ep 10R_BL_Ep 10R_BU_Ep ## 1 2 2 1 2 2 ## ## growing stable ## 1 1 4 ## 2 9 5 ## 3 1 0 ## ## LY PDL1 PDL1+LY Vehicle ## 1 2 2 0 4 ## 2 2 6 4 7 ## 3 0 0 1 3 ## ## Infiltrating restricted ## 1 5 0 ## 2 4 7 ## 3 0 0 7.2 No. samples in comparisons Separate out the tables into CD45, DN and Ep fractions. Compare Differences based on treatment (and treatment vs control) Specific treatments vs control Growing vs stable (overall) Growing vs stable (in each subgroup) Below, we check the number of samples in each subgroup: ## , , = inf ## ## ## LY PDL1 PDL1+LY Vehicle ## CD45 3 4 2 5 ## DN 3 2 2 4 ## Ep 3 3 0 3 ## ## , , = res ## ## ## LY PDL1 PDL1+LY Vehicle ## CD45 2 4 3 4 ## DN 0 6 2 5 ## Ep 0 5 2 1 Note that based on the above tables, there some comparisons which are slightly imbalanced: There are few “stable” samples for comparisons LY samples are overwhelmingly “infiltrating” 7.3 Set-up cell-type specifoc the comparisons Setup the following comparisons for each cell type: expression ~ growing + treatment + batch (exclude 1) (start with vehicle vs some treatment) 4 categories only: immunotherapy vs non-immuno Separate out the tables into CD45, DN and Ep fractions. Compare: Treatment (EpddsTreat) Comp4: Growth + any immunotherapy treatment (Epdds) Comp8: Growth + immunotherapy (EpddsTreatG) Growth alone: (EpddsGrowth) MH index: (EpddsStrMH) Interacting Fraction (EpddsStrIF) knn values (EpddsStrknn) CD8 content (EpddsCD8) Manual scoring spatial (EpddsSpatMan) MH index + CD8 frac (Epddscd8MH) We remove genes which have 0 counts in more than half the samples, and genes which have a row sum less than \\(10^{(log10(mean(rowsums))-log10(sd(rowsums)))}\\). These comparisons are saved in the temporary outputfile outputs/subfraction_analysis_2020-12-07.RData. In each comparison, there are 13134 genes compared. 7.4 PCA plots Below, we look at PCA plots with information on treatment, growth, spatial patterns overlaid. These are separated based on cell type 7.4.1 EpCAM 7.4.2 CD45 7.4.3 DN 7.5 Collating results and running GSEA In this section, we combine all the comparisons together for downstream analysis, including number of differential genes per comparisons number of samples per comparison write the output to file (outputs/DESeq/Ep_growth_treat.xlsx) For GSEA we convert rat to human symbols run overlap analysis if there are more than 3 hits (outputs/DESeq/HyperGeo_Ep_growth_treat.xlsx) run gene set enrichment analysis on all samples (outputs/DESeq/GSEA_Ep_growth_treat.xlsx) all outputs saved to outputs/all_differential_comparisons.RData) ## ## growingcontrol growingimm stablecontrol stableimm ## 2 9 2 7 "],["deseq-analysis-1.html", "Chapter 8 DESeq analysis 8.1 Summary of comparisons 8.2 Summary of comaprisons 8.3 Growing vs stable emphasis", " Chapter 8 DESeq analysis 8.1 Summary of comparisons Quick plot of the differences in number of differential genes: Notes: Comparison Type Main cell type impacted Treatment CD45+, PDL1+LY in the DN, LY may affect Ep growth Ep and CD45 growth in control CD and DN Spatial Patterns CD45, Ep Spatial, high cd8 all cases 8.2 Summary of comaprisons Pearson correlation: Pearson correlation of all the samples Unlist all genes, and pick out genes which are impacted in at least 1 comparison, and base expression &gt;100 columns are colored by: Spatial Distribution (MH), Growth, Treatment, CD8 content Differential genes: top 100 variable genes DEG in at least 2 samples differential genes in each comparison shown Gene sets: c2, c5, Process networks, metacore, hallmark 8.2.1 EPCAM samples Note that there are a subset of samples different from the other based on CD8, growth and MH index (6RB, 3NB, 10LD, 8LD, 11ND) but these parameters don’t group the other samples well There is a small subset of samples which have high expression of CCls and based on the top variable genes, there seems to be three types of epithelial cases. We can also view this in the form of what is highly expressed in each comparison. Below is a heatmap of the fold changes: Below, we visualise the enrichment scores using different gene sets and 8.2.2 CD45 comparisons 8.2.3 DN samples 8.3 Growing vs stable emphasis Below, we focus specifically on the growing vs stable comparison in greater depth. Here, we look at the 3 different fractions in greater depth and look at volcano plots of DEG and heatmaps of differential genes. Samples are colored according to whether they are growing or stable 8.3.1 DN fraction 8.3.2 CD fraction 8.3.3 Ep Fraction 8.3.4 Specific pathways The above plots suggest that there could be a different in growing and stable based on : inflammation Kras signalling MHC presentation checkpoint proteins We can pull out the genes in these sets and visualise the relative expression in a heatmap in the DN, CD45 and Ep samples: Note that red is growing and green is stable 8.3.4.1 DN samples: Note the distribution of growing/stable in DN is: 21, 9 8.3.4.2 CD45 samples: Note the distribution of growing/stable in CD is: 26, 8 8.3.4.3 Epithelial samples: "],["deseq-analysis-2.html", "Chapter 9 DESeq analysis 9.1 CD45 samples 9.2 Epithelial samples", " Chapter 9 DESeq analysis This document sets up DESeq runs to compare: CD45 samples Ep samples according to size of the cohort samples 9.1 CD45 samples In section 6.2, we have noticed that some DN samples had expression of epithelial markers. Here, we perform a differential gene expression analysis to find genes which are different between these two fractions. Below is a summary of the number of differential genes, using p value cut off of 0.05 and log2 fold change of 1.5 and base expression of 100+. 9.1.1 PCA plot First, have a look at the samples in a PCA plot: do they separate based on size: 9.1.2 Differential Gene Expression ## [1] &quot;significant differential genes&quot; ### GSEA Run GSEA. Here, we will look specifically at the Process Network pathways which are enriched ## -Preprocessing for input gene list and hit list ... ## --Removing genes without values in geneList ... ## --Removing duplicated genes ... ## --Converting annotations ... ## -- 671 genes (out of 11288) could not be mapped to any identifier, and were removed from the data. ## -- 25 genes (out of 330) could not be mapped to any identifier, and were removed from the data. ## --Ordering Gene List decreasingly ... ## -Preprocessing complete! ## --183 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c2List! ## --1127 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5BP! ## --342 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5MF! ## --154 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5CC! ## --1 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named ProcessNetworks! ## --419 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named MetPathway! ## -Performing hypergeometric analysis ... ## -Hypergeometric analysis complete ## ## -Performing gene set enrichment analysis using HTSanalyzeR2... ## --Calculating the permutations ... ## -Gene set enrichment analysis using HTSanalyzeR2 complete ## ============================================== ## ## -No of genes in Gene set collections: ## input above min size ## c2List 2199 2016 ## c5BP 7530 6403 ## c5MF 1663 1321 ## c5CC 999 845 ## ProcessNetworks 158 157 ## MetPathway 1480 1061 ## Hallmark 50 50 ## ## ## -No of genes in Gene List: ## input valid duplicate removed converted to entrez ## Gene List 11386 11386 11288 10617 ## ## ## -No of hits: ## input preprocessed ## Hits 330 305 ## ## ## -Parameters for analysis: ## minGeneSetSize pValueCutoff pAdjustMethod ## HyperGeo Test 5 0.05 BH ## ## minGeneSetSize pValueCutoff pAdjustMethod nPermutations exponent ## GSEA 5 0.05 BH 100 1 ## ## ## -Significant gene sets (adjusted p-value&lt; 0.05 ): ## c2List c5BP c5MF c5CC ProcessNetworks MetPathway Hallmark ## HyperGeo 10 24 10 16 0 0 3 ## GSEA 288 674 203 110 34 147 11 ## Both 9 18 10 12 0 0 1 9.2 Epithelial samples 9.2.1 PCA plot First, have a look at the samples in a PCA plot: do they separate based on size: ## [1] &quot;significant differential genes&quot; 9.2.2 GSEA Run GSEA. Here, we will look specifically at the Process Network pathways which are enriched ## -Preprocessing for input gene list and hit list ... ## --Removing genes without values in geneList ... ## --Removing duplicated genes ... ## --Converting annotations ... ## -- 654 genes (out of 11873) could not be mapped to any identifier, and were removed from the data. ## -- 3 genes (out of 12) could not be mapped to any identifier, and were removed from the data. ## --Ordering Gene List decreasingly ... ## -Preprocessing complete! ## --156 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c2List! ## --957 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5BP! ## --312 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5MF! ## --132 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named c5CC! ## --403 gene sets don&#39;t have &gt;= 5 overlapped genes with universe in gene set collection named MetPathway! ## -Performing hypergeometric analysis ... ## -Hypergeometric analysis complete ## ## -Performing gene set enrichment analysis using HTSanalyzeR2... ## --Calculating the permutations ... ## -Gene set enrichment analysis using HTSanalyzeR2 complete ## ============================================== ## ## -No of genes in Gene set collections: ## input above min size ## c2List 2199 2043 ## c5BP 7530 6573 ## c5MF 1663 1351 ## c5CC 999 867 ## ProcessNetworks 158 158 ## MetPathway 1480 1077 ## Hallmark 50 50 ## ## ## -No of genes in Gene List: ## input valid duplicate removed converted to entrez ## Gene List 11956 11956 11873 11219 ## ## ## -No of hits: ## input preprocessed ## Hits 12 9 ## ## ## -Parameters for analysis: ## minGeneSetSize pValueCutoff pAdjustMethod ## HyperGeo Test 5 0.05 BH ## ## minGeneSetSize pValueCutoff pAdjustMethod nPermutations exponent ## GSEA 5 0.05 BH 100 1 ## ## ## -Significant gene sets (adjusted p-value&lt; 0.05 ): ## c2List c5BP c5MF c5CC ProcessNetworks MetPathway Hallmark ## HyperGeo 0 0 0 0 0 0 0 ## GSEA 254 784 173 107 43 77 12 ## Both 0 0 0 0 0 0 0 "],["erpgr-subtyping.html", "Chapter 10 ER/Pgr Subtyping 10.1 In-house classifier 10.2 PAM50 (Parker) scoring 10.3 Clustering based on random genes 10.4 Consolidating the different results", " Chapter 10 ER/Pgr Subtyping In this section, we will look at whether there are differences in rat subtype using the following approaches: Creating our own subtyping approach using specific markers of interest (e.g. using PAM clustering) Using known gene list Using random genes (top 50, 100, 200 etc variable genes) PAM50 subtyping using the methods published by Parker et al. This method uses rsem scores to classify samples. As the DN samples do have keratin expression, we will also try to determine the subtypes in these samples too. In the below analyses, we will conduct this subtyping as follows: progression specific epithelial cohort characterisation specific epithelial cohort dn specific cohort (progression) 10.1 In-house classifier The selected gene list includes three lists: A. is a mroe comprehensive list containing epithelial, mesenchymal markers and proliferation markers, B. has a more narrow list of subtype specific markers ‘Ar’, ‘Cd24’, ‘Cdh1’, ‘Foxa1’, ‘Gata3’, ‘Krt8’, ‘Krt18’, ‘Krt5’, ‘Vim’, ‘Erbb2’, ‘Esr1’, ‘Pgr’, ‘Mki67’, ‘Pcna’ ‘Ar’, ‘Foxa1’, ‘Gata3’, ‘Erbb2’, ‘Esr1’, ‘Pgr’ We will be using variance stabilised counts in this section. Firstly, we will look at the progression cohort. Note that the overlap between the two gene-sets are similar, and the heatmap is row-scaled. ## ColB ## ColA Basal Lum ## Basal 11 0 ## Lum 1 8 We can perform a similar analysis to the characterisation cohort: DN samples: ## ColF ## ColE Basal Lum ## Basal 9 7 ## Lum 11 3 We can collate these different scores and assess whether there are similarities with PgR and ER staining: Finally, look at whether any of the above samples have similar DN and Ep calls: it appears that this call is random, and the subtype does not dictate growth rate ## [1] &quot;extended list&quot; ## , , = growing ## ## ## Basal Lum ## Basal 2 3 ## Lum 2 3 ## ## , , = stable ## ## ## Basal Lum ## Basal 1 2 ## Lum 2 1 ## [1] &quot;narrow list&quot; ## , , = growing ## ## ## Basal Lum ## Basal 3 2 ## Lum 3 2 ## ## , , = stable ## ## ## Basal Lum ## Basal 3 0 ## Lum 1 2 10.2 PAM50 (Parker) scoring Here, we have used rsem counts in PAM50 subtyping. Plot all samples together and compare the confidence and scores in different subtypes: There is overlap between the LumB and Her2 scores, similarly Normal and LumA scores are similar We can pull out the main markers of interest: ER, PGR, Erbb2 and Ki67 (or PCNA). We also compare these expression distribution of these markers to CD45, DN and Ep overall: Notes: Pgr highest in luminal samples Esr1 dynamic range is lower Ar is higher in basal samples Pcna is higher in Basal heatmap based on the previous markers: Based on the above calls, we can condense the calls: Her2, LumB are sumilar and can be combined with LumA Normal and Basal are most likely most similar 10.3 Clustering based on random genes In this section we randomly select the most variable 200, 500, 1000, 2000 genes: we use both the standard deviation and coefficient of variation (sd normalised by the mean) to select these most variable genes. Below is a correlation plot which visualises the concordance between the different methods. 10.4 Consolidating the different results Below is a concordance map of the similarity between the different metrics calculated as \\[ \\frac{N_{b,b}+N_{l,l}}{N_{total}} \\] where \\(N_{b,b}\\) is the number of cases which are basal in two comparisons and \\(N_{l,l}\\) the number of cases which are luminal in both comparisons. Note that the values extend from 0.5 to 1, which indicates that any two methods overlap more than just by chance. There is good overlap between the in-house specific list characterisation, and some overlap between pam50 calling and in-house short list. Below is a summary of the average expression values of the classes defined by the different methods: The targeted lists show differences in esr1, pgr, erbb2, pcna Ar has differing directions for the pam classifications Random genes selected show differences in pgr, erbb2, Ar and perhaps Mki67 We can summarise the outputs for each sample below PAM50 pamlong pamshort top200sd top500sd top1000sd top2000sd 10L_D_Ep Basal Basal Basal 1 1 1 1 10R_BL_Ep Lum Lum Lum 1 1 2 2 10R_BU_Ep Lum NA NA 2 2 2 2 11L_B_Ep Lum Lum Lum 2 2 2 2 11N_D_Ep Lum Lum Basal 1 1 2 2 11R_D_Ep Lum Lum Lum 1 1 2 2 11R_C_Ep Basal Lum Lum 2 2 2 2 12L_D_Ep Basal Basal Basal 1 1 2 2 14N_C_Ep Lum Lum Lum 1 1 2 2 14N_D_Ep Basal Basal Basal 1 1 2 2 14R_B_Ep Lum Basal Basal 1 1 2 2 15N_C_Ep Basal Basal Basal 1 1 2 2 16L_C_Ep Lum Lum Lum 1 1 2 2 17N_D_Ep Lum Lum Lum 1 1 2 2 2N__Ep Lum Basal Basal 1 1 1 1 3N_B_Ep Basal Basal Basal 1 1 1 1 3R_C_Ep Lum Lum Lum 1 1 2 2 6R_B_Ep Lum Basal Basal 1 1 2 2 7N_A_Ep Lum Basal Basal 1 1 2 2 8L_D_Ep Basal Basal Basal 1 1 2 2 8R_CU_Ep Basal Basal Basal 1 1 2 2 "],["signature-analysis.html", "Chapter 11 Signature analysis 11.1 MHC signature analysis 11.2 Cancer pathways", " Chapter 11 Signature analysis In this section, we use a combination of gene-set enrichment analysis, heatmap visualisation and XX to investigate differences in PAM50 expression Major signalling pathways MHC expression signatures 11.1 MHC signature analysis Look if there is an association between MHC class I and class II and checkpoint proteins with growth in the different fractions. The summary appears: class I: association with stable in ep samples class II: low expression in DN stable sampels MHC presentation: higher in stable samples Ep (and also the characterisation cohort in general), may also be the case in DN samples 11.1.1 MHC-I 11.1.2 MHC-II 11.1.3 MHC presentation proteins 11.2 Cancer pathways In this section, we will assess whether certain fractions (eg. ep or dn) or certain tumors depend on specific cancer signalling axes. We will utilise the following information: Common cancer pathways listed by Bailey et al: This includes PIk3CA, cell cycle, Myc, tp53, notch, TGFB manually curated list of breast-specific genes (esr1, gata3, erbb2, pgr, tp53) 11.2.1 ssGSEA Figure out the signalling pathway expression (e.g using ssGSEA). From top to bottom, the color codes are: cd8 content infiltration cd8 Growht Fraction treatment From the above plots: higher Hippom Notch RTK Wnt and TGFB signalling in DN samples LY epithelial samples are enriched in cell cycle genes 11.2.2 regression model for covariates Linear model: Create a linear model to explain the above, focusing on the Progression cohort. I.e. Signature Score ~ Fraction + Treatment + CD8Fraction + Spatial Score + GrowthRate + Tumour size + PAM50 Note that the reference levels are: Fraction: DN Treatment: Vehicle PAM50: basal We see: TP53 and Wnt pathways associated with CD8 content (particularly in CD8 low samples) TP53 more associated basal DN, and with treatment in DN samples, infiltrating tumors TGFB signalling higher in ep treated ith PDL1+LY Focus specifically on the DN and Ep samples separately: Associations: notch signalling with LY treatment TGFB with PDL1+LY treatment Ras and Wnt signalling lower CD8Fraction TP53 with CD8 fraction 11.2.3 Taking into account directionality Do the same scoring, taking into account oncogenic vs tumor suppressor activity (i.e.) Usually, there is no difference. The pathway is increased either way Do a regression analysis for TSG vs ONCO signatures in this pathway Looking at up vs down genes: are any of these differentially expressed? ## [1] big big big small small big big small small small ## Levels: big small "],["immune-estimation.html", "Chapter 12 Immune estimation 12.1 ssGSEA 12.2 Deconvolution methods", " Chapter 12 Immune estimation In this section, we will look at a number of methods for immune estimation: ssGSEA using known signatures: This includes the Thorsson signatures, as well as signatures for activation and dysfunction as described by Tirosh and in the supplementary tables from Gil del Alcazar. Deconvolution methods (CIBERSORT, TIMER etc) 12.1 ssGSEA Below, we use the GSVA package and TPM counts to assess variability in the different signatures. We will compare this to: growth CD8 counts spatial patterns (infiltrating vs restricted, MH index) ## ## inf res ## 34 34 ## [1] 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ## [26] 29 30 31 32 33 34 35 36 37 38 Based on wilcoxon tests for differences between growth, cd8 content, spatial arrangement, we can also pull out the significantly different signatures and plot these below: For the MH scores and the CD8 scores, we can do a correlation analysis using the raw values 12.2 Deconvolution methods Deconvolution was performed using the TIMER website, which lists results from TIMER, XCELL, CIBERSORT, EPIC, MMPCOUNTER For TIDE, we need to: compute log(RPKM+1) values Determine the values of the reference/or compute a sample average Subtract the two We can convert from Rat gene names to Human and exclude all the non mapping gnes. TPM counts were used for this analysis (using Rat gene names) 12.2.1 Overview of the cell types Below, we will look at the enrichment scores of specific cell types compared to others using these different methods. It appears that most methods have scores which skews towards high representation of T cells: TIMER for example shows an enrichment of dendritic and CD8 T cells. EPIC in contrast shows enrichment for CD4+ and to a lesser extend CD8 T cells MMPCOUNTER puts an unusually large weighting to T cells and this does not fit our FACS analysis XCELL enriches for T cells 12.2.2 TEMP: comparison of running Char and Prog cohorts separately? Associations with size? Perform a correlation test between all of the information above and tumor size 12.2.3 Comparison with FACS data In this section, we compare how well the estimates from RNAseq deconvolution methods associate with FACS data. We can plot associations between the different cell types below, here selecting: Bcells CD8 T cells M2 macophage M1 macrophage 12.2.4 Associate with Treatment Look at association with treatment, growth and spatial infiltration for each method. Associations with treatment: higher CD4, CD8 in most treatments growth: stable associated with higher CD8 infiltration: more neutrophils and CD8? maybe CD4 cells Using wilcox tests for significance, we can make the above comparisons and see if there is an association with outcome: There are differences in B-cell content between LY vs V comaprisons using xcell and cibersort Macrophages are different in PDL1+LY 12.2.5 Association with Growth 12.2.6 Association with infiltration ### Summary of the outcome LYvs.Vehicle PDL1vs.Vehicle PDL1+LYvs.Vehicle Grow.Stable Inf.res CIBERSORT 0.4126984 0.5476190 1.0000000 0.5880289 0.0663337 CIBERSORT-ABS 0.4126984 1.0000000 0.6623377 0.6426471 0.0495504 EPIC 0.3046181 0.9093820 0.8169239 0.4024275 0.1322345 facs 0.0265187 0.1979593 0.0265187 0.1028077 0.1447036 MMCPCOUNTER 0.0004218 0.0110240 0.0372030 0.0027499 0.2435679 QUANTISEQ 0.8735909 0.1566299 0.3301798 0.4282170 0.2935335 TIMER 0.8930363 0.7899436 0.1930218 0.6167393 0.0515526 XCELL 0.0656851 0.0521035 0.0311469 0.2495453 0.1320186 facs 0.9047619 0.6904762 0.5367965 1.0000000 0.6889111 CIBERSORT 0.3710934 0.4237108 NaN 0.0572674 0.4962425 CIBERSORT-ABS 0.3710934 0.4237108 NaN 0.0572674 0.4962425 QUANTISEQ 0.2857143 0.3095238 0.1610557 0.0707781 0.1103319 XCELL 0.1111111 0.0555556 0.0519481 0.0043197 0.4559441 facs 0.2857143 0.2222222 0.5367965 0.2749226 0.8639361 CIBERSORT 0.2857143 0.0317460 0.2467532 0.1574303 0.7756244 CIBERSORT-ABS 0.1904762 0.0317460 0.0519481 0.0968008 0.9546454 QUANTISEQ 0.2622393 0.4633439 0.1908413 0.0288101 0.4652088 XCELL 0.5555556 0.4633439 0.5830249 0.0069691 0.6789034 CIBERSORT 0.1904762 0.6904762 0.5367965 0.0144737 0.7756244 CIBERSORT-ABS 0.1904762 1.0000000 0.2467532 0.0144737 0.9546454 facs 0.1904762 1.0000000 0.3290043 0.4377967 0.6069930 MMCPCOUNTER 0.1312104 0.0720057 0.4652088 0.3530684 0.6413095 QUANTISEQ 0.5023350 0.4237108 0.3613104 0.5293681 NaN XCELL 0.1399825 0.2491526 0.0995755 0.0047464 1.0000000 CIBERSORT NaN NaN 0.4652088 0.2084128 0.2763029 CIBERSORT-ABS NaN NaN 0.4652088 0.2084128 0.2763029 facs 0.7301587 0.5476190 0.6623377 0.8167957 0.8639361 QUANTISEQ 0.2404208 0.1797125 0.1363802 0.3228308 0.4962425 TIMER 0.5555556 1.0000000 0.9307359 0.1348039 0.9546454 XCELL 1.0000000 1.0000000 0.7792428 0.4181370 0.8571364 facs 0.6666667 0.5333333 0.3333333 0.4206349 0.0952381 EPIC 0.9047619 0.3095238 0.5367965 0.6991744 0.1810190 MMCPCOUNTER 0.2857143 0.4206349 0.3290043 0.0004902 0.8639361 QUANTISEQ 0.9047619 0.4206349 0.9307359 0.0264435 0.3884116 XCELL 0.4126984 0.5476190 0.9307359 0.0296956 0.7756244 facs 0.3333333 0.2666667 1.0000000 0.0317460 0.1666667 CIBERSORT 0.2857143 0.3095238 0.1255411 0.3928793 0.5286713 CIBERSORT-ABS 0.1904762 0.6904762 0.1255411 0.5880289 0.9546454 EPIC 0.9047619 0.6904762 0.0303030 0.2749226 0.2721279 QUANTISEQ 0.5385943 0.0317460 0.0519481 0.7807063 0.9525866 TIMER 0.4126984 1.0000000 0.4285714 0.0674923 0.6069930 XCELL 1.0000000 0.8412698 0.9307359 0.0017028 0.4559441 facs 1.0000000 0.2666667 0.3333333 0.3095238 0.0238095 CIBERSORT 0.9047619 1.0000000 0.7922078 0.0455624 0.8639361 CIBERSORT-ABS 0.9047619 0.4206349 0.5367965 0.0186017 0.7756244 QUANTISEQ 0.5555556 0.4206349 0.5367965 0.9384675 0.5286713 XCELL 0.7301587 0.1507937 0.1255411 0.1826883 0.5286713 CIBERSORT 0.2857143 0.0555556 0.2467532 0.1574303 0.7756244 CIBERSORT-ABS 0.1904762 0.0317460 0.0519481 0.1146285 0.9546454 EPIC 0.1111111 0.0952381 0.1774892 0.0034056 0.7756244 facs 0.1904762 0.2222222 0.7922078 0.4854231 0.9546454 QUANTISEQ 0.4126984 0.5476190 0.1669941 0.0054748 0.1112920 TIMER 0.2622393 0.3457418 0.1908413 0.5171621 0.0883763 XCELL 0.1111111 0.2222222 0.1774892 0.0024252 0.3884116 CIBERSORT 0.2857143 0.2222222 0.2722293 0.1653588 1.0000000 CIBERSORT-ABS 0.4126984 0.2222222 0.2722293 0.2845377 0.7680770 EPIC 0.4126984 0.1507937 0.0173160 0.3113777 0.6889111 facs 0.3333333 0.5333333 0.3333333 0.0555556 0.5476190 QUANTISEQ 0.5023350 1.0000000 0.3413145 1.0000000 0.4961158 TIMER 0.2008251 0.0669553 0.0616637 0.4219366 0.1084083 XCELL 0.2857143 0.0952381 0.1774892 0.7573013 0.3276723 "],["bcr-clonotype-analysis.html", "Chapter 13 BCR clonotype analysis 13.1 Processing summary 13.2 Summary Stats 13.3 Diversity metrics 13.4 Compare the characterisation cohort 13.5 Associate with clinicopathological data 13.6 Associate with signature scores 13.7 Check whether the clonotype percentages match with gsva signatures or CD20 populations", " Chapter 13 BCR clonotype analysis 13.1 Processing summary Fastq files have previously been run through TRUST4 using the Rn6 BCR annotations using the following code (not run here). Note that the bcr/tcr .fa files were assembled using the ensembl annotation (these annotations are not present in the UCSC genomic files). Annotation files for the rn6 BCR regions are available at IMGT, but TCR regions are not available # obtain the gene names for rat: library(biomaRt) human = useEnsembl(&quot;ensembl&quot;, mirror=&quot;useast&quot;, dataset = &quot;hsapiens_gene_ensembl&quot;) rat = useEnsembl(&quot;ensembl&quot;, mirror=&quot;useast&quot;, data=&quot;rnorvegicus_gene_ensembl&quot;) TS = human_igg_trv_list Hum2RatProt = getLDS(attributes = c(&quot;hgnc_symbol&quot;, &quot;ensembl_transcript_id&quot;), filters = &quot;hgnc_symbol&quot;, values = TS , mart = human, attributesL = c(&quot;rgd_symbol&quot;, &quot;ensembl_transcript_id”, “ensemble_gene_id&quot;), martL = rat, uniqueRows=T) write.table(unique(Hum2RatProt$ensemble_gene_id), &quot;ensbl_rat_bcr.txt&quot;, quote=F, row.names=F,colnames=F) # obtain the tcr/bcr.fa file #(Note that BuildDatabaseFa.pl needs to be edited on lines 95, 102, 114 and 121 to use transcript_id or gene_id instead) perl BuildDatabaseFa.pl Rattus_norvegicus.Rnor_6.0.dna_sm.toplevel.fa Rattus_norvegicus.Rnor_6.0.99.gtf ensbl_rat_bcr.txt &gt; bcrtcr_rat_ens.fa # Obtain the reference annotation file perl BuildImgtAnnot.pl Rattus_norvegicus &gt; Rnor_IMGT+C.fa # Run TRUST (below is single end) ./run-trust4 -u 20170125_NMU7_Tumor_RLU_CD45_CGDA5146_S1_R1_001.fastq.gz -f bcrtcr_rat_ens.fa --ref Rnor_IMGT+C.fa 13.2 Summary Stats Firstly, look at the number of BCR regions which have been identified by TRUST4. In green are the CD45 populations, which as expected appear to have a higher number of clonotypes compared to the epithelial and the double-negative populations (in read and orange). We will refine the above plot to contain only the CD45 population and assess: number of clonotypes number of clonotypes with at least 2 reads number of clonotypes which have a complete CDR3a region Note: although this does not look like a big drop, the data is plotted on a log-scale. For example, in the control 4 (first column) a quarter of the clonotypes have at least 2 counts and about half have a complete CDR3 sequence. For the following analyses, the clonotypes are filtered to only clonotypes with at least 2 supporting reads and a complete VDJ read . When applying this restriction, we have the following distribution of BCR regions. Almost all the epithelial cases do not have supporting reads, and few of the DN cases have supporting reads too. 13.3 Diversity metrics We will assess BCR diversity using the following metrics: ** Shannon index ** The shannon index is computed by: filtering through reads of interest recalculate the fraction such that the new list sums to 1 compute entropy as the sum of log(freq_x)*freq_x amongst all populations x compute the maximum entropy expected for that case -log(1/N), where N is the number of populations present to determine confidence intervals, bootstrap the population (500 times) and compute the expected entropy ** Gini index ** The Gini index can be considered as an inverse of the Shannon index ** Top Clonotypes ** We will see the proportion of the BCR repertoire which is computed using the top 10 frequent clones. This will give an idea of whether there is a clonal expansion The following plot demonstrates the relationship between the above metrics Notice that some samples have very few clones. An example is 5RB which is represented by a single clonotype, accounting for the absence of a Gini or shannon index 13.4 Compare the characterisation cohort In the characterisation cohort, we have 3 cases which have CD45 samples in both the tumor and a matched NMU treated mammary gland. Is there a difference in the clonotypes between these samples? 13.5 Associate with clinicopathological data We will associate the following metrics: total unique clones diversity with the following immune data: CD45 fraction (from FACS) CD8 fraction (from WSI) MH-mixing indices Tumor Size Growth Treatment 13.6 Associate with signature scores Compare to B cell counts and activation status based on RNA-seq B cell signature enrichments scores (from RNA data) B cell frequencies based on FACS: 13.7 Check whether the clonotype percentages match with gsva signatures or CD20 populations associate with immune signature scores (ssgsea) fdr adjust the correlation p values "],["whole-genome-sequencing-mutations.html", "Chapter 14 Whole Genome Sequencing Mutations 14.1 Data 14.2 Plots 14.3 Coding variants 14.4 Overview of the mutations 14.5 Metacore analysis of commonly mutated pathways", " Chapter 14 Whole Genome Sequencing Mutations Whole genome sequencing was performed on XX samples by the new york genome centre. The pipeline involves: Insert information on the NYGC pipeline here 14.1 Data In this section, we load the maf output files and create lists which filter out coding mutations Determine mutational signatures by: Creating bed files with genomic locations of the SNP +- 1 base location Extracting the nucleotide sequence using bedtools Convert all mutations to C &gt; N and T &gt; N to obtain 96 mutational signatures run with single sample SigProfiler to obtain the signature scores Annotate data with common human variants ## [1] &quot;no of mutations&quot; ## C1R-tumor C2N-tumor C2R1-tumor C2R2-tumor C2R3-tumor C4P-tumor ## 240153 262425 235677 222717 238324 258677 14.1.1 Extract mutation signatures Annotate the files so that the nucleotide codon can be extracted based on the genome file. See the bash file extract-trinucleotide-forSigProfiler.sh to see the output of this. The output table $fout3 should have 6 columns with the genomic location, the reference and alt allele and codon context. TBed=lapply(AllMutWGS, function(x) cbind(as.character(x$Chromosome), x$Start_Position-2, x$End_Position+1, as.character(x$Reference_Allele), as.character(x$Tumor_Seq_Allele2))) TBed=lapply(TBed, function(x) x[which(nchar(x[ ,4])==1), ]) sapply(1:length(TBed), function(x) write.table(TBed[[x]], file=paste(names(TBed)[x], &quot;tricodon.bed&quot;, sep=&quot;_&quot;),col.names=F, row.names = F, sep=&quot;\\t&quot;, quote = F)) ## bedtools command bedtools getfasta -fi ../Genomic_Files/rn6.fa -bed $f -tab -fo $fout f3() { awk &#39;{print $1, $2, $3, $4 ,$5}&#39; &quot;$1&quot;; }; paste &lt;(f3 $f) &lt;(f3 $fout) &gt; $fout2 awk &#39;{if (length($7)==3) print $1, $2, $3, $4, $5, toupper($7)}&#39; $fout2 &gt; $fout3 ## see the bash file extract-trinucleotide-forSigProfiler.sh to see the output of this. Following running the above bash script, we can run the following extract the tri-nucleotide sequence FFiles=dir(&quot;../data/tricodon_mut_sigs/&quot;, &quot;*.txt&quot;,full.names=T) OutputList=sapply(FFiles, function(x) FindTriNucleotideContext(x)) TableOut=sapply(1:ncol(OutputList), function(x) unlist(OutputList[3, x])) a1=basename(FFiles) a2=sapply(strsplit(a1, &quot;_&quot;), function(x) x[1]) TableOut=cbind(as.character(unlist(OutputList[1, 1])), as.character(unlist(OutputList[2, 1])), TableOut) colnames(TableOut)=c(&quot;MutationType&quot;,&quot;Nutrinucleotide&quot;, paste(&quot;BRCA&quot;, a2, sep=&quot;::&quot;)) write.csv(TableOut, file=&quot;../data/tricodon_mut_sigs/output4SigProfiler.csv&quot;, sep = &quot;,&quot;, row.names = F) This is then run in python (sigprofiler) with the following code: module load gcc module load python/3.7.4 from SigProfilerExtractor import spss_pcwag (spss uses only vcf files) spss_pcwag.single_sample_pcwag(&quot;output4SigProfiler.csv&quot;, output=&quot;example_output&quot;) The results from this analysis are shown below 14.1.2 Annotate the data with human common variants From this analysis, below are the genes with mutations in known human hotpot mutations in common genes L1 AAno Gene AAno.1 AA1 Variant HumGene RatSequence RatProt HumSequence HumProt HumAAno 166 NMU12-tumor-LA 12 Hras 12 G E HRAS VVVGAGGVGKS ENSRNOP00000022363 VVVGAGGVGKS ENSP00000380722 12 168 NMU12-tumor-LA 264 Tp53 264 G R TP53 SGNLLGRDSFE ENSRNOP00000047840 SGNLLGRNSFE ENSP00000352610 266 131 NMU1-tumor 118 Pik3ca 118 G D PIK3CA LNREIGFVIGM ENSRNOP00000072496 LNREIGFAIGM ENSP00000263967 118 181 NMU12-tumor-LA 542 Pik3ca 542 E K PIK3CA RDPLSEITEQE ENSRNOP00000072496 RDPLSEITEQE ENSP00000263967 542 155 NMU1-tumor 3016 Atm 3016 R H ATM NKVAERVLMRL ENSRNOP00000045529 NKVAERVLMRL ENSP00000388058 3008 And here, we plot the frequency of these different mutations 14.2 Plots 14.2.1 Quick overview WGS all mutations summary: Look at the overall mutation burden, and the tumor mutational burden, defined as # coding mutations per MB. The following plot lists tumors in increasing size Make plots of: overall types of mutations per sample (ranked by size) correlation between mutation type and size type of mutation? 14.2.2 Coding variants &amp; TMB There are a few ways of figuring out the TMB. We can report the number of mutations (missense, insertion/deletion, frameshifts, nonsense) normalise the above value to the known length of coding regions in the rat genome (UCSC exon length 43,423,804) plot of TMB vs objective response rate: there is no true relationship between final tumor size and mutational burden. Could also be confounded by subclonality 14.3 Coding variants 14.3.1 Sites which are commonly mutated? Could this be a variant (SD strain “rsSNP”) or is it actually a mutation? Variants were annotated with snpeff. Raw data from this was obtained from https://www.biorxiv.org/content/10.1101/412924v1.full Note that the nihRats package may not be required here. We probably just want the harlan snps Look at the distribution of mutations: Whole genome 1188 genes in more than 2 animals (1435 in at least 2) 59 variants were identified as population variant in Harlan 47 in charles river (6 are novel in this cohort only) Cosmic genes: 42 sites which have mutations in more than 2 animals 50 sites in more than 1 animal 5 sites which have been identified in GWAS studies of harlan rats. On average, the variant is found at a frequency of ~15%. The CR set, these variants appear in 50% of the population 4 of the 5 rats from above were identified in 0 sites in the nih dbSNP database for rats Here, compare the frequencies of the most common mutations in our population with those reported in the harlan and charles river data-bases: filter out mutatations occuring in 2+ samples ## [1] 1093 freq.Freq gene VariantClass Cosmic variable value 140 11 Prf1 Missense_Mutation 1 HarlanFreq 0.4528715 699 3 Rnf213 Missense_Mutation 1 HarlanFreq 0.1402893 700 3 Rnf213 Missense_Mutation 1 HarlanFreq 0.1402893 701 3 Rnf213 Missense_Mutation 1 HarlanFreq 0.1411662 805 3 Tcf3 Missense_Mutation 1 HarlanFreq 0.0679527 953 2 Ptpn13 Missense_Mutation 1 HarlanFreq 0.0271811 1792 3 Rnf213 Missense_Mutation 1 CRFreq 0.5264045 1793 3 Rnf213 Missense_Mutation 1 CRFreq 0.5264045 1794 3 Rnf213 Missense_Mutation 1 CRFreq 0.5365169 1898 3 Tcf3 Missense_Mutation 1 CRFreq 0.1488764 14.4 Overview of the mutations 14.4.1 All mutations SNPs are removed from this analysis: based on frequencies in the harlan cohort Color codes: black: pink: green: blue: Note that in this table, the distribution of samples with mutations is as follows: 2042, 342, 196, 222, 65, 43, 30, 25, 23, 23, 15, 14, 10, 11, 7, 7, 1, 1, 1, 1, 1 The number of genes which have shared mutations in 10 or more samples is: 92, which is why we have use these values here. The number of genes which are cosmic associated are: 162 and the number which appear in more than 1 sample is 44. These genes are tabulated below: 14.5 Metacore analysis of commonly mutated pathways Save these lists for metacore Load the metacore results: ## Inflammation_IL-2 signaling Signal transduction_ESR1-nuclear pathway ## C1R-tumor 2 8 ## C2N-tumor 0 0 ## C2R1-tumor 2 1 ## C2R2-tumor 2 2 ## C2R3-tumor 2 2 ## C4P-tumor 0 4 ## Signal Transduction_Cholecystokinin signaling ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 2 ## C4P-tumor 0 ## Signal transduction_NOTCH signaling ## C1R-tumor 9 ## C2N-tumor 4 ## C2R1-tumor 4 ## C2R2-tumor 4 ## C2R3-tumor 2 ## C4P-tumor 4 ## Signal transduction_ESR1-membrane pathway ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 3 ## C2R2-tumor 0 ## C2R3-tumor 2 ## C4P-tumor 1 ## Cell adhesion_Integrin priming Inflammation_IL-6 signaling ## C1R-tumor 8 1 ## C2N-tumor 0 4 ## C2R1-tumor 6 2 ## C2R2-tumor 1 4 ## C2R3-tumor 3 1 ## C4P-tumor 3 2 ## Cell adhesion_Cadherins DNA damage_MMR repair ## C1R-tumor 4 4 ## C2N-tumor 3 0 ## C2R1-tumor 7 2 ## C2R2-tumor 4 1 ## C2R3-tumor 6 2 ## C4P-tumor 6 3 ## Cell adhesion_Integrin-mediated cell-matrix adhesion ## C1R-tumor 6 ## C2N-tumor 0 ## C2R1-tumor 5 ## C2R2-tumor 2 ## C2R3-tumor 2 ## C4P-tumor 2 ## Development_EMT_Regulation of epithelial-to-mesenchymal transition ## C1R-tumor 7 ## C2N-tumor 4 ## C2R1-tumor 6 ## C2R2-tumor 4 ## C2R3-tumor 5 ## C4P-tumor 4 ## Reproduction_Feeding and Neurohormone signaling ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## Cell cycle_G1-S Growth factor regulation ## C1R-tumor 4 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 2 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Blood vessel morphogenesis ## C1R-tumor 5 ## C2N-tumor 5 ## C2R1-tumor 8 ## C2R2-tumor 6 ## C2R3-tumor 5 ## C4P-tumor 7 ## Cell adhesion_Platelet aggregation ## C1R-tumor 4 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 1 ## Cell adhesion_Attractive and repulsive receptors ## C1R-tumor 1 ## C2N-tumor 1 ## C2R1-tumor 5 ## C2R2-tumor 1 ## C2R3-tumor 3 ## C4P-tumor 2 ## Signal transduction_ERBB-family signaling ## C1R-tumor 5 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 2 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Neurogenesis_Axonal guidance ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 6 ## C2R2-tumor 1 ## C2R3-tumor 4 ## C4P-tumor 1 ## Cell adhesion_Cell-matrix interactions ## C1R-tumor 12 ## C2N-tumor 6 ## C2R1-tumor 3 ## C2R2-tumor 2 ## C2R3-tumor 2 ## C4P-tumor 4 ## Development_Regulation of angiogenesis ## C1R-tumor 12 ## C2N-tumor 3 ## C2R1-tumor 8 ## C2R2-tumor 6 ## C2R3-tumor 4 ## C4P-tumor 3 ## Reproduction_Progesterone signaling Muscle contraction ## C1R-tumor 3 6 ## C2N-tumor 1 3 ## C2R1-tumor 3 1 ## C2R2-tumor 2 0 ## C2R3-tumor 2 0 ## C4P-tumor 3 2 ## Cytoskeleton_Cytoplasmic microtubules ## C1R-tumor 6 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 2 ## C4P-tumor 5 ## Development_Neurogenesis in general ## C1R-tumor 9 ## C2N-tumor 1 ## C2R1-tumor 6 ## C2R2-tumor 3 ## C2R3-tumor 3 ## C4P-tumor 8 ## Reproduction_Male sex differentiation Cell cycle_Meiosis ## C1R-tumor 6 6 ## C2N-tumor 0 1 ## C2R1-tumor 4 2 ## C2R2-tumor 3 1 ## C2R3-tumor 3 2 ## C4P-tumor 0 1 ## Development_ERK5 in cell proliferation and neuronal survival ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 1 ## C4P-tumor 1 ## Development_Hedgehog signaling ## C1R-tumor 7 ## C2N-tumor 2 ## C2R1-tumor 2 ## C2R2-tumor 1 ## C2R3-tumor 1 ## C4P-tumor 4 ## Cardiac development_Wnt_beta-catenin, Notch, VEGF, IP3 and integrin signaling ## C1R-tumor 10 ## C2N-tumor 1 ## C2R1-tumor 3 ## C2R2-tumor 1 ## C2R3-tumor 2 ## C4P-tumor 1 ## Development_Neuromuscular junction ## C1R-tumor 6 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 3 ## Inflammation_Kallikrein-kinin system ## C1R-tumor 6 ## C2N-tumor 8 ## C2R1-tumor 4 ## C2R2-tumor 4 ## C2R3-tumor 2 ## C4P-tumor 4 ## Proteolysis_Connective tissue degradation Cell cycle_S phase ## C1R-tumor 9 5 ## C2N-tumor 15 2 ## C2R1-tumor 3 5 ## C2R2-tumor 2 3 ## C2R3-tumor 3 5 ## C4P-tumor 14 4 ## Cell adhesion_Platelet-endothelium-leucocyte interactions ## C1R-tumor 5 ## C2N-tumor 5 ## C2R1-tumor 5 ## C2R2-tumor 5 ## C2R3-tumor 4 ## C4P-tumor 6 ## Immune response_IL-3 signaling via ERK and PI3K ## C1R-tumor 2 ## C2N-tumor 3 ## C2R1-tumor 4 ## C2R2-tumor 2 ## C2R3-tumor 3 ## C4P-tumor 2 ## NF-AT signaling in cardiac hypertrophy ## C1R-tumor 4 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 4 ## Development_Prolactin receptor signaling ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Immune response_M-CSF-receptor signaling pathway ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Negative regulation of WNT/Beta-catenin signaling in the cytoplasm ## C1R-tumor 0 ## C2N-tumor 3 ## C2R1-tumor 3 ## C2R2-tumor 2 ## C2R3-tumor 4 ## C4P-tumor 2 ## CHDI_DEGs from Replication data_Causal network ## C1R-tumor 3 ## C2N-tumor 2 ## C2R1-tumor 0 ## C2R2-tumor 3 ## C2R3-tumor 0 ## C4P-tumor 0 ## IGF family, invasion and metastasis in colorectal cancer ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 1 ## Development_Positive regulation of WNT/Beta-catenin signaling in the cytoplasm ## C1R-tumor 1 ## C2N-tumor 2 ## C2R1-tumor 2 ## C2R2-tumor 3 ## C2R3-tumor 5 ## C4P-tumor 3 ## PI3K signaling in gastric cancer ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Immune response_IL-4 signaling pathway ## C1R-tumor 3 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Role of HDAC and calcium/calmodulin-dependent kinase (CaMK) in control of skeletal myogenesis ## C1R-tumor 2 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 2 ## CHDI_Correlations from Discovery data_Causal network ## C1R-tumor 1 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## Immune response_Function of MEF2 in T lymphocytes ## C1R-tumor 2 ## C2N-tumor 2 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Signal transduction_Angiotensin II/ AGTR1 signaling via p38, ERK and PI3K ## C1R-tumor 3 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 2 ## CHDI_Correlations from Replication data_Causal network (positive correlations) ## C1R-tumor 3 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Signal transduction_Angiotensin II/ AGTR1 signaling via JAK/STAT ## C1R-tumor 3 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 3 ## Development_Fetal brown fat cell differentiation ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 2 ## C2R3-tumor 2 ## C4P-tumor 2 ## Signal transduction_Angiotensin II/AGTR1 signaling via Notch, Beta-catenin and NF-kB pathways ## C1R-tumor 4 ## C2N-tumor 1 ## C2R1-tumor 1 ## C2R2-tumor 1 ## C2R3-tumor 2 ## C4P-tumor 3 ## Cytoskeleton remodeling_FAK signaling ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## WNT signaling in proliferative-type melanoma cells ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## Cytoskeleton remodeling_Hyaluronic acid/ CD44 signaling pathways ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## EGF- and HGF-dependent stimulation of metastasis in gastric cancer ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## CHDI_Correlations from Replication data_Cytoskeleton and adhesion module ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 1 ## Role of adhesion of SCLC cells in tumor progression ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Mechanisms of CAM-DR in multiple myeloma ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## CHDI_Correlations from Replication data_Causal network (negative correlations) ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 1 ## C2R3-tumor 1 ## C4P-tumor 0 ## Aberrant B-Raf signaling in melanoma progression ## C1R-tumor 1 ## C2N-tumor 2 ## C2R1-tumor 2 ## C2R2-tumor 1 ## C2R3-tumor 2 ## C4P-tumor 1 ## Development_Thromboxane A2 signaling pathway ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## IGF-1 signaling in multiple myeloma ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## Chemotaxis_Lysophosphatidic acid signaling via GPCRs ## C1R-tumor 3 ## C2N-tumor 1 ## C2R1-tumor 2 ## C2R2-tumor 2 ## C2R3-tumor 3 ## C4P-tumor 1 ## Cell cycle_Role of Nek in cell cycle regulation ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 1 ## High shear stress-induced platelet activation ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## Development_Negative regulation of WNT/Beta-catenin signaling in the nucleus ## C1R-tumor 3 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## wtCFTR and deltaF508-CFTR traffic / Clathrin coated vesicles formation (normal and CF) ## C1R-tumor 0 ## C2N-tumor 1 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## Development_The role of GDNF ligand family/ RET receptor in cell survival, growth and proliferation ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 2 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 1 ## Chemotaxis_SDF-1/ CXCR4-induced chemotaxis of immune cells ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## Proliferative action of Gastrin in gastric cancer ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## Development_Positive regulation of WNT/Beta-catenin signaling at the receptor level ## C1R-tumor 2 ## C2N-tumor 1 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 ## Development_Regulation of cytoskeleton proteins in oligodendrocyte differentiation and myelination ## C1R-tumor 2 ## C2N-tumor 1 ## C2R1-tumor 1 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 2 ## Neurogenesis_NGF/ TrkA MAPK-mediated signaling ## C1R-tumor 3 ## C2N-tumor 1 ## C2R1-tumor 1 ## C2R2-tumor 2 ## C2R3-tumor 1 ## C4P-tumor 1 ## Muscle contraction_S1P2 receptor-mediated smooth muscle contraction ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## EGFR signaling pathway in colorectal cancer ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 1 ## C2R2-tumor 1 ## C2R3-tumor 0 ## C4P-tumor 0 ## Langerhans cell migration to lymph nodes in allergic contact dermatitis ## C1R-tumor 2 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 1 ## Stem cells_Pancreatic cancer stem cells in tumor metastasis ## C1R-tumor 1 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 1 ## C4P-tumor 0 ## Role of cell adhesion molecules in progression of pancreatic cancer ## C1R-tumor 0 ## C2N-tumor 0 ## C2R1-tumor 0 ## C2R2-tumor 0 ## C2R3-tumor 0 ## C4P-tumor 0 "],["mutations-in-rna.html", "Chapter 15 Mutations in RNA 15.1 Haplotype caller 15.2 Load files 15.3 Identifying polymorphisms: compare frequencies in CD45 and Ep data 15.4 Find coding mutations which are specific to ep cells 15.5 Filtering WGS data based on CD45 data", " Chapter 15 Mutations in RNA In this section, we will check RNA data for the common mutations identified in the previous section. Some of these mutations could be uncharacterised polymoprphisms, and if this is the case, we will see in both CD45 and Epithelial fractions 15.1 Haplotype caller Mutational calling from RNA data was performed using haplotype caller. The key steps are: run haplotype caller run snpeff to annotate from snpsift to convert to a text file that can be read Note that a dbSNP file is needed to filter for polymorphisms. We have used the harlan variants to perform filtering due to similarity in population frequencies in the previous section An example of the code is shown here: From processing the mutational information: Header information - Genotypes: GT: genotype AD: Allelic depths for the ref and alt alleles in the order listed DP: Approximate read depth (reads with MQ=255 or with bad mates are filtered) GQ: Genotype Quality PL: Normalized, Phred-scaled likelihoods for genotypes Header info: Info AC: Allele count in genotypes, for each ALT allele, in the same order as listed AF: Allele Frequency, for each ALT allele, in the same order as listed AN: Total number of alleles in called genotypes DB: dbSNP Membership DP: Approximate read depth; some reads may have been filtered ExcessHet: Phred-scaled p-value for exact test of excess heterozygosity FS: Phred-scaled p-value using Fisher’s exact test to detect strand bias MLEAC: Maximum likelihood expectation (MLE) for the allele counts (not necessarily the same as the AC) MLEAF: Maximum likelihood expectation (MLE) for the allele frequency (not necessarily the same as the AF) MQ: RMS Mapping Quality QD:Variant Confidence/Quality by Depth SOR: Symmetric Odds Ratio of 2x2 contingency table to detect strand bias SnpEff Annotations: Allele : C Annotation: missense_variant Annotation_Impact MODERATE Gene_Name Raet1l Gene_ID ENSRNOG00000040300 Feature_Type transcript Feature_ID ENSRNOT00000062027.4 Transcript_BioType protein_coding HGVS.c c.1017C&gt;G HGVS.p p.Cys339Trp cDNA.pos / cDNA.length 1017/1185 CDS.pos / CDS.length 1017/1185 AA.pos / AA.length 339/394 missense_variant|MODERATE|Raet1l|ENSRNOG00000040300|transcript|ENSRNOT00000062027.4|protein_coding|6/7|c.1017C&gt;G|p.Cys339Trp|1017/1185|1017/1185|339/394|| AC=2;AF=1.00;AN=2;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.99;SOR=0.874;ANN=GC|frameshift_variant&amp;splice_region_variant|HIGH|Reps1|ENSRNOG00000059224|transcript|ENSRNOT00000089607.1|protein_coding|8/29|c.119dupC|p.Gln41fs|142/2608|120/1842|40/613||INFO_REALIGN_3_PRIME;LOF=(Reps1|ENSRNOG00000059224|2|0.50) AC=2;AF=1.00;AN=2;BaseQRankSum=1.593;ClippingRankSum=0.000;DP=9;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=33.20;ReadPosRankSum=0.765;SOR=1.609;ANN=AT|frameshift_variant&amp;stop_gained|HIGH|Pacs1|ENSRNOG00000020350|transcript|ENSRNOT00000027632.5|protein_coding|3/24|c.464dupA|p.Tyr155fs|464/2886|464/2886|155/961||;LOF=(Pacs1|ENSRNOG00000020350|1|1.00);NMD=(Pacs1|ENSRNOG00000020350|1|1.00) 15.2 Load files 15.3 Identifying polymorphisms: compare frequencies in CD45 and Ep data Search for whether mutations in the cosmic set is present in the RNA data. We will firstly look at the 90 most common genes, and then repeat the same for the top cosmic genes. 15.4 Find coding mutations which are specific to ep cells Here, look for mutations from RNA which are present in the epithelial cells specific ## quartz_off_screen ## 2 Location specific mutations: There are 6 mutations which are found in both the RNA and WGS data (2+ samples, not found in RNAseq) 15.5 Filtering WGS data based on CD45 data Use the entire list for WGS Find mutations in CD45 (either) and remove ## quartz_off_screen ## 2 ## quartz_off_screen ## 2 "],["associating-expression-with-mutations.html", "Chapter 16 Associating expression with Mutations 16.1 Expression of genes in common 16.2 Expression of genes with key mutations 16.3 Expression of common mutations? 16.4 Expression of immune related genes in the CD45 population 16.5 Cancer Specific Pathways", " Chapter 16 Associating expression with Mutations Also plot the expression of the corresponding genes here, if the epithelial RNA data is present. Note, with this early batch, the DN population was not sorted by FACS nor sequenced. The following samples have matching WGX data: C2N__CD45, C2N__Ep, NMU12_RL_Ep, NMU12_LA_Ep, NMU14__Ep, NMU12_LA_CD45, NMU13_RAU_CD45, NMU14__CD45 from samples C2N_, NMU12_LA, NMU12_RL, NMU13_RAU, NMU14_ 16.1 Expression of genes in common Compare RNA mut freq &amp; expression values ## C2N__Ep C2R__Ep C5R__Ep NMU10_LL_Ep NMU12_LA_Ep NMU12_RL_Ep ## Ctgf 21854360 2 2 0 0 0 0 ## Dsc2 11829313 0 0 2 0 0 0 ## Enpep 233713639 1 1 1 0 0 0 ## Hps4 50293000 0 0 0 0 0 2 ## Igsf3 203832077 0 0 0 0 0 0 ## Klhl22 87693945 0 0 0 0 0 0 ## NMU13_LLU_Ep NMU14__Ep NMU7_RLU_Ep NMU13_LAU_Ep ## Ctgf 21854360 0 0 0 0 ## Dsc2 11829313 0 0 0 0 ## Enpep 233713639 0 0 0 0 ## Hps4 50293000 0 0 0 0 ## Igsf3 203832077 2 0 0 0 ## Klhl22 87693945 2 0 2 0 16.2 Expression of genes with key mutations We can still look at expression of genes of interest. Eg. C2N may be enriched in kalikrein systen, connective tissue degradation NMU12_LA in endothelium_leukocyte interactions, IL6 signalling NMU12 RL in NOTCH signalling? ## quartz_off_screen ## 2 ## quartz_off_screen ## 2 16.3 Expression of common mutations? Run the following to plot this for both the cd45 fraction as well as the epithelial fraction: 16.3.1 Look at cancer specific pathways ## quartz_off_screen ## 2 16.4 Expression of immune related genes in the CD45 population Initially do a search for the mutations shown before, also can do immune specific mutations Immune specific mutations 16.4.0.1 Combine the two fractions together 16.5 Cancer Specific Pathways Also separate out the TS and OG: change the first two lines of this to list this informaiton 16.5.1 Compute co-occurence matrices Use all genes in WGS coding Firstly by genomic location: pull out the top mutations occurring in at least 5 samples: this gives approximately 7000 loci. "],["haplotype-caller-1.html", "Chapter 17 haplotype caller", " Chapter 17 haplotype caller "],["trichrome-staining.html", "Chapter 18 Trichrome staining 18.1 Associations with cellular fraction (wsi) 18.2 Associations with growth and spatial patterns", " Chapter 18 Trichrome staining Quantification of trichrome staining was performed in Qupath using the following steps: image is loaded as a “DAB” image using “gold standard” trichrome-stained images with good stroma and epithelial content, estimate the stain vectors The output matrix was: XXX Perform color deconvolution A pixel classifier was used to estimate trichrome content A pixel classifier was used to estimate tumor content A snippet of the qupath script is shown below: 18.1 Associations with cellular fraction (wsi) 18.2 Associations with growth and spatial patterns "]]
